Arylmethylene heterocycles as Kv1.3 potassium shaker channel blockers
Novel Kv1.3 channel blockers with specific structural motifs address the need for selective and long-acting inhibitors, effectively treating autoimmune diseases, cancer, and cardiovascular disorders with reduced side effects.
Patent Information
- Application Number
- JP2022546589
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-10-07
- Filing Date
- 2020-10-06
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2040-10-06
AI Technical Summary
There is a need for the development of novel Kv1.3 channel blockers that are long-acting and selective to treat chronic inflammatory diseases without cardiotoxicity and neurotoxicity, as existing peptide inhibitors like shk-186 have short circulating half-lives and non-specificity.
Development of compounds with specific structural motifs that selectively block Kv1.3 potassium channels, including variations in substituents such as ORa, NRaRb, and NRb(C=O)Ra, which are synthesized to treat conditions like autoimmune diseases, cancer, and cardiovascular disorders.
The compounds effectively inhibit Kv1.3 channels, providing therapeutic benefits for autoimmune diseases, cancer, and cardiovascular disorders with minimal side effects by selectively targeting these channels without affecting other potassium channel subtypes.
Smart Images

Figure 0007578704000001 
Figure 0007578704000002 
Figure 0007578704000003
Abstract
Description
[Technical Field]
[0001] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 911,655, filed October 7, 2019, the entire contents of which are incorporated herein by reference.
[0002] This patent disclosure contains material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction of the patent document or the patent disclosure, as it appears in the U.S. Patent and Trademark Office patent file or records, but otherwise reserves any and all copyright rights whatsoever.
[0003] Incorporation by Reference All documents cited herein are incorporated by reference in their entirety.
[0004] The present invention relates generally to the field of pharmacology. More specifically, the present invention relates to compounds and compositions useful as pharmaceuticals as potassium channel blockers. [Background technology]
[0005] Voltage-gated Kv1.3 potassium (K +Kv1.3 channels are expressed in lymphocytes (T and B lymphocytes), the central nervous system, and other tissues, regulating numerous physiological processes such as neurotransmitter release, heart rate, insulin secretion, and neuronal excitability. Kv1.3 channels regulate membrane potential, thereby indirectly affecting calcium signaling in human effector memory T cells. Effector memory T cells are mediators of several conditions, including multiple sclerosis, type 1 diabetes, psoriasis, spondylitis, periodontitis, and rheumatoid arthritis. Upon activation, effector memory T cells increase their expression of Kv1.3 channels. Among human B cells, naive and early memory B cells express low numbers of Kv1.3 channels when resting. In contrast, class-switched memory B cells express high numbers of Kv1.3 channels. Furthermore, Kv1.3 channels promote calcium homeostasis, which is necessary for T cell receptor-mediated cell activation, gene transcription, and proliferation (Panyi, G., et al., 2004, Trends Immunol., 565-569). Blockade of Kv1.3 channels in effector memory T cells suppresses activities such as calcium signaling, cytokine production (interferon-γ, interleukin-2), and cell proliferation.
[0006] Autoimmune diseases are a family of disorders resulting from tissue damage caused by attacks from the body's own immune system. Such diseases can affect a single organ, as in multiple sclerosis and type 1 diabetes, or can involve multiple organs, as in the case of rheumatoid arthritis and systemic lupus erythematosus. Treatment is generally palliative, using anti-inflammatory and immunosuppressive drugs that can have severe side effects. The need for more effective treatments has led to the search for drugs that can selectively inhibit the function of effector memory T cells, which are known to be involved in the pathogenesis of autoimmune diseases. It is believed that these inhibitors can ameliorate autoimmune disease symptoms without compromising protective immune responses. Effector memory T cells (TEMs) express numerous Kv1.3 channels and depend on these channels for their function. In vivo, Kv1.3 channel blockers paralyze TEMs at sites of inflammation and prevent their reactivation in inflamed tissues. Kv1.3 channel blockers do not affect the motility of naive and central memory T cells within lymph nodes. Inhibition of the function of these cells by selectively blocking Kv1.3 channels offers the potential for effective treatment of autoimmune diseases with minimal side effects.
[0007] Multiple sclerosis (MS) is caused by autoimmune damage to the central nervous system (CNS). Symptoms include muscle weakness and paralysis, which severely impact the quality of life for patients. MS progresses rapidly, unpredictably, and ultimately leads to death. Kv1.3 channels are also highly expressed in autoreactive effector memory T cells of MS patients (Wulff H., et al., 2003, J. Clin. Invest., 1703-1713; Rus H., et al., 2005, PNAS, 11094-11099). Animal models of multiple sclerosis have been successfully treated using Kv1.3 channel blockers.
[0008] Therefore, the compound that is selective Kv1.3 channel blocker is a potential therapeutic agent as immunosuppressant or immune system modulator.Kv1.3 channel is also considered as a therapeutic target for treating obesity and enhancing peripheral insulin sensitivity in patients with type 2 diabetes.These compounds can also be used to prevent transplant rejection and treat immunological (for example, autoimmune) and inflammatory disorders.
[0009] Tubulointerstitial fibrosis (TIF) is a progressive connective tissue deposition in the renal parenchyma that leads to the deterioration of renal function. It is involved in the pathology of chronic kidney disease, chronic renal failure, nephritis, and glomerular inflammation, and is a common cause of end-stage renal failure. Overexpression of Kv1.3 channels in lymphocytes promotes proliferation and may contribute to the underlying pathology of these kidney diseases, leading to chronic inflammation and excessive stimulation of cell-mediated immunity, which are contributing factors in the progression of tubulointerstitial fibrosis. Inhibition of lymphocyte Kv1.3 channel currents suppresses renal lymphocyte proliferation and ameliorates the progression of renal fibrosis (Kazama I., et al., 2015, Mediators Inflamm., 1-12).
[0010] Kv1.3 channels also play a role in gastroenterological disorders, including inflammatory bowel diseases (IBDs) such as ulcerative colitis (UC) and Crohn's disease. UC is a chronic IBD characterized by excessive T cell infiltration and cytokine production. UC can impair quality of life and lead to life-threatening complications. High levels of Kv1.3 channels in CD4+ and CD8+ T cells in the inflamed mucosa of UC patients have been associated with the production of pro-inflammatory compounds in active UC. Kv1.3 channels are thought to serve as a marker of disease activity, and pharmacological blockade may constitute a novel immunosuppressive strategy in UC. Current treatment regimens for UC, including corticosteroids, salicylates, and anti-TNFα agents, are insufficient for many patients (Hansen LK, et al., 2014, J. Crohn's Colitis, 1378-1391). Crohn's disease is a type of IBD that can affect any part of the digestive tract. Crohn's disease is thought to be the result of intestinal inflammation caused by a T cell-driven process that is usually initiated by harmless bacteria. Therefore, Kv1.3 channel inhibition can be used to treat Crohn's disease.
[0011] In addition to T cells, Kv1.3 channels are also expressed in microglia, where they are involved in inflammatory cytokine and nitric oxide production and microglia-mediated neuronal death. In humans, strong Kv1.3 channel expression is observed in microglia in the frontal cortex of patients with Alzheimer's disease and in CD68 in multiple sclerosis brain lesions. + It has been found on activated microglia in infarcted rodent and human brains. It has been suggested that Kv1.3 channel blockers can preferentially target detrimental pro-inflammatory microglial function. Kv1.3 channels are expressed on activated microglia in the infarcted rodent and human brains. Higher Kv1.3 channel current density is observed in acutely isolated microglia from the infarcted hemisphere than in microglia isolated from the contralateral hemisphere in a mouse model of stroke (Chen YJ, et al., 2017, Ann. Clin. Transl. Neurol., 147-161).
[0012] Kv1.3 channel expression is elevated in microglia in human Alzheimer's disease brains, suggesting that Kv1.3 channels are a pathologically relevant microglial target in Alzheimer's disease (Rangaraju S., et al., 2015, J. Alzheimers Dis., 797-808). Soluble AβOs enhance microglial Kv1.3 channel activity. Kv1.3 channels are required for AβO-induced microglial proinflammatory activation and neurotoxicity. Kv1.3 channel expression / activity is upregulated in transgenic Alzheimer's disease animals and human Alzheimer's disease brains. Pharmacological targeting of microglial Kv1.3 channels can affect hippocampal synaptic plasticity and reduce amyloid deposition in APP / PS1 mice. Therefore, Kv1.3 channels may be a therapeutic target for Alzheimer's disease.
[0013] Kv1.3 channel blockers may also be useful in ameliorating pathology in cardiovascular disorders such as ischemic stroke, where activated microglia contribute significantly to the subsequent expansion of the infarct.
[0014] Kv1.3 channel expression is associated with the regulation of proliferation, apoptosis, and cell survival in multiple cell types. These processes are crucial for cancer progression. In this context, Kv1.3 channels located in the inner mitochondrial membrane can interact with the apoptosis regulator Bax (Serrano-Albarras, A., et al., 2018, Expert Opin. Ther. Targets, 101-105). Therefore, inhibitors of Kv1.3 channels can be used as anticancer drugs.
[0015] Several peptide toxins with multiple disulfide bonds derived from spiders, scorpions, and sea anemones are known to block Kv1.3 channels. A few selective and potent peptide inhibitors of Kv1.3 channels have been developed. A synthetic derivative of stichodactyla toxin (shk) with unnatural amino acids (shk-186) is the most advanced peptide toxin. Shk has demonstrated efficacy in preclinical models and is currently undergoing phase I clinical trials for the treatment of psoriasis. Shk can suppress TEM cell proliferation and result in improvement in animal models of multiple sclerosis. Unfortunately, Shk also binds to closely related Kvi channel subtypes found in the CNS and heart. To avoid potential cardiotoxicity and neurotoxicity, selective Kv1.3 channel inhibitors are needed. Furthermore, small peptides such as shk-186 are rapidly eliminated from the body after administration, resulting in short circulatory half-lives and frequent dosing events. Therefore, there is a need for the development of long-acting, selective Kv1.3 channel inhibitors for the treatment of chronic inflammatory diseases. Summary of the Invention [Problem to be solved by the invention]
[0016] Therefore, there remains a need for the development of novel Kv1.3 channel blockers as pharmaceutical agents. [Means for solving the problem]
[0017] In one aspect, the structure of Formula I
[0018] [ka] Compounds useful as potassium channel blockers are described having the formula: wherein the various substituents are defined herein. The compounds of formula I described herein block Kv1.3 potassium (K +) channels and can be used to treat a variety of conditions. Methods for synthesizing these compounds are also described herein. The pharmaceutical compositions and methods of using these compositions described herein are useful for treating conditions in vitro and in vivo. Such compounds, pharmaceutical compositions, and methods of treatment have several clinical uses, including as pharmaceutically active agents and in methods of treating cancer, immunological disorders, central nervous system (CNS) disorders, inflammatory disorders, gastroenterological disorders, metabolic disorders, cardiovascular disorders, renal disease, or a combination thereof.
[0019] In one embodiment, a compound of formula I or a pharmaceutically acceptable salt thereof
[0020] [ka] (In the formula, Z is OR a , N.R. a R b , or NR b (C=O)R a and; X1 is H, halogen, CN, alkyl, halogenated alkyl, cycloalkyl, cycloalkenyl, or halogenated cycloalkyl; X2 is H, halogen, CN, alkyl, alkyl halide, cycloalkyl, or cycloalkyl halide; X3 is H, halogen, fluoroalkyl, or alkyl; or X1 and X2 and the carbon atoms to which they are attached together form an optionally substituted 6-membered aryl; or X2 and X3 and the carbon atoms to which they are attached together form an optionally substituted 6-membered aryl; R3 is H, halogen, or alkyl; or X1 and R3 and the carbon atom to which they are attached together form an optionally substituted 6-membered aryl; R1 and R2 are each independently H, alkyl, (CR6R7) n4 ORa , (CR6R7) n4 NR a R b , (CR6R7) n4 NR a (C=O)R b , (CR6R7) n4 NR a SO2R b , or (CR6R7) n4 CONR a R b or R1, R2 and the carbon atom to which they are attached together form a 3- to 5-membered carbocyclic ring; R4 is H, alkyl, alkyl halide, optionally substituted cycloalkyl, (CR6R7) n4 OR c , (CR6R7) n4 (C=O)R c , (C=O)(CR6R7) n4 R c , (CR6R7) n4 COOR c , (CR6R7) n4 NR c (C=O)R d , (CR6R7) n4 (C=O)NR c R d , (C=O)(CR6R7) n4 NR c R d , (CR6R7) n4 (C=O)(C=O)NR c R d , (C=O)(CR6R7) n4 OR c , (CR6R7) n4 SO2R c , (CR6R7) n4 SO2NR c R d , optionally substituted saturated heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl-aryl, optionally substituted alkyl-heteroaryl, optionally substituted alkyl-heterocycle, optionally substituted alkyl-cycloalkyl, or optionally substituted cycloalkyl-alkyl; each occurrence of R5 is independently H, alkyl, cycloalkyl, or oxo; or two R5 groups, taken together with the carbon atoms to which they are attached, form a 3- to 7-membered optionally substituted saturated carbocyclic ring; or two R5 groups are attached to different carbon atoms on the ring and together form a bond or an alkyl chain containing 1 to 3 carbons; each occurrence of R6 and R7 is independently H, alkyl, or cycloalkyl; R a and R b each occurrence of is independently H, alkyl, cycloalkyl, saturated heterocycle, aryl, or heteroaryl; or R a and R b together with the nitrogen atom to which they are attached form an optionally substituted heterocycle containing a nitrogen atom and 0 to 3 additional heteroatoms each selected from the group consisting of N, O, and S; R c and R d each occurrence is independently H, alkyl, alkyl substituted by 1 to 4 substituents, each of which is independently halogen, OR or N(R), alkenyl, optionally substituted cycloalkyl, optionally substituted bicycloalkyl, optionally substituted spiroalkyl, optionally substituted saturated heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl-aryl, optionally substituted alkyl-heteroaryl, optionally substituted alkyl-heterocycle, optionally substituted alkyl-cycloalkyl, or optionally substituted cycloalkyl-alkyl; or R c and R d together with the nitrogen atom to which they are attached form an optionally substituted heterocycle containing a nitrogen atom and 0 to 3 additional heteroatoms each selected from the group consisting of N, O, and S; each occurrence of R8 is independently H, alkyl, or an optionally substituted heterocycle; or two R8 groups, taken together with the nitrogen atom to which they are attached, form an optionally substituted heterocycle containing a nitrogen atom and 0-3 additional heteroatoms each selected from the group consisting of N, O, and S; R9 is H, alkyl, halogen, or (CR6R7) n4 OR b and; X1, X2, X3, R1, R2, R3, R4, R5, R6, R7, R9, R, if applicable a , R b , R c , and R d The alkyl, cycloalkyl, spiroalkyl, bicycloalkyl, heterocycle, aryl, and heteroaryl groups in the formula (I) are, where valence permits, alkyl, cycloalkyl, halogenated cycloalkyl, halogenated alkyl, halogen, CN, -(CH2) 0~2 OR8, N(R8)2, (C=O)C 1~4 optionally substituted with 1 to 4 substituents independently selected from the group consisting of alkyl, (C=O)N(R8)2, and oxo; each occurrence of n1 is independently, where valence allows, an integer from 0 to 3; each occurrence of n2 and n3 is independently an integer from 0 to 2; each occurrence of n4 is independently an integer from 0 to 3) is described.
[0021] In any one of the embodiments described herein, each occurrence of n2 and n3 is independently an integer from 0 to 1.
[0022] In any one of the embodiments described herein, the structural motif
[0023] [ka] but,
[0024] [ka] It has the following structure.
[0025] In any one of the embodiments described herein, the structural motif
[0026] [ka] but,
[0027] [ka] It has the following structure.
[0028] In any one of the embodiments described herein, the structural motif
[0029] [ka] but,
[0030] [ka] It has the following structure.
[0031] In any one of the embodiments described herein, at least one occurrence of R1 and R2 is H or alkyl.
[0032] In any one of the embodiments described herein, at least one occurrence of R1 and R2 is (CR6R7) n4 OR a , (CR6R7) n4 NR a R b , (CR6R7) n4 NR a (C=O)R b , (CR6R7) n4 NR a SO2R b , or (CR6R7) n4 CONR a R b is.
[0033] In any one of the embodiments described herein, at least one occurrence of R1 and R2 is OR a or NR a R b is.
[0034] In any one of the embodiments described herein, R1, R2 and the carbon atom to which they are attached together form a 3- to 5-membered carbocyclic ring.
[0035] In any one of the embodiments described herein, R and R are each independently H, Me, OH, CHOH, NH, NHMe, NMe, CHNH, CONH, CONHMe, CONMe, NH(C=O)Me, NMe(C=O)Me,
[0036] [ka] is.
[0037] In any one of the embodiments described herein, R4 is H, alkyl, halogenated alkyl, or cycloalkyl.
[0038] In any one of the embodiments described herein, R4 is H, Me, or ethyl fluoride.
[0039] In any one of the embodiments described herein, R4 is (CR6R7) n4 OR c , (CR6R7) n4 COR c , (C=O)(CR6R7) n4 R c , (CR6R7) n4 COOR c , (CR6R7) n4 NR c (C=O)R d , (CR6R7) n4 (C=O)NR c R d, (CR6R7) n4 (C=O)(C=O)NR c R d , (C=O)(CR6R7) n4 OR c , (CR6R7) n4 SO2R c , or (CR6R7) n4 SO2NR c R d is.
[0040] In any one of the embodiments described herein, R4 is (CR6R7)2OR c , (C=O)R c , (C=O)(CR6R7) 1-2 R c , COOR c , (CR6R7) 1-2 NR c (C=O)R d , (C=O)NR c R d , (CR6R7) n4 (C=O)(C=O)NR c R d , (C=O)(CR6R7) 1-2 OR c , SO2R c , or SO2NR c R d is.
[0041] In any one of the embodiments described herein, R4 is (CH2)2OH, (CH2)2OMe, (C=O)H, (C=O)Me, (C=O)CH2OH, (C=O)CHOMe, (C=O)Et, (C=O)Ph, (C=O)isopropyl, (C=O)NH2, (C=O)NHMe, (C=O)NMe2, (C=O)CH2NH2, (C=O)CH2NHMe, (C=O)CH(OH)CH2OH, (C=O)CH(OMe)CH2OH, (C=O)CH(OH)CHOMe, (C=O)(C=O)NMe2, (C=O)OMe, SO2Me, SO2Et, SO2CH2OH, SO2CH2OMe, SON2NH2, SON2NHMe, or SONMe2.
[0042] In any one of the embodiments described herein, R4 is (C=O)R c , (C=O)(CR6R7) 1~2 R c , (C=O)(CR6R7) 1~2 OR c , or SO2R c and;R c is selected from the group consisting of H, alkyl, alkyl substituted with 1 to 4 substituents each independently selected from the group consisting of halogen, OR and N(R), alkenyl, optionally substituted cycloalkyl, optionally substituted bicycloalkyl, optionally substituted spiroalkyl, optionally substituted saturated heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl-aryl, optionally substituted alkyl-heteroaryl, optionally substituted alkyl-heterocycle, optionally substituted alkyl-cycloalkyl, and optionally substituted cycloalkyl-alkyl.
[0043] In any one of the embodiments described herein, R c or R d H, Me, Et,
[0044] [ka] is.
[0045] In any one of the embodiments described herein, R c or R d but
[0046] [ka] and the heterocycle, when valence permits, is selected from the group consisting of one or more of cyano, cycloalkyl, fluoroalkyl, fluorocycloalkyl, halogen, OH, NH, oxo, or (C=O)C 1~4 Optionally substituted with alkyl.
[0047] In any one of the embodiments described herein, R c However, when valence allows, alkyl, halogen, CN, -(CH2) 0~2 and cycloalkyl, spiroalkyl, or bicycloalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of OR, N(R), (C=O)N(R), and oxo.
[0048] In any one of the embodiments described herein, R c However, when valence allows, alkyl, halogen, CN, -(CH2) 0~2 each optionally substituted with 1 to 4 substituents independently selected from the group consisting of OR, N(R), (C=O)N(R), and oxo;
[0049] [ka] is.
[0050] In any one of the embodiments described herein, R4 is an optionally substituted saturated heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl-aryl, optionally substituted alkyl-heteroaryl, optionally substituted alkyl-heterocycle, optionally substituted cycloalkyl, optionally substituted alkyl-cycloalkyl, or optionally substituted cycloalkyl-alkyl.
[0051] In any one of the embodiments described herein, R4 is
[0052] [ka] and the heterocycle, when valence permits, is selected from the group consisting of one or more of cyano, cycloalkyl, fluoroalkyl, fluorocycloalkyl, halogen, OH, NH, oxo, or (C=O)C 1~4 Optionally substituted with alkyl.
[0053] In any one of the embodiments described herein, R4 may be selected from alkyl, halogen, CN, -(CH2), ... 0~2 cycloalkyl optionally substituted with 1 to 4 substituents each independently selected from the group consisting of OR8, N(R8)2, (C=O)N(R8)2, and oxo.
[0054] In any one of the embodiments described herein, R4 may be selected from alkyl, halogen, CN, -(CH2), ... 0~2 each optionally substituted with 1 to 4 substituents independently selected from the group consisting of OR, N(R), (C=O)N(R), and oxo;
[0055] [ka] is.
[0056] In any one of the embodiments described herein, R4 is
[0057] [ka]
[0058] [ka] or a tautomer thereof.
[0059] In any one of the embodiments described herein, at least one occurrence of R5 is H, alkyl, or cycloalkyl.
[0060] In any one of the embodiments described herein, at least one occurrence of R5 is oxo.
[0061] In any one of the embodiments described herein, the two R5 groups are attached to different carbon atoms on the ring and together form a bond or an alkyl chain containing 1 to 3 carbons.
[0062] In any one of the embodiments described herein, two R5 groups together with the carbon atoms to which they are attached form a 3- to 7-membered optionally substituted saturated carbocyclic ring.
[0063] In any one of the embodiments described herein, R a and R b At least one of is independently H, alkyl, cycloalkyl, saturated heterocycle, aryl, or heteroaryl.
[0064] In any one of the embodiments described herein, R a and R b together with the nitrogen atom to which they are attached form an optionally substituted heterocycle containing the nitrogen atom and 0 to 3 additional heteroatoms each selected from the group consisting of N, O, and S.
[0065] In any one of the embodiments described herein, each occurrence of R6 and R7 is independently H or alkyl.
[0066] In any one of the embodiments described herein, R9 is H, alkyl, or halogen.
[0067] In any one of the embodiments described herein, R9 is (CR6R7) n4 OR b is.
[0068] In any one of the embodiments described herein, R9 is H, F, or OH.
[0069] In any one of the embodiments described herein, Z is OR a , N.R. a R b , or NR b (C=O)R a is.
[0070] In any one of the embodiments described herein, Z is OH, OMe, NH2, NHMe, or NMe2.
[0071] In any one of the embodiments described herein, Z is OH.
[0072] In any one of the embodiments described herein, X 1 is H, halogen, fluorinated alkyl, or alkyl.
[0073] In any one of the embodiments described herein, X1 is H, F, Cl, Br, Me, CF3, or CF2Cl.
[0074] In any one of the embodiments described herein, X 1 is Me or Cl.
[0075] In any one of the embodiments described herein, X2 is H, halogen, fluorinated alkyl, or alkyl.
[0076] In any one of the embodiments described herein, X2 is H, F, Cl, Br, Me, CF3, or CF2Cl.
[0077] In any one of the embodiments described herein, X2 is Cl.
[0078] In any one of the embodiments described herein, X3 is H, F, Cl, Br, fluorinated alkyl, or alkyl.
[0079] In any one of the embodiments described herein, X3 is H, F, Cl, or CF3.
[0080] In any one of the embodiments described herein, the structural moiety
[0081] [ka] each of which is substituted by R3;
[0082] [ka] It has the following structure.
[0083] In any one of the embodiments described herein, R3 is H or alkyl.
[0084] In any one of the embodiments described herein, R3 is halogen.
[0085] In any one of the embodiments described herein, the compound has the structure of Formula II
[0086] [ka] (R 3’ each occurrence is independently H, halogen, or alkyl; n6 is an integer between 0 and 2) It has.
[0087] In any one of the embodiments described herein, R 3’ At least one occurrence of is H or alkyl.
[0088] In any one of the embodiments described herein, R 3’ At least one occurrence of is a halogen.
[0089] In any one of the embodiments described herein, at least one occurrence of R8 is H, alkyl, or an optionally substituted heterocycle.
[0090] In any one of the embodiments described herein, R8 is H, Me, Et, Pr, Bu, or
[0091] [ka] and the heterocycle, when valence permits, is selected from the group consisting of one or more of cyano, cycloalkyl, fluoroalkyl, fluorocycloalkyl, halogen, OH, NH, oxo, or (C=O)C 1~4 Optionally substituted with alkyl.
[0092] In any one of the embodiments described herein, two R groups, together with the nitrogen atom to which they are attached, form an optionally substituted heterocycle containing the nitrogen atom and 0-3 additional heteroatoms each selected from the group consisting of N, O, and S.
[0093] In any one of the embodiments described herein, n1 is 0, 1, 2, or 3.
[0094] In any one of the embodiments described herein, n4 is 0, 1, or 2.
[0095] In any one of the embodiments described herein, R c or R dis independently H, alkyl, alkyl substituted with 1 to 4 substituents each independently selected from the group consisting of halogen, OR and N(R), alkenyl, optionally substituted cycloalkyl, optionally substituted bicycloalkyl, optionally substituted spiroalkyl, optionally substituted saturated heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl-aryl, optionally substituted alkyl-heteroaryl, optionally substituted alkyl-heterocycle, optionally substituted alkyl-cycloalkyl, or optionally substituted cycloalkyl-alkyl.
[0096] In any one of the embodiments described herein, R c and R d together with the nitrogen atom to which they are attached form an optionally substituted heterocycle containing the nitrogen atom and 0 to 3 additional heteroatoms each selected from the group consisting of N, O, and S.
[0097] In any one of the embodiments described herein, R c or R d At least one occurrence of independently H, Me, Et,
[0098] [ka] is.
[0099] In any one of the embodiments described herein, R c or R d At least one occurrence of independently
[0100] [ka] and the heterocycle, when valence permits, is selected from the group consisting of one or more of cyano, cycloalkyl, fluoroalkyl, fluorocycloalkyl, halogen, OH, NH, oxo, or (C=O)C 1~4 Optionally substituted with alkyl.
[0101] In any one of the embodiments described herein, R c or R d At least one occurrence of independently, when valence permits, alkyl, halogen, CN, -(CH2) 0~2 and cycloalkyl, spiroalkyl, or bicycloalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of OR, N(R), (C=O)N(R), and oxo.
[0102] In any one of the embodiments described herein, R c or R d At least one occurrence of independently, when valence permits, alkyl, halogen, CN, -(CH2) 0~2 each optionally substituted with 1 to 4 substituents independently selected from the group consisting of OR, N(R), (C=O)N(R), and oxo;
[0103] [ka] is.
[0104] In any one of the embodiments described herein, the compound is selected from the group consisting of compounds 1-338 in Table 1.
[0105] In another aspect, a pharmaceutical composition is described comprising at least one compound according to any one of the embodiments described herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
[0106] In yet another aspect, a method of treating a condition in a mammalian species in need thereof is described, comprising the step of administering to the mammalian species a therapeutically effective amount of at least one compound according to any one of the embodiments described herein, or a pharmaceutically acceptable salt thereof, wherein the condition is selected from the group consisting of cancer, immunological disorders, central nervous system (CNS) disorders, inflammatory disorders, gastroenterological disorders, metabolic disorders, cardiovascular disorders, and kidney diseases.
[0107] In any one of the embodiments described herein, the immunological disorder is transplant rejection or an autoimmune disease.
[0108] In any one of the embodiments described herein, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, or type I diabetes.
[0109] In any one of the embodiments described herein, the central nervous system (CNS) disorder is Alzheimer's disease.
[0110] In any one of the embodiments described herein, the inflammatory disorder is an inflammatory skin condition, arthritis, psoriasis, spondylitis, periodontitis, or inflammatory neuropathy.
[0111] In any one of the embodiments described herein, the gastroenterological disorder is inflammatory bowel disease.
[0112] In any one of the embodiments described herein, the metabolic disorder is obesity or type II diabetes.
[0113] In any one of the embodiments described herein, the cardiovascular disorder is ischemic stroke.
[0114] In any one of the embodiments described herein, the kidney disease is chronic kidney disease, nephritis, or chronic renal failure.
[0115] In any one of the embodiments described herein, the condition is selected from the group consisting of cancer, transplant rejection, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, type I diabetes, Alzheimer's disease, inflammatory skin conditions, inflammatory neuropathy, psoriasis, spondylitis, periodontitis, Crohn's disease, ulcerative colitis, obesity, type II diabetes, ischemic stroke, chronic kidney disease, nephritis, chronic renal failure, and combinations thereof.
[0116] In any one of the embodiments described herein, the mammalian species is human.
[0117] In yet another aspect, a method of blocking Kv1.3 potassium channels in a mammalian species in need thereof is described, comprising administering to the mammalian species a therapeutically effective amount of at least one compound according to any one of the embodiments described herein, or a pharmaceutically acceptable salt thereof.
[0118] In any one of the embodiments described herein, the mammalian species is human.
[0119] Any one of the embodiments disclosed herein can be appropriately combined with any other embodiment disclosed herein.A combination of any one of the embodiments disclosed herein with any other embodiment disclosed herein is expressly contemplated.In particular, the selection of one or more embodiments for a certain substituent can be appropriately combined with the selection of one or more specific embodiments for any other substituent.Such a combination can be made with any one or more embodiments of the application described herein or any formula described herein. DETAILED DESCRIPTION OF THE INVENTION
[0120] definition The following are definitions of terms used herein. Unless otherwise specified, the initial definition provided for a group or term herein applies to that group or term throughout the specification, whether individually or as part of another group. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art.
[0121] The terms "alkyl" and "alk" refer to straight- or branched-chain alkane (hydrocarbon) groups containing 1 to 12 carbon atoms, preferably 1 to 6 carbon atoms. Exemplary "alkyl" groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, and the like. The term "(C1-C4) alkyl" refers to straight- or branched-chain alkane (hydrocarbon) groups containing 1 to 4 carbon atoms, such as methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, and isobutyl. "Substituted alkyl" refers to an alkyl group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents include, but are not limited to, one or more of the following groups: hydrogen, halogen (e.g., a single halogen substituent or multiple halo substituents, in the latter case forming a group such as an alkyl group with a CF group or CCl), cyano, nitro, oxo (i.e., =0), CF, OCF, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e, S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR d , C(=O)R a , C(=O)NR b R c , OC(=O)R a , OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a , or NR b P(=O)2R e (In the formula, R a each occurrence of is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl; R b , R c and R d each occurrence of is independently hydrogen, alkyl, cycloalkyl, heterocycle, aryl, or b and R c optionally form a heterocyclic ring together with the N to which they are attached; R e is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl.) In some embodiments, groups such as alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkenyl, heterocycle, and aryl can themselves be optionally substituted.
[0122] The term "alkenyl" refers to a straight or branched chain hydrocarbon group containing 2 to 12 carbon atoms and at least one carbon-carbon double bond. Exemplary such groups include ethenyl or allyl. The term "C2-C6 alkenyl" includes ethylenyl, propenyl, 2-propenyl, (E)-but-2-enyl, (Z)-but-2-enyl, 2-methy(E)-but-2-enyl, 2-methy(Z)-but-2-enyl, 2,3-dimethyl-but-2-enyl, (Z)-pent-2-enyl, (E)-pent-1-enyl, (Z)-hex-1-enyl, (E)-penta- "Alkenyl" refers to a straight-chain or branched-chain hydrocarbon group containing 2 to 6 carbon atoms and at least one carbon-carbon double bond, such as (Z)-2-enyl, (Z)-hex-2-enyl, (E)-hex-2-enyl, (Z)-hex-1-enyl, (E)-hex-1-enyl, (Z)-hex-3-enyl, (E)-hex-3-enyl, and (E)-hexa-1,3-dienyl. "Substituted alkenyl" refers to an alkenyl group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents include, but are not limited to, one or more of the following groups: hydrogen, halogen, alkyl, halogenated alkyl (i.e., an alkyl group having a single halogen substituent or multiple halogen substituents such as a CF3 group or CCl3), cyano, nitro, oxo (i.e., =0), CF3, OCF3, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)ORd , C(=O)R a , C(=O)NR b R c , OC(=O)R a , OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a , or NR b P(=O)2R e (In the formula, R a each occurrence of is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl; R b , R c and R d each occurrence of is independently hydrogen, alkyl, cycloalkyl, heterocycle, aryl, or b and R c optionally form a heterocyclic ring together with the N to which they are attached; R e each occurrence is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl.) The exemplary substituents themselves may be optionally substituted.
[0123] The term "alkynyl" refers to a straight- or branched-chain hydrocarbon group containing 2 to 12 carbon atoms and at least one carbon-carbon triple bond. Exemplary such groups include ethynyl. The term "C2-C6 alkynyl" refers to a straight- or branched-chain hydrocarbon group containing 2 to 6 carbon atoms and at least one carbon-carbon triple bond, such as ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, pent-1-ynyl, pent-2-ynyl, hex-1-ynyl, hex-2-ynyl, hex-3-ynyl, etc. "Substituted alkynyl" refers to an alkynyl group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents include, but are not limited to, one or more of the following groups: hydrogen, halogen (e.g., a single halogen substituent or multiple halo substituents, in the latter case forming a group such as an alkyl group with a CF group or CCl), cyano, nitro, oxo (i.e., =0), CF, OCF, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR d , C(=O)R a , C(=O)NR b R c , OC(=O)R a , OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. dC(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a , or NR b P(=O)2R e (In the formula, R a each occurrence of is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl; R b , R c and R d each occurrence of is independently hydrogen, alkyl, cycloalkyl, heterocycle, aryl, or b and R c optionally form a heterocyclic ring together with the N to which they are attached; R e each occurrence is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl.) The exemplary substituents themselves may be optionally substituted.
[0124] The term "cycloalkyl" refers to a fully saturated cyclic hydrocarbon group containing 1 to 4 rings and 3 to 8 carbons per ring. "C3-C7 cycloalkyl" refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. "Substituted cycloalkyl" refers to a cycloalkyl group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents include, but are not limited to, one or more of the following groups: hydrogen, halogen (e.g., a single halogen substituent or multiple halo substituents, in the latter case forming a group such as a CF3 group or an alkyl group with CCl3), cyano, nitro, oxo (i.e., =0), CF3, OCF3, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, aryl, OR a , S.R. a , S(=O)R e, S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR d , C(=O)R a , C(=O)NR b R c , OC(=O)R a , OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a , or NR b P(=O)2R e (In the formula, R a each occurrence of is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl; R b , R c and R d each occurrence of is independently hydrogen, alkyl, cycloalkyl, heterocycle, aryl, or b and R c optionally form a heterocyclic ring together with the N to which they are attached; R eis independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl. Exemplary substituents may themselves be optionally substituted. Exemplary substituents also include spiro-linked or fused ring substituents, particularly spiro-linked cycloalkyl, spiro-linked cycloalkenyl, spiro-linked heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, wherein the cycloalkyl, cycloalkenyl, heterocycle, and aryl substituents may themselves be optionally substituted.
[0125] The term "cycloalkenyl" refers to a partially unsaturated cyclic hydrocarbon group containing 1 to 4 rings and 3 to 8 carbons per ring. Exemplary such groups include cyclobutenyl, cyclopentenyl, cyclohexenyl, and the like. "Substituted cycloalkenyl" refers to a cycloalkenyl group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents include, but are not limited to, one or more of the following groups: hydrogen, halogen (e.g., a single halogen substituent or multiple halo substituents, the latter forming a group such as a CF3 group or an alkyl group with CCl3), cyano, nitro, oxo (i.e., ═O), CF3, OCF3, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR d , C(=O)R a, C(=O)NR b R c , OC(=O)R a , OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a , or NR b P(=O)2R e (In the formula, R a each occurrence of is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl; R b , R c and R d each occurrence of is independently hydrogen, alkyl, cycloalkyl, heterocycle, aryl, or b and R c optionally form a heterocyclic ring together with the N to which they are attached; R e is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl. Exemplary substituents may themselves be optionally substituted. Exemplary substituents also include spiro-linked or fused ring substituents, particularly spiro-linked cycloalkyl, spiro-linked cycloalkenyl, spiro-linked heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, wherein the cycloalkyl, cycloalkenyl, heterocycle, and aryl substituents may themselves be optionally substituted.
[0126] The term "aryl" refers to a cyclic aromatic hydrocarbon group having one to five aromatic rings, particularly a monocyclic or bicyclic group, such as phenyl, biphenyl, or naphthyl. When containing two or more aromatic rings (e.g., bicyclic), the aromatic rings of the aryl group can be linked at a single point (e.g., biphenyl) or fused (e.g., naphthyl, phenanthrenyl, etc.). The term "fused aromatic ring" refers to a molecular structure having two or more aromatic rings, in which two adjacent aromatic rings share two carbon atoms. "Substituted aryl" refers to an aryl group substituted with one or more substituents, preferably one to three substituents, at any available point of attachment. Exemplary substituents include, but are not limited to, one or more of the following groups: hydrogen, halogen (e.g., a single halogen substituent or multiple halo substituents, in the latter case forming a group such as an alkyl group with a CF group or CCl), cyano, nitro, oxo (i.e., =0), CF, OCF, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR d , C(=O)R a , C(=O)NR b R c , OC(=O)R a , OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R.d S(=O)NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a , or NR b P(=O)2R e (In the formula, R a each occurrence of is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl; R b , R c and R d each occurrence of is independently hydrogen, alkyl, cycloalkyl, heterocycle, aryl, or b and R c optionally form a heterocyclic ring together with the N to which they are attached; R e is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl. Exemplary substituents may themselves be optionally substituted. Exemplary substituents also include fused cyclic groups, particularly fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, and the cycloalkyl, cycloalkenyl, heterocycle, and aryl substituents may themselves be optionally substituted.
[0127] The term "biaryl" refers to two aryl groups linked by a single bond. The term "biheteroaryl" refers to two heteroaryl groups linked by a single bond. Similarly, the term "heteroaryl-aryl" refers to a heteroaryl group and an aryl group linked by a single bond, and the term "aryl-heteroaryl" refers to an aryl group and a heteroaryl group linked by a single bond. In certain embodiments, the number of ring atoms in the heteroaryl and / or aryl ring is used to specify the aryl or heteroaryl ring size of the substituent. For example, 5,6-heteroaryl-aryl refers to a substituent in which a 5-membered heteroaryl is linked to a 6-membered aryl group. Other combinations and ring sizes can be specified similarly.
[0128] The term "carbocycle" or "carbon cycle" refers to a fully saturated or partially saturated cyclic hydrocarbon group containing one to four rings and three to eight carbons per ring, or a cyclic aromatic hydrocarbon group having one to five aromatic rings, such as phenyl, biphenyl, or naphthyl, particularly a monocyclic or bicyclic group. The term "carbocycle" encompasses cycloalkyl, cycloalkenyl, cycloalkynyl, and aryl, as defined above. The term "substituted carbocycle" refers to a carbocycle or carbocyclic group substituted at any available point of attachment with one or more substituents, preferably one to four substituents. Exemplary substituents include, but are not limited to, those described above for substituted cycloalkyl, substituted cycloalkenyl, substituted cycloalkynyl, and substituted aryl. Exemplary substituents also include spiro-linked or fused ring substituents at any available point of attachment, particularly spiro-linked cycloalkyl, spiro-linked cycloalkenyl, spiro-linked heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, wherein the cycloalkyl, cycloalkenyl, heterocycle, and aryl substituents themselves may be optionally substituted.
[0129] The terms "heterocycle" and "heterocyclic" refer to fully saturated, or partially or fully unsaturated, cyclic groups (e.g., 3- to 7-membered monocyclic, 7- to 11-membered bicyclic, or 8- to 16-membered tricyclic ring systems) containing aromatic (i.e., "heteroaryl") groups, having at least one heteroatom in at least one carbon atom-containing ring. Each ring of a heterocyclic group can independently be saturated, or partially or fully unsaturated. Each ring of a heteroatom-containing heterocyclic group can have 1, 2, 3, or 4 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur atoms, with the nitrogen and sulfur heteroatoms optionally being oxidized and the nitrogen heteroatom optionally being quaternized. (The term "heteroarylium" refers to a heteroaryl group bearing a quaternized nitrogen atom, thus carrying a positive charge.) A heterocyclic group can be attached to the remainder of the molecule at any heteroatom or carbon atom in the ring or ring system. Exemplary monocyclic heterocyclic groups include azetidinyl, pyrrolidinyl, pyrrolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, Examples of aryl include 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, hexahydrodiazepinyl, 4-piperidonyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, triazolyl, tetrazolyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane, and tetrahydro-1,1-dioxothienyl.Exemplary bicyclic heterocyclic groups include indolyl, indolinyl, isoindolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzothienyl, benzo[d][1,3]dioxolyl, dihydro-2H-benzo[b][1,4]oxazine, 2,3-dihydrobenzo[b][1,4]dioxinyl, quinuclidinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, , benzofurazanyl, dihydrobenzo[d]oxazole, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (such as furo[2,3-c]pyridinyl, furo[3,2-b]pyridinyl or furo[2,3-b]pyridinyl), dihydroisoindolyl, dihydroquinazolinyl (such as 3,4-dihydro-4-oxoquinazolinyl), triazinylazepinyl, tetrahydroquinolinyl, etc. Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, acridinyl, phenanthridinyl, xanthenyl, etc.
[0130] "Substituted heterocycle" and "substituted heterocyclic" (e.g., "substituted heteroaryl") refer to a heterocycle or heterocyclic group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents include, but are not limited to, one or more of the following groups: hydrogen, halogen (e.g., a single halogen substituent or multiple halo substituents, in the latter forming a group such as a CF3 group or an alkyl group with CCl3), cyano, nitro, oxo (i.e., =0), CF3, OCF3, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2Re , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR d , C(=O)R a , C(=O)NR b R c , OC(=O)R a , OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a , or NR b P(=O)2R e (In the formula, R a each occurrence of is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl; R b , R c and R d each occurrence of is independently hydrogen, alkyl, cycloalkyl, heterocycle, aryl, or b and R c optionally form a heterocyclic ring together with the N to which they are attached; R eis independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl). Exemplary substituents may themselves be optionally substituted. Exemplary substituents also include spiro-linked or fused ring substituents at any available point of attachment, particularly spiro-linked cycloalkyl, spiro-linked cycloalkenyl, spiro-linked heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, wherein the cycloalkyl, cycloalkenyl, heterocycle, and aryl substituents may themselves be optionally substituted.
[0131] The term "oxo" refers to a ring that may be attached to a carbon ring atom on a carbocyclic or heterocyclic ring.
[0132] [ka] When an oxo substituent is attached to a carbon ring atom on an aromatic group, such as an aryl or heteroaryl, the bonds on the aromatic ring can be rearranged to meet valence requirements. For example, a pyridine with a 2-oxo substituent is
[0133] [ka] may have the structure
[0134] [ka] Also included are the tautomeric forms thereof:
[0135] The term "alkylamino" refers to a group having the structure -NHR', where R' is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, as defined herein. Examples of alkylamino groups include, but are not limited to, methylamino, ethylamino, n-propylamino, iso-propylamino, cyclopropylamino, n-butylamino, tert-butylamino, neopentylamino, n-pentylamino, hexylamino, cyclohexylamino, and the like.
[0136] The term "dialkylamino" refers to a group having the structure -NRR', where R and R' are each independently alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, or heterocycle or substituted heterocycle, as defined herein. R and R' can be the same or different dialkylamino moieties. Examples of dialkylamino groups include, but are not limited to, dimethylamino, methylethylamino, diethylamino, methylpropylamino, di(n-propyl)amino, di(iso-propyl)amino, di(cyclopropyl)amino, di(n-butyl)amino, di(tert-butyl)amino, di(neopentyl)amino, di(n-pentyl)amino, di(hexyl)amino, di(cyclohexyl)amino, and the like. In certain embodiments, R and R' are linked to form a cyclic structure. The resulting cyclic structure can be aromatic or non-aromatic. Examples of the resulting cyclic structures include, but are not limited to, aziridinyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, imidazolyl, 1,3,4-triazinolyl, and tetrazolyl.
[0137] The term "halogen" or "halo" refers to chlorine, bromine, fluorine or iodine.
[0138] The term "substituted" refers to embodiments in which a molecule, molecular moiety, or substituent (e.g., an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl group or any other group disclosed herein) is substituted with one or more substituents, preferably 1 to 6 substituents, at any available point of attachment, where valence allows. Exemplary substituents include, but are not limited to, one or more of the following groups: hydrogen, halogen (e.g., a single halogen substituent or multiple halo substituents, in the latter case forming a group such as a CF3 group or an alkyl group with CCl3), cyano, nitro, oxo (i.e., =0), CF3, OCF3, alkyl, halogen-substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR d , C(=O)R a , C(=O)NR b R c , OC(=O)R a , OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)NR b R c , N.R. d P(=O)NR b R c , N.R.b C(=O)R a , or NR b P(=O)2R e (In the formula, R a each occurrence of is independently hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl; R b , R c and R d each occurrence of is independently hydrogen, alkyl, cycloalkyl, heterocycle, aryl, or b and R c optionally form a heterocyclic ring together with the N to which they are attached; R e is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl). In the above exemplary substituents, groups such as alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkenyl, heterocycle, and aryl may themselves be optionally substituted. The term "optionally substituted" refers to embodiments in which a molecule, molecular moiety, or substituent (e.g., an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, or aryl group or any other group disclosed herein) may or may not be substituted with one or more of the substituents described above.
[0139] Unless otherwise specified, any heteroatom with unsatisfied valences is assumed to have sufficient hydrogen atoms to satisfy the valences.
[0140] The compounds of the present invention may form salts, and these salts are also within the scope of the present invention. Reference to a compound of the present invention is understood to include reference to its salts, unless otherwise indicated. As used herein, the term "salt" refers to acidic and / or basic salts formed with inorganic and / or organic acids and bases. Furthermore, when a compound of the present invention contains both a basic moiety, such as, but not limited to, pyridine or imidazole, and an acidic moiety, such as, but not limited to, a carboxylic acid, zwitterions ("internal salts") may be formed and are included in the term "salt" as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful, for example, in isolation or purification steps that may be used during preparation. Salts of the compounds of the present invention can be formed, for example, by reacting a compound described herein with, for example, an equivalent amount of an acid or base in a medium, such as a medium in which the salt precipitates, or in an aqueous medium, followed by lyophilization.
[0141] The compounds of the present invention containing a basic moiety, such as, but not limited to, an amine or a pyridine or imidazole ring, can form salts with a variety of organic and inorganic acids. Exemplary acid addition salts include acetate (such as those formed with acetic acid or trihaloacetic acid, e.g., trifluoroacetic acid), adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, hydroxyethanesulfonate, and the like. Salts include phosphates (e.g., 2-hydroxyethanesulfonate), lactate, maleate, methanesulfonate, naphthalenesulfonate (e.g., 2-naphthalenesulfonate), nicotinate, nitrate, oxalate, pectinate, persulfate, phenylpropionate (e.g., 3-phenylpropionate), phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate (including those formed with sulfuric acid), sulfonate, tartrate, thiocyanate, toluenesulfonate such as tosylate, undecanoate, and the like.
[0142] The compounds of the present invention that contain an acidic moiety, such as, but not limited to, a phenol or a carboxylic acid, can form salts with various organic and inorganic bases. Exemplary base salts include ammonium salts, alkali metal salts (e.g., sodium salts, lithium salts, and potassium salts), alkaline earth metal salts (e.g., calcium salts and magnesium salts), salts with organic bases (e.g., organic amines), such as benzathine, dicyclohexylamine, hydrabamine (formed with N,N-bis(dehydroabietyl)ethylenediamine), N-methyl-D-glucamine, N-methyl-D-glycamide, t-butylamine, and salts with amino acids such as arginine and lysine. Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfate), long chain halides (e.g., decyl chloride, bromide, and iodide, lauryl, myristyl, and stearyl), aralkyl halides (e.g., benzyl and phenethyl bromides), and the like.
[0143] Prodrugs and solvates of the compounds of the present invention are also contemplated herein.The term "prodrug" as used herein refers to a compound that, when administered to a subject, undergoes chemical conversion by metabolic or chemical processes to produce the compounds of the present invention, or their salts and / or solvates.Solvates of the compounds of the present invention include, for example, hydrates.
[0144] The compounds of the present invention, and their salts or solvates, may exist in their tautomeric form (e.g., as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention. As used herein, any depicted structure of a compound includes its tautomeric form.
[0145] All stereoisomers of the present compounds, including enantiomeric and diastereomeric forms (e.g., those that may exist due to asymmetric carbon atoms on various substituents), are contemplated within the scope of the present invention. Individual stereoisomers of the present compounds may be, for example, substantially free of other isomers (e.g., as pure or substantially pure optical isomers having the specified activity), e.g., as racemates, or admixed with all other stereoisomers or other selected stereoisomers. Chiral centers of the present invention may have the S or R configuration as defined by the 1974 Recommendations of the International Union of Pure and Applied Chemistry (IUPAC). Racemic forms can be resolved by physical methods, such as, for example, fractional crystallization, separation, or crystallization of diastereomeric derivatives, or separation by chiral column chromatography. Individual optical isomers can be obtained from the racemates by any suitable method, including, but not limited to, conventional methods such as, for example, salt formation with an optically active acid followed by crystallization.
[0146] After preparation, the compounds of the present invention are preferably isolated and purified to obtain compositions containing 90% by weight or more, e.g., 95% by weight or more, 99% by weight or more of the compound (a "substantially pure" compound), which are then used or formulated as described herein. Such "substantially pure" compounds of the present invention are also contemplated herein as part of the present invention.
[0147] All configurational isomers of the compounds of the present invention are contemplated, in admixture or in pure or substantially pure form. The definition of the compounds of the present invention encompasses both cis (Z) and trans (E) alkene isomers, as well as both cis and trans isomers of cyclic hydrocarbon or heterocyclic rings.
[0148] Throughout the specification, groups and substituents thereof may be chosen to provide stable moieties and compounds.
[0149] The definitions of specific functional groups and chemical terms are described in more detail herein. For the purposes of the present invention, chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Edition, inside cover, and specific functional groups are generally defined as described therein. Furthermore, general principles of organic chemistry, as well as specific functional moieties and reactivities, are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito (1999), the entire contents of which are incorporated herein by reference.
[0150] Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures thereof, as being within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are intended to be included in the present invention.
[0151] Isomeric mixtures containing any of a variety of isomer ratios can be utilized by the present invention. For example, when combining only two isomers, mixtures containing isomer ratios of 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0 are all contemplated by the present invention. Those skilled in the art will readily appreciate that similar ratios are contemplated for more complex isomer mixtures.
[0152] The present invention also includes isotopically labeled compounds that are identical to the compounds disclosed herein, except that one or more atoms have been replaced by an atom having an atomic mass or mass number different from that usually found in nature. Examples of isotopes that can be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, e.g., 2 H, 3 H, 13 C. 11 C. 14 C. 15 N, 18 O. 17 O. 31 P, 32 P, 35 S, 18 F, and 36 Cl. Compounds of the present invention, or enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, that contain the above isotopes and / or other isotopes of other atoms are within the scope of the present invention. Certain isotopically labeled compounds of the present invention, e.g., 3 H and 14 Those incorporating radioactive isotopes such as 1C are useful in drug and / or substrate tissue distribution assays. Tritiated isotopes, i.e. 3 H, and carbon-14 isotopes, i.e. 14 C is particularly preferred due to its ease of preparation and detectability. 2 Substitution with heavy isotopes such as H can confer certain therapeutic advantages due to greater metabolic stability, e.g., increased in vivo half-life or reduced dosage requirements, and therefore may be preferred in some circumstances. Isotopically labeled compounds can generally be prepared by following the procedures disclosed in the following schemes and / or examples by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
[0153] For example, if a specific enantiomer of a compound of the present invention is desired, it can be prepared by asymmetric synthesis or by derivatization with an asymmetric auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to yield the pure desired enantiomer. Alternatively, if the molecule contains a basic functional group such as amino, or an acidic functional group such as carboxyl, diastereomeric salts can be formed with an appropriate optically active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, followed by recovery of the pure enantiomer.
[0154] It is understood that the compounds described herein can be substituted with any number of substituents or functional moieties. In general, the term "substituted," whether preceded by the term "optionally" or not, and whether the substituent is included in the formula of the invention, refers to the replacement of a hydrogen radical in a given structure with the radical of the specified substituent. When more than one position in any given structure can be substituted with more than one substituent selected from the specified group, the substituents can be the same or different at all positions. As used herein, the term "substituted" is intended to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. For purposes of this invention, heteroatoms, such as nitrogen, can have hydrogen substituents and / or any permissible substituents of organic compounds described herein that satisfy the valence of the heteroatom. Furthermore, this invention is not intended to be limited in any manner by the permissible substituents of organic compounds. Combinations of substituents and variables envisioned by this invention are preferably those that result in the formation of stable compounds useful, for example, in the treatment of proliferative disorders. As used herein, the term "stable" refers to compounds that preferably have sufficient stability to permit manufacture and maintain compound integrity for a period of time sufficient to be detected, preferably to be useful for the purposes detailed herein.
[0155] As used herein, the terms "cancer," and equivalently, "tumor," refer to a condition in which abnormally replicating cells of host origin are present in a detectable amount in a subject. Cancer can be malignant or non-malignant. Cancers or tumors include, but are not limited to, biliary tract cancer; brain cancer; breast cancer; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric (stomach) cancer; intraepithelial neoplasia; leukemia; lymphoma; liver cancer; lung cancer (e.g., small cell and non-small cell); melanoma; neuroblastoma; oral cancer; ovarian cancer; pancreatic cancer; prostate cancer; rectal cancer; renal (kidney) cancer; sarcoma; skin cancer; testicular cancer; thyroid cancer; and other carcinomas and sarcomas. Cancer can be primary or metastatic. Diseases other than cancer may be associated with mutational changes in components of the Ras signaling pathway, and the compounds disclosed herein can be used to treat these non-cancer diseases. Such non-cancer diseases may include neurofibromatosis; Leopard syndrome; Noonan syndrome; Regius syndrome; Costello syndrome; cardio-facio-cutaneous syndrome; hereditary gingival fibromatosis type 1; autoimmune lymphoproliferative syndrome; and capillary malformation-arteriovenous malformation.
[0156] As used herein, "effective amount" refers to any amount necessary or sufficient to achieve or promote a desired outcome. In some cases, the effective amount is a therapeutically effective amount. A therapeutically effective amount is any amount necessary or sufficient to promote or achieve a desired biological response in a subject. The effective amount for any particular application may vary depending on factors such as the disease or condition being treated, the specific drug being administered, the size of the subject, or the severity of the disease or condition. Those skilled in the art can empirically determine the effective amount of a particular drug without undue experimentation.
[0157] As used herein, the term "subject" refers to a vertebrate. In one embodiment, the subject is a mammal or mammalian species. In one embodiment, the subject is a human. In other embodiments, the subject is a non-human vertebrate, including, but not limited to, non-human primates, laboratory animals, livestock, racehorses, domestic animals, and non-domestic animals.
[0158] compound Novel compounds are described as Kv1.3 potassium channel blockers. Applicants have surprisingly discovered that the compounds disclosed herein exhibit potent Kv1.3 potassium channel inhibitory properties. Furthermore, applicants have surprisingly discovered that the compounds disclosed herein selectively block Kv1.3 potassium channels and do not block hERG channels, and therefore have desirable cardiovascular safety profiles.
[0159] In one embodiment, a compound of formula I or a pharmaceutically acceptable salt thereof
[0160] [ka] (In the formula, Z is OR a , N.R. a R b , or NR b (C=O)R a and; X1 is H, halogen, CN, alkyl, halogenated alkyl, cycloalkyl, cycloalkenyl, or halogenated cycloalkyl; X2 is H, halogen, CN, alkyl, alkyl halide, cycloalkyl, or cycloalkyl halide; X3 is H, halogen, fluoroalkyl, or alkyl; or X1 and X2 and the carbon atoms to which they are attached together form an optionally substituted 6-membered aryl; or X2 and X3 and the carbon atoms to which they are attached together form an optionally substituted 6-membered aryl; R3 is H, halogen, or alkyl; or X1 and R3 and the carbon atom to which they are attached together form an optionally substituted 6-membered aryl; R1 and R2 are each independently H, alkyl, (CR6R7) n4 OR a , (CR6R7) n4 NR a R b , (CR6R7) n4 NR a (C=O)R b , (CR6R7) n4 NR a SO2R b , or (CR6R7) n4 CONR a R b or R1, R2 and the carbon atom to which they are attached together form a 3- to 5-membered carbocyclic ring; R4 is H, alkyl, alkyl halide, optionally substituted cycloalkyl, (CR6R7) n4 OR c , (CR6R7) n4 (C=O)R c , (C=O)(CR6R7) n4 R c , (CR6R7) n4 COOR c , (CR6R7) n4 NR c (C=O)R d , (CR6R7) n4 (C=O)NR c R d , (C=O)(CR6R7) n4 NR c R d , (CR6R7) n4 (C=O)(C=O)NR c R d , (C=O)(CR6R7) n4 OR c , (CR6R7) n4 SO2R c , (CR6R7) n4 SO2NR c R d, optionally substituted saturated heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl-aryl, optionally substituted alkyl-heteroaryl, optionally substituted alkyl-heterocycle, optionally substituted alkyl-cycloalkyl, or optionally substituted cycloalkyl-alkyl; each occurrence of R5 is independently H, alkyl, cycloalkyl, or oxo; or two R5 groups, taken together with the carbon atoms to which they are attached, form a 3- to 7-membered optionally substituted saturated carbocyclic ring; or two R5 groups are attached to different carbon atoms on the ring and together form a bond or an alkyl chain containing 1 to 3 carbons; each occurrence of R6 and R7 is independently H, alkyl, or cycloalkyl; R a and R b each occurrence of is independently H, alkyl, cycloalkyl, saturated heterocycle, aryl, or heteroaryl; or R a and R b together with the nitrogen atom to which they are attached form an optionally substituted heterocycle containing a nitrogen atom and 0 to 3 additional heteroatoms each selected from the group consisting of N, O, and S; R c and R d each occurrence is independently H, alkyl, alkyl substituted by 1 to 4 substituents, each of which is independently halogen, OR or N(R), alkenyl, optionally substituted cycloalkyl, optionally substituted bicycloalkyl, optionally substituted spiroalkyl, optionally substituted saturated heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl-aryl, optionally substituted alkyl-heteroaryl, optionally substituted alkyl-heterocycle, optionally substituted alkyl-cycloalkyl, or optionally substituted cycloalkyl-alkyl; or R c and R dtogether with the nitrogen atom to which they are attached form an optionally substituted heterocycle containing a nitrogen atom and 0 to 3 additional heteroatoms each selected from the group consisting of N, O, and S; each occurrence of R8 is independently H, alkyl, or an optionally substituted heterocycle; or two R8 groups, taken together with the nitrogen atom to which they are attached, form an optionally substituted heterocycle containing a nitrogen atom and 0-3 additional heteroatoms each selected from the group consisting of N, O, and S; R9 is H, alkyl, halogen, or (CR6R7) n4 OR a and; Alkyl, cycloalkyl, spiroalkyl, bicycloalkyl, heterocycle, aryl, and heteroaryl are, where valence permits, alkyl, cycloalkyl, halogenated cycloalkyl, halogenated alkyl, halogen, CN, -(CH2) 0~2 OR8, N(R8)2, (C=O)C 1~4 optionally substituted with 1 to 4 substituents independently selected from the group consisting of alkyl, (C=O)N(R8)2, and oxo; each occurrence of n1 is independently, where valence allows, an integer from 0 to 3; each occurrence of n2 and n3 is independently an integer from 0 to 2; each occurrence of n4 is independently an integer from 0 to 3) is described.
[0161] In some embodiments, each occurrence of n2 and n3 is independently an integer from 0 to 2. In some embodiments, n2 and n3 are each 0. In other embodiments, n2 and n3 are each 1. In still other embodiments, n2 and n3 are each 2. In some embodiments, n2 and n3 are 0 and 1, respectively. In some embodiments, n2 and n3 are 0 and 2, respectively. In some embodiments, n2 and n3 are 1 and 2, respectively.
[0162] In some embodiments, the structural motif
[0163] [ka] but,
[0164] [ka] wherein the various substituents are defined herein. In some embodiments, the structural motif
[0165] [ka] but,
[0166] [ka] wherein the various substituents are defined herein. In some embodiments, the structural motif
[0167] [ka] but,
[0168] [ka] wherein the various substituents are defined herein. It has the following structure.
[0169] In any one of the embodiments described herein, R a and R b Each occurrence of may independently be H, alkyl, cycloalkyl, saturated heterocycle, aryl, or heteroaryl. In some embodiments, R a and R b is independently H, alkyl, or cycloalkyl. a and R bis independently a saturated heterocycle, an aryl, or a heteroaryl. a and R b together with the nitrogen atom to which they are attached form an optionally substituted heterocycle containing a nitrogen atom and 0 to 3 additional heteroatoms each selected from the group consisting of N, O, and S.
[0170] In some embodiments, R1 and R2 are each H or alkyl. In some embodiments, R1 and R2 are both H. In some embodiments, at least one of R1 and R2 is alkyl, such as Me, Et, propyl, isopropyl, n-butyl, iso-butyl, or sec-butyl. In some embodiments, R1 and R2 are H and alkyl, respectively.
[0171] In some embodiments, at least one occurrence of R1 and R2 is (CR6R7) n4 OR a or (CR6R7) n4 NR a R b In some embodiments, at least one occurrence of R1 and R2 is (CR6R7) 0~2 NR a R b NR a R b Non-limiting examples include NH, NHMe, NMe, NHEt, NMeEt, NEt, NHPr, NMePr, NEtPr, NH(iso-Pr), and N(iso-Pr). In some embodiments, at least one occurrence of R and R is (CRR). 0~2 OR a OR a Non-limiting examples of include OH, OMe, OEt, OPr, O-iso-Pr, OBu, O-tert-Bu, and O-sec-Bu. In some embodiments, at least one occurrence of R and R is OR. a or NR a R b is.
[0172] In some embodiments, at least one occurrence of R1 and R2 is (CR6R7) 0~2 NR a (C=O)R b , (CR6R7) n4 NR a SO2R b , or (CR6R7) 0~2 CONR a R b NR a (C=O)R b Non-limiting examples of include NH(C=O)Me, NMe(C=O)Me, NH(C=O)Et, NMe(C=O)Et, NEt(C=O)Et, NH(C=O)Pr, NMe(C=O)Pr, NEt(C=O)Pr, NH(C=O)(iso-Pr), NMe(C=O)(iso-Pr), and NEt(C=O)(iso-Pr). CONR a R b Non-limiting examples include (C=O)NH, (C=O)NHMe, (C=O)NMe, (C=O)NHEt, (C=O)NMeEt, (C=O)NEt, (C=O)NHPr, (C=O)NMePr, (C=O)NEtPr, (C=O)NH(iso-Pr), and (C=O)N(iso-Pr).
[0173] In other embodiments, R1, R2, and the carbon atom to which they are attached together form a 3- to 5-membered carbocyclic ring. In some specific embodiments, R1, R2, and the carbon atom to which they are attached together form a cyclopropyl, cyclobutyl, or cyclopentyl.
[0174] In some embodiments, R and R are each independently H, Me, OH, CHOH, NH, NHMe, NMe, CHNH, CONH, CONHMe, CONMe, NH(C=O)Me, NMe(C=O)Me,
[0175] [ka] is.
[0176] In some embodiments, R4 is H, alkyl, halogenated alkyl, or cycloalkyl. In some specific embodiments, R4 is H, Me, CF3, or ethyl fluoride.
[0177] In other embodiments, R4 is (CR6R7) n4 OR c , (CR6R7) n4 COR c , (C=O)(CR6R7) n4 R c , (CR6R7) n4 COOR c , (CR6R7) n4 NR c (C=O)R d , (CR6R7) n4 (C=O)NR c R d , (C=O)(CR6R7) n4 NR c R d , (CR6R7) n4 (C=O)(C=O)NR c R d , (C=O)(CR6R7) n4 OR c , (CR6R7) n4 SO2R c , or (CR6R7) n4 SO2NR c R d In some specific embodiments, n4 is 0. In other specific embodiments, n4 is 1 or 2. In some specific embodiments, R4 is (CR6R7)2OR c , (C=O)R c , (C=O)(CR6R7) 1~2 R c , COOR c , (CR6R7) 1~2 NR c (C=O)R d , (C=O)NR c R d , (CR6R7) n4 (C=O)(C=O)NR c R d , (C=O)(CR6R7) 1~2OR c , SO2R c , or SO2NR c R d In some specific embodiments, CR6R7 is CH2, CHMe, CMe2, CHEt, or CEt2. In some specific embodiments, R4 is (CH2)2OH, (CH2)2OMe, (C=O)H, (C=O)Me, (C=O)CH2OH, (C=O)CHOMe, (C=O)CH(OH)CH2OH, (C=O)CH(OMe)CH2OH, (C=O)CH(OH)CHOMe, (C=O)Et, (C=O)Ph, (C=O)isopropyl, (C=O)NH2, (C=O)NHMe, (C=O)NMe2, (C=O)CH2NH2, (C=O)CH2NHMe, (C=O)(C=O)NMe2, (C=O)OMe, SO2Me, SO2Et, SO2CH2OH, SO2CH2OMe, SO2NH2, SO2NHMe, or SO2NMe2. In other embodiments, R4 is (C=O)CH(OH)CH2OH, (C=O)CH(OMe)CH2OH, or (C=O)CH(OH)CH2OMe.
[0178] In other embodiments, R4 is (C=O)R c , (C=O)(CR6R7) 1~2 R c , (C=O)(CR6R7) 1~2 OR c , or SO2R c and;R c is selected from the group consisting of H, alkyl, alkyl substituted with 1 to 4 substituents each independently selected from the group consisting of halogen, OR and N(R), alkenyl, optionally substituted cycloalkyl, optionally substituted bicycloalkyl, optionally substituted spiroalkyl, optionally substituted saturated heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl-aryl, optionally substituted alkyl-heteroaryl, optionally substituted alkyl-heterocycle, optionally substituted alkyl-cycloalkyl, and optionally substituted cycloalkyl-alkyl.
[0179] In some embodiments, R c or R d H, Me, Et,
[0180] [ka] is.
[0181] In some embodiments, R c but
[0182] [ka] and the heterocycle, when valence permits, is selected from the group consisting of one or more of cyano, cycloalkyl, fluoroalkyl, fluorocycloalkyl, halogen, OH, NH, oxo, or (C=O)C 1~4 Optionally substituted with alkyl.
[0183] In some embodiments, R c However, when valence allows, alkyl, halogen, CN, -(CH2) 0~2 In other embodiments, R is a cycloalkyl, spiroalkyl, or bicycloalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of OR, N(R), (C=O)N(R), and oxo. c However, when valence allows, alkyl, halogen, CN, -(CH2) 0~2 each optionally substituted with 1 to 4 substituents independently selected from the group consisting of OR, N(R), (C=O)N(R), and oxo;
[0184] [ka] is.
[0185] In still other embodiments, R4 is an optionally substituted saturated heterocycle, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted alkyl-aryl, an optionally substituted alkyl-heteroaryl, an optionally substituted alkyl-heterocycle, an optionally substituted alkyl-cycloalkyl, or an optionally substituted cycloalkyl-alkyl. In some specific embodiments, R4 is
[0186] [ka] and the heterocycle, when valence permits, is selected from the group consisting of one or more of cyano, cycloalkyl, fluoroalkyl, fluorocycloalkyl, halogen, OH, NH, oxo, or (C=O)C 1~4 Optionally substituted with alkyl.
[0187] In still other embodiments, R4 is, where valences permit, alkyl, halogen, CN, -(CH2) 0~2 In other embodiments, R is cycloalkyl optionally substituted with 1 to 4 substituents independently selected from the group consisting of OR, N(R), (C=O)N(R), and oxo. In other embodiments, R is alkyl, halogen, CN, -(CH), where valence allows. 0~2 each optionally substituted with 1 to 4 substituents independently selected from the group consisting of OR, N(R), (C=O)N(R), and oxo;
[0188] [ka] is.
[0189] In some embodiments, R8 is H or alkyl. In other embodiments, R8 is an optionally substituted heterocycle. In still other embodiments, two R8 groups, together with the nitrogen atom to which they are attached, form an optionally substituted heterocycle containing a nitrogen atom and 0-3 additional heteroatoms each selected from the group consisting of N, O, and S.
[0190] In some specific embodiments, R4 is
[0191] [ka]
[0192] [ka] or a tautomer thereof.
[0193] In some embodiments, R5 is H, alkyl, or cycloalkyl. In some specific embodiments, R5 is H. In other specific embodiments, R5 is Me, Et, Pr, iso-Pr, Bu, iso-Bu, sec-Bu, or tert-Bu. In other specific embodiments, R5 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In other specific embodiments, R5 is oxo.
[0194] In other embodiments, two R5 groups, together with the carbon atoms to which they are attached, form a 3- to 7-membered, optionally substituted, saturated carbocyclic ring. In yet other embodiments, two R5 groups are attached to different carbon atoms on the ring and, together, form a bond or an alkyl chain containing 1 to 3 carbons.
[0195] In some embodiments, each occurrence of R and R is independently H or alkyl. In some specific embodiments, CR R is CH, CHMe, CMe, CHEt, or CEt. In some specific embodiments, CR R is CH.
[0196] In some embodiments, R9 is H, alkyl, or halogen. In other embodiments, R9 is (CR6R7) n4 OR b In some specific embodiments, R9 is H, F, or OH.
[0197] In any one of the embodiments described herein, Z is OR a , N.R. a R b , or NR b (C=O)R a In some embodiments, Z is OH, OMe, NH, NHMe, or NMe. In some embodiments, Z is OH.
[0198] In any one of the embodiments described herein, X1 can be H, halogen, fluorinated alkyl, or alkyl. In some embodiments, X1 is cycloalkyl or cycloalkenyl. In some embodiments, X1 is H, F, Cl, Br, Me, CF3, or CF2Cl. In some embodiments, X1 is H, F, or Cl. In some embodiments, X1 is Me or Cl.
[0199] In any one of the embodiments described herein, X2 can be H, halogen, fluorinated alkyl, or alkyl. In some embodiments, X2 is H, F, Cl, Br, Me, CF3, or CF2Cl. In some embodiments, X2 is Cl or Br. In some embodiments, X2 is Cl.
[0200] In any one of the embodiments described herein, X3 is H, F, Cl, Br, fluorinated alkyl, or alkyl. In some embodiments, X3 is H, F, Cl, or CF3.
[0201] In some embodiments, the structural moiety
[0202] [ka] each of which is substituted by R3;
[0203] [ka] It has the following structure.
[0204] In some embodiments, the compound of formula I has the structure of formula II.
[0205] [ka] (wherein n6 is an integer of 0 to 2; R 3’ each occurrence is independently H, halogen, or alkyl; other substituents are as defined herein. In some embodiments, R 3’ is H or alkyl. Non-limiting examples of alkyl include Me, Et, propyl, isopropyl, n-butyl, iso-butyl, or sec-butyl. In other embodiments, R 3’ is halogen. In some embodiments, n6 is 0. In some embodiments, n6 is 1. In some embodiments, n6 is 2.
[0206] In any one of the embodiments described herein, R3 is H, halogen, or alkyl. In some embodiments, R3 is H. In other embodiments, R3 is alkyl, such as Me, Et, propyl, isopropyl, n-butyl, iso-butyl, or sec-butyl. In still other embodiments, R3 is F, Cl, or Br.
[0207] In any one of the embodiments described herein, at least one occurrence of R8 is H, alkyl, or an optionally substituted heterocycle. In some embodiments, R8 is H, Me, Et, Pr, Bu, or
[0208] [ka] and the heterocycle, when valence permits, is selected from the group consisting of one or more of cyano, cycloalkyl, fluoroalkyl, fluorocycloalkyl, halogen, OH, NH, oxo, or (C=O)C 1~4 Optionally substituted with alkyl.
[0209] In other embodiments, two R groups, together with the nitrogen atom to which they are attached, form an optionally substituted heterocycle containing the nitrogen atom and 0-3 additional heteroatoms each selected from the group consisting of N, O, and S.
[0210] In some embodiments, n1 is 0, 1, 2, or 3. In some specific embodiments, n1 is 0 or 1. In some embodiments, n4 is 0, 1, or 2. In some embodiments, n4 is 0 or 1. In some specific embodiments, n4 is 0.
[0211] In any one of the embodiments described herein, R c or R d is independently H, alkyl, alkyl substituted with 1 to 4 substituents each independently selected from the group consisting of halogen, OR and N(R), alkenyl, optionally substituted cycloalkyl, optionally substituted bicycloalkyl, optionally substituted spiroalkyl, optionally substituted saturated heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl-aryl, optionally substituted alkyl-heteroaryl, optionally substituted alkyl-heterocycle, optionally substituted alkyl-cycloalkyl, or optionally substituted cycloalkyl-alkyl.
[0212] In some embodiments, R c and R dtogether with the nitrogen atom to which they are attached form an optionally substituted heterocycle containing the nitrogen atom and 0 to 3 additional heteroatoms each selected from the group consisting of N, O, and S.
[0213] In some specific embodiments, R c or R d At least one occurrence of independently H, Me, Et,
[0214] [ka] is.
[0215] In some specific embodiments, R c or R d At least one occurrence of independently
[0216] [ka] and the heterocycle, when valence permits, is selected from the group consisting of one or more of cyano, cycloalkyl, fluoroalkyl, fluorocycloalkyl, halogen, OH, NH, oxo, or (C=O)C 1~4 Optionally substituted with alkyl.
[0217] In some specific embodiments, R c or R d At least one occurrence of independently, when valence permits, alkyl, halogen, CN, -(CH2) 0~2 and cycloalkyl, spiroalkyl, or bicycloalkyl, each optionally substituted with 1 to 4 substituents independently selected from the group consisting of OR, N(R), (C=O)N(R), and oxo.
[0218] In some specific embodiments, R c or R d At least one occurrence of independently, when valence permits, alkyl, halogen, CN, -(CH2)0~2 each optionally substituted with 1 to 4 substituents independently selected from the group consisting of OR, N(R), (C=O)N(R), and oxo;
[0219] [ka] is.
[0220] In some embodiments, the compound of formula I is selected from the group consisting of compounds 1-338 shown in Table 1 below.
[0221] [Table 1-1]
[0222] [Table 1-2]
[0223] Preparation method The following are general synthetic schemes for preparing the compounds of the present invention. These schemes are illustrative and are not intended to limit the possible techniques that one skilled in the art can use to prepare the compounds disclosed herein. Different methods will be apparent to those skilled in the art. Furthermore, the various steps of the synthesis can be performed in an alternative sequence or order to obtain the desired compounds. The following reactions are illustrative, but not limiting, of the preparation of some of the starting materials and compounds disclosed herein.
[0224] Schemes 1-9 below describe synthetic routes that can be used to synthesize compounds of the present invention, such as compounds having the structure of Formula I, or precursors thereof. Various modifications of these methods to achieve results similar to those of the present invention provided below may occur to those skilled in the art. In the following embodiments, synthetic routes are described using compounds I-4, I-6, I-4a, I-6a, I-7, I-7b, I-10, I-10a, and I-13 as examples. Other compounds of Formula I can be prepared by using methods similar to those described in Schemes 1-9 or by using methods known in the art. The general synthetic routes described in Schemes 1-9 and the examples described in the Examples section below illustrate the methods used to prepare the compounds described herein.
[0225] As shown in Scheme 1, compound I-4 can be prepared from compound I-1a or I-1b.
[0226] [ka]
[0227] Compounds I-1a, I-1b, I-2a, I-2b, and I-2c can be prepared by any method known in the art. As shown in Scheme 1, "Br / I" refers to a Br or I substituent, and PG refers to a protecting group. Non-limiting examples of protecting groups include Me, allyl, Ac, Boc, other alkoxycarbonyl groups, dialkylaminocarbonyl, or other protecting groups known in the art suitable for use as protecting groups for OH or NH. Other substituents are defined herein. As shown in Scheme 1, Step i, intermediate ketone I-3 can be synthesized by the Friedel-Crafts reaction of protected phenol I-1a with appropriately protected acid chloride I-2a in the presence of a Lewis acid. A non-limiting example of a Lewis acid is aluminum chloride III. Alternatively, aryl bromide or iodide I-1b can be converted to the corresponding Grignard reagent by treatment with, for example, isopropylmagnesium chloride (R is isopropyl) or to the corresponding aryllithium reagent by treatment with butyllithium (Step ii). The resulting organometallic reagent reacts with Weinreb amide I-2b to form ketone I-3. Ketone I-3 can be reduced to alcohol I-4 using a suitable reducing agent (Step v). Non-limiting examples of suitable reducing agents include NaBH4. Furthermore, aryl bromide or iodide I-1b can be converted to the corresponding Grignard reagent by treatment with, for example, isopropylmagnesium chloride (R is isopropyl) or to the corresponding aryllithium reagent by treatment with butyllithium, and the resulting organometallic reagent reacts with aldehyde I-2c to give benzylic alcohol I-4 (Step vi). Benzylic alcohol I-4 can be oxidized to ketone I-3 using an oxidizing agent, for example, Dess-Martin periodinane. The protecting groups of compound I-4 can then be selectively removed and the resulting compound with free NH and / or phenolic OH groups can be optionally converted to a compound of formula I using methods known in the art.
[0228] As shown in Scheme 2, compound I-6 can be prepared from compounds I-1b, I-2d, or I-3.
[0229] [ka]
[0230] Compound I-1b or I-2d can be prepared by any method known in the art. Compound I-3 can be prepared by the method shown in Scheme 1. As shown in Scheme 2, "Br / I" refers to a Br or I substituent, and PG refers to a protecting group. Non-limiting examples of protecting groups include Me, allyl, Ac, Boc, other alkoxycarbonyl groups, dialkylaminocarbonyl, or another protecting group known in the art suitable for use as a protecting group for OH or NH. Other substituents are defined herein. As shown in Scheme 2, Step i, a compound having formula I (wherein R comprises an amino group) (e.g., compound I-6) can be obtained from ketone I-3 by forming sulfinyl imine I-5 by heating ketone I-3 with an alkyl sulfinimide, such as t-butyl sulfinimide (i.e., R is alkyl, such as t-butyl), in the presence of a Lewis acid (e.g., titanium tetraethoxide). Reduction of sulfinylimine I-5 with a reducing agent, such as sodium borohydride or diisobutylaluminum hydride (DIBAL), affords sulfinimide I-6 (Step ii). Single enantiomers of compound I-6 can be prepared by methods known in the art. Alternatively, compound I-6 can be synthesized directly by forming a Grignard or organolithium reagent from I-1b and reacting the Grignard or organolithium reagent with sulfinylimine I-2d (prepared from I-2c in Scheme 1 using methods known in the art) as shown in Step iii. The protecting groups of compound I-6 can then be selectively removed, and the resulting compound with free NH and / or phenolic OH groups can be optionally converted to a compound of Formula I using methods known in the art.
[0231] As shown in Scheme 3, compounds I-3a, I-4a, and I-6a can be prepared from compounds I-1d and I-2b, I-1d and I-2c, and I-1d and I-2d, respectively.
[0232] [ka]
[0233] Compounds I-1d, I-2b, I-2c, and I-2d can be prepared by any method known in the art. As shown in Scheme 3, PG refers to a protecting group. Non-limiting examples of protecting groups include Me, allyl, Ac, Boc, other alkoxycarbonyl groups, dialkylaminocarbonyl, or another protecting group known in the art suitable for use as a protecting group for OH or NH. Other substituents are defined herein. As shown in Scheme 3, Steps i, ii, or iii, a suitably protected phenol, such as diethylcarbamate I-1d, can be activated by lithiation ortho to the carbamate and reacted with Weinreb amide I-2b (Step i), aldehyde I-2c (Step ii), or sulfinyl imine I-2d (Step iii), as shown in Scheme 3. The protecting groups of compounds I-4a and I-6a can then be selectively removed, and the resulting compounds having free NH and / or phenolic OH groups can be optionally converted to compounds of formula I using methods known in the art. Ketone I-3a can be reduced using a suitable reducing agent (e.g., NaBH) to give the corresponding alcohol (not shown). The protecting groups of the resulting alcohol can then be selectively removed, and the resulting compounds having free NH and / or phenolic OH groups can be optionally converted to compounds of formula I using methods known in the art.
[0234] As shown in Scheme 4, compounds I-4, I-3″, and I-7 can be prepared from compound I-3.
[0235] [ka]
[0236] Compound I-3 can be prepared by the method shown in Scheme 1. As shown in Scheme 4, PG refers to a protecting group. Non-limiting examples of protecting groups include Me, allyl, Ac, Boc, other alkoxycarbonyl groups, dialkylaminocarbonyl, or other protecting groups known in the art suitable for use as protecting groups for OH or NH. Other substituents are defined herein. As shown in Scheme 4, for compounds of Formula I (where R = R = H) (e.g., compound I-7), ketone I-3 is reduced to alcohol I-4 with a reducing agent (e.g., sodium borohydride; step i). Alcohol I-4 is then reduced with a silane, such as triethylsilane, in the presence of a Lewis acid, such as boron trifluoride etherate, or an acid, such as trifluoroacetic acid, to give compound I-7 (step ii). When the nitrogen protecting group is Boc, the nitrogen protecting group is removed under these conditions to give benzylic cyclic amine I-7. For compounds where R is alkyl, ketone I-3 is treated with an appropriate alkyl-Grignard reagent (e.g., RMeBr) to give alcohol I-3' (step iii). As shown in Scheme 4, step iv, alcohol I-3' can be reduced with triethylsilane to remove the OH group using a procedure similar to that used in step ii to give compound I-3" (if the nitrogen protecting group is Boc, the nitrogen protecting group is removed under these conditions). The protecting groups of compounds I-3" and I-7 can then be selectively removed, and the resulting compounds' free phenolic OH groups can be optionally converted to compounds of Formula I using methods known in the art.
[0237] Compound I-7b can be prepared from compounds I-8 and I-9 as shown in Scheme 5.
[0238] [ka]
[0239] Compounds I-8, I-9a, and I-9 can be prepared by any method known in the art. As shown in Scheme 5, PG refers to a protecting group. Non-limiting examples of protecting groups include Me, allyl, Ac, Boc, other alkoxycarbonyl groups, dialkylaminocarbonyl, or other protecting groups known in the art suitable for use as protecting groups for OH or NH. Other substituents are defined herein. As shown in Scheme 5, another route for preparing compounds of Formula I (where R = R = H and n = n = 1) is to react benzyl bromide I-8 with pyridine boronic acid or boronic ester I-9 (where R is H or alkyl) using a palladium catalyst, such as tetrakistriphenylphosphine palladium, to give benzyl pyridine I-10 (Step i). Reduction of pyridine I-10 with a reducing agent (e.g., hydrogen over platinum oxide in the presence of an acid, such as HCl) gives benzyl piperidine I-7b. Alternatively, vinyl boronate I-9a can be used following similar steps (steps iii and iv) to give compound I-7b. A base such as NaCO can be used in steps I and iii. The protecting groups of compound I-7b can then be selectively removed, and the resulting compound with free NH and phenolic OH groups can be optionally converted to a compound of formula I using methods known in the art.
[0240] As shown in Scheme 6, compound I-7 can be prepared from compounds I-1b and I-11.
[0241] [ka]
[0242] Compounds I-11 and I-1b can be prepared by any method known in the art. As shown in Scheme 6, PG refers to a protecting group. Non-limiting examples of protecting groups include Me, allyl, Ac, Boc, other alkoxycarbonyl groups, dialkylaminocarbonyl, or other protecting groups known in the art suitable for use as protecting groups for OH or NH. Other substituents are defined herein. As shown in Scheme 6, another route to compounds of Formula I (where R = R = H) is hydroboration of exocyclic alkenyl cyclic amine I-8 using a palladium catalyst (e.g., Pd(dppf)Cl) and coupling the resulting boronate with bromo or iodophenol I-1b. The protecting group of compound I-7 can then be selectively removed, and the resulting compound with free NH and / or phenolic OH groups can be optionally converted to compounds of Formula I using methods known in the art.
[0243] Compound I-7 can also be prepared from compounds I-1b and I-12, as shown in Scheme 7.
[0244] [ka]
[0245] Compounds I-12 and I-1b can be prepared by any method known in the art. As shown in Scheme 7, PG refers to a protecting group. Non-limiting examples of protecting groups include Me, allyl, Ac, Boc, other alkoxycarbonyl groups, dialkylaminocarbonyl, or other protecting groups known in the art suitable for use as protecting groups for OH or NH. Other substituents are defined herein. As shown in Scheme 7, another route to compounds of Formula I (where R = R = H) is the photoredox reaction of bromophenol I-1b and bromomethyl cyclic amine I-12 using tristrimethylsilylsilane, a combination of iridium and nickel catalysts (e.g., Ir[dF(CF3)ppy]2(dtbbpy)PF6 and NiCl2, respectively) under irradiation with blue LED light. The protecting groups of compound I-7 can then be selectively removed and the resulting compound with free NH and / or phenolic OH groups can be optionally converted to a compound of formula I using methods known in the art.
[0246] Compound I-13 can be prepared from compounds I-8 and I-2d as shown in Scheme 8.
[0247] [ka]
[0248] Compounds I-8 and I-2d can be prepared by methods known in the art. As shown in Scheme 8, PG refers to a protecting group. Non-limiting examples of protecting groups include Me, allyl, Ac, Boc, other alkoxycarbonyl groups, dialkylaminocarbonyl, or other protecting groups known in the art suitable for use as protecting groups for OH or NH. Other substituents are defined herein. As shown in Scheme 8, compounds of Formula I having a substituent R can be obtained by reacting a cyclic amine I-2d containing an electron-withdrawing group (EWG), such as an ester or nitrile, with benzyl bromide I-8 in the presence of a base such as sodium hexamethyldisilazide to give compound I-13. Any suitable base can be used in this reaction. The ester or nitrile group (or other electron-withdrawing group) of compound I-13 can be converted to an R group within the scope defined herein by methods known in the art. The protecting groups of the resulting compound having the desired R group can then be selectively removed, and the resulting compound having free NH and / or phenolic OH groups can be optionally converted to a compound of formula I using methods known in the art.
[0249] Compounds of formula I with other R and R substituents can be synthesized, for example, from ketones I-3 by reductive amination, Wittig reaction followed by cyclopropanation or hydroboration, or from alcohols I-4 by conversion to the corresponding bromides and displacement of the bromide with nucleophiles.
[0250] As shown in Scheme 9, compounds of Formula (I) (where R1 is NH2, n2=1 and n3=1) (e.g., compounds I-16 and I-17) can be prepared from compounds I-1e and I-14.
[0251] [ka]
[0252] Compounds I-14 and I-1e can be prepared by any method known in the art. As shown in Scheme 9, the three-component reaction of phenol I-1e, pyridine aldehyde I-14, and acetamide is carried out by heating all three components with aluminum trichloride, optionally without a solvent, to give acetamide I-15. The pyridine is reduced to piperidine I-16 by hydrogenation over platinum oxide, and acid hydrolysis gives amine I-17.
[0253] The reactions described in Schemes 1-9 can be carried out in a suitable solvent. Suitable solvents include, but are not limited to, acetonitrile, methanol, ethanol, dichloromethane, DMF, THF, MTBE, or toluene. The reactions described in Schemes 1-9 can be carried out under an inert atmosphere, such as nitrogen or argon, or in a sealed tube. The reaction mixture can be heated in a microwave or at an elevated temperature. Suitable elevated temperatures include, but are not limited to, 40, 50, 60, 80, 90, 100, 110, 120°C or higher, or the reflux / boiling temperature of the solvent used. Alternatively, the reaction mixture can be cooled in a cooling bath at a temperature below room temperature, such as 0, -10, -20, -30, -40, -50, -78, or -90°C. The reaction can be worked up by removing the solvent or by partitioning the organic solvent phase with one or more aqueous phases, each optionally containing NaCl, NaHCO3, or NHCl. The solvent of the organic phase can be removed by evaporation under reduced pressure in vacuo, and the resulting residue can be purified using a silica gel column or HPLC.
[0254] Pharmaceutical Composition The present invention also provides pharmaceutical compositions comprising at least one compound described herein, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
[0255] In yet another aspect, the present invention provides pharmaceutical compositions comprising at least one compound selected from the group consisting of compounds of formula I described herein and a pharmaceutically acceptable carrier or diluent.
[0256] In certain embodiments, the composition is in the form of a hydrate, solvate, or pharmaceutically acceptable salt. The composition can be administered to a subject by any suitable route of administration, including, but not limited to, oral and parenteral.
[0257] As used herein, the phrase "pharmaceutically acceptable carrier" means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, that is involved in carrying or transporting the pharmaceutical agent from one organ or part of the body to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials that can be used as pharmaceutically acceptable carriers include: sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository wax; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as butylene glycol; polyols such as glycerin, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer; and other non-toxic compatible substances used in pharmaceutical preparations.The term "carrier" refers to a natural or synthetic organic or inorganic ingredient that combines with active ingredients to facilitate application. The components of the pharmaceutical compositions also are capable of being co-mingled with the compounds of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.
[0258] As noted above, certain embodiments of the pharmaceutical agent may be provided in the form of a pharmaceutically acceptable salt. The term "pharmaceutically acceptable salt" in this context refers to the relatively non-toxic, inorganic and organic acid addition salts of the compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds of the present invention, or by separately reacting the purified compounds of the present invention in their free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulfonate. (See, e.g., Berge et al., (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19).
[0259] Pharmaceutically acceptable salts of the present compounds include conventional non-toxic salts or quaternary ammonium salts of the compounds, e.g., from non-toxic organic or inorganic acids. For example, such conventional non-toxic salts include salts derived from inorganic acids such as hydrochloride, hydrobromide, sulfate, sulfamate, phosphate, nitrate, and the like; and salts prepared from organic acids such as acetate, butyonic acid, succinate, glycolate, stearate, lactate, malate, tartrate, citrate, ascorbate, palmitate, maleate, hydroxymaleate, phenylacetate, glutamate, benzoate, salicylate, sulfanilate, 2-acetoxybenzoate, fumarate, toluenesulfonate, methanesulfonate, ethanedisulfonate, oxalate, isothionic acid, and the like.
[0260] In other cases, the compounds of the present invention may contain one or more acidic functional groups and therefore can form pharmaceutically acceptable salts with pharmaceutically acceptable bases. In these instances, the term "pharmaceutically acceptable salts" refers to the relatively non-toxic inorganic and organic base addition salts of the compounds of the present invention. These salts can also be prepared in situ during the final isolation and purification of the compound, or by separately reacting the purified compound in its free acid form with a suitable base, such as a hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation, ammonia, or a pharmaceutically acceptable organic primary, secondary, or tertiary amine. Representative alkali or alkaline earth salts include lithium, sodium, potassium, calcium, magnesium, and aluminum salts. Representative organic amines useful for forming base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. (See, for example, Berge et al., supra.)
[0261] Wetting agents, emulsifiers, and lubricants, such as sodium lauryl sulfate, magnesium stearate, and polyethylene oxide-polybutylene oxide copolymers, as well as coloring agents, release agents, coating agents, sweetening, flavoring, and perfuming agents, preservatives, and antioxidants can also be present in the composition.
[0262] Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, and / or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any method well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of compound which produces a therapeutic effect. Generally, this amount will range from about 1% to about 99% of the active ingredient, preferably from about 5% to about 70%, and most preferably from about 10% to about 30%.
[0263] Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
[0264] Formulations of the present invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavor base, usually sucrose and acacia or tragacanth), powder, granules, each containing a predetermined amount of a compound of the present invention as an active ingredient, or as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as a troche (using an inert base, such as gelatin and glycerin, or sucrose and acacia), and / or as a mouthwash, etc. The compounds of the present invention may also be administered as a bolus, electuary, or paste.
[0265] In the solid dosage forms of the present invention for oral administration (such as capsules, tablets, pills, dragees, powders, granules, etc.), the active ingredient is mixed with one or more pharmaceutically acceptable carriers such as sodium citrate or dicalcium phosphate, and / or any of the following: fillers or extenders such as starch, lactose, sucrose, glucose, mannitol, and / or silicic acid; binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and / or acacia; humectants such as glycerol; agar, calcium carbonate, potato, etc. Disintegrating agents such as maize or tapioca starch, alginic acid, certain silicates, sodium carbonate, and sodium starch glycolate; solution retarders such as paraffin; absorption accelerators such as quaternary ammonium compounds; wetting agents such as cetyl alcohol, glycerol monostearate, and polyethylene oxide-polybutylene oxide copolymers; absorbents such as kaolin and bentonite clay; lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof; and coloring agents. In the case of capsules, tablets, and pills, the pharmaceutical composition may also contain buffering agents. Similar types of solid compositions can also be used as fillers in soft and hard-filled gelatin capsules, using excipients such as lactose or milk sugar, and high molecular weight polyethylene glycols.
[0266] Tablets can be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared using binders (e.g., gelatin or hydroxybutylmethylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate or cross-linked sodium carboxymethylcellulose), surfactants, or dispersants. Molded tablets can be made by molding a mixture of powdered compounds moistened with an inert liquid diluent in a suitable machine.
[0267] Tablets and other solid dosage forms of the pharmaceutical compositions of the present invention, such as sugar-coated tablets, capsules, pills, and granules, can be optionally scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulation art. They can also be formulated to provide delayed or controlled release of the active ingredient therein, for example, using various proportions of hydroxybutylmethylcellulose, other polymer matrices, liposomes, and / or microspheres that provide the desired release profile. They can be sterilized, for example, by filtration through a bacteria-retaining filter or by incorporating sterilizing agents into the form of a sterile solid composition that can be dissolved in sterile water or some other sterile injectable medium immediately before use. These compositions can also optionally contain opacifying agents and can be compositions that release the active ingredient only, or preferentially, in a certain part of the digestive tract, optionally in a delayed manner. Examples of implant compositions that can be used include polymeric substances and waxes. The active ingredient can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
[0268] The liquid dosage form for oral administration of the compound of the present invention includes pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.In addition to the active ingredient, the liquid dosage form may contain solubilizers and emulsifiers, such as inert diluents commonly used in the art, such as water or other solvents, ethyl alcohol, isobutyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, butylene glycol, 1,3-butylene glycol, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofuran alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof.In addition, cyclodextrins, such as hydroxybutyl-β-cyclodextrin, can be used to solubilize the compound.
[0269] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
[0270] Suspensions may contain, in addition to the active compounds, suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.
[0271] Dosage forms for topical or transdermal administration of a compound of the present invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and any preservatives, buffers, or propellants that may be required.
[0272] The ointments, pastes, creams and gels may contain, in addition to the active compounds of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonite, silicic acid, talc and zinc oxide, or mixtures thereof.
[0273] Powders and sprays can contain, in addition to the compounds of the present invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, for example, propane and butane.
[0274] Transdermal patches have the additional advantage of providing controlled delivery of the compound of the present invention to the body.Such dosage forms can be prepared by dissolving or dispersing the drug in a suitable medium.Absorption enhancers can also be used to increase the flux of the drug of the present invention across the skin.The rate of such flux can be controlled by providing a rate-controlling membrane or dispersing the compound in a polymer matrix or gel.
[0275] Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of the present invention.
[0276] Pharmaceutical compositions of the present invention suitable for parenteral administration comprise one or more compounds of the present invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, which may contain antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic with the blood of the intended recipient, or suspending or thickening agents, or sterile powders that can be reconstituted into sterile injectable solutions or dispersions immediately before use.
[0277] In some cases, it is desirable to delay the absorption of drugs from subcutaneous or intramuscular injections to prolong the drug's effect. This can be achieved by using a liquid suspension of crystalline or amorphous material with poor water solubility. In this case, the rate of absorption of the drug depends on its dissolution rate, which may depend on the crystal size and crystalline form. Alternatively, delayed absorption of parenterally administered drug forms can be achieved by dissolving or suspending the drug in an oil vehicle. One strategy for depot injection involves the use of polyethylene oxide-polypropylene oxide copolymers, whose vehicles are fluid at room temperature but solidify at body temperature.
[0278] Injectable depot forms are prepared by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. The drug release rate can be controlled depending on the drug-to-polymer ratio and the properties of the specific polymer used. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations can also be prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.
[0279] When the compounds of the present invention are administered to humans and animals as pharmaceuticals, they may be given as they are or as pharmaceutical compositions containing, for example, 0.1% to 99.5% (more preferably, 0.5% to 90%) of the active ingredient in combination with a pharmaceutically acceptable carrier.
[0280] The compounds and pharmaceutical compositions of the present invention can be used in combination therapy, i.e., the compounds and pharmaceutical compositions can be administered simultaneously with, before, or after one or more other desired therapeutic agents or medical procedures.The specific combination of treatments (therapeutic agents or procedures) used in combination regimens will take into account the compatibility of the desired therapeutic agents and / or procedures and the desired therapeutic effect to be achieved.It will also be understood that the treatments used can achieve the desired effect for the same disorder (for example, the compounds of the present invention can be administered simultaneously with another therapeutic agent).Non-limiting examples of other therapeutic agents include biological and small molecule anti-cancer agents, immunomodulators, immunosuppressants, anti-inflammatory agents, anti-arthritic agents, corticosteroids, antidiarrheal agents, anticoagulants, and antithrombotic agents.
[0281] The compounds of the present invention can be administered intravenously, intramuscularly, intraperitoneally, subcutaneously, topically, orally, or by other acceptable means. The compounds can be used to treat arthritic conditions in mammals (e.g., humans, livestock and domestic animals), racehorses, birds, lizards, and any other organisms that can tolerate the compounds.
[0282] The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention, which may optionally be labeled with a notice in a form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals or biological products, reflecting approval by that agency of the manufacture, use, or sale for human administration.
[0283] Administration to subjects In yet another aspect, the present invention provides a method of treating a condition in a mammalian species in need thereof, comprising the step of administering to the mammalian species a therapeutically effective amount of at least one compound selected from the group consisting of compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein the condition is selected from the group consisting of cancer, immunological disorders, central nervous system (CNS) disorders, inflammatory disorders, gastroenterological disorders, metabolic disorders, cardiovascular disorders, and renal diseases.
[0284] In some embodiments, the cancer is selected from the group consisting of biliary tract cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma, colon cancer, endometrial cancer, esophageal cancer, gastric (stomach) cancer, intraepithelial neoplasia, leukemia, lymphoma, liver cancer, lung cancer, melanoma, neuroblastoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal (kidney) cancer, sarcoma, skin cancer, testicular cancer, and thyroid cancer.
[0285] In some embodiments, the inflammatory disorder is an inflammatory skin condition, arthritis, psoriasis, spondylitis, periodontitis, or inflammatory neuropathy. In some embodiments, the gastroenterological disorder is an inflammatory bowel disease, such as Crohn's disease or ulcerative colitis.
[0286] In some embodiments, the immunological disorder is transplant rejection or an autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, or type I diabetes). In some embodiments, the central nervous system (CNS) disorder is Alzheimer's disease.
[0287] In some embodiments, the metabolic disorder is obesity or type II diabetes. In some embodiments, the cardiovascular disorder is ischemic stroke. In some embodiments, the kidney disease is chronic kidney disease, nephritis, or chronic renal failure.
[0288] In some embodiments, the mammalian species is human.
[0289] In some embodiments, the condition is selected from the group consisting of cancer, transplant rejection, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, type I diabetes, Alzheimer's disease, inflammatory skin conditions, inflammatory neuropathy, psoriasis, spondylitis, periodontitis, inflammatory bowel disease, obesity, type II diabetes, ischemic stroke, chronic kidney disease, nephritis, chronic renal failure, and combinations thereof.
[0290] In yet another aspect, a method of blocking Kv1.3 potassium channels in a mammalian species in need thereof is described, comprising administering to the mammalian species a therapeutically effective amount of at least one compound of formula I, or a pharmaceutically acceptable salt thereof.
[0291] In some embodiments, the compounds described herein are selective in blocking the Kv1.3 potassium channel with minimal or no off-target inhibitory activity against other potassium channels, or against calcium or sodium channels. In some embodiments, the compounds described herein do not block the hERG channel, and therefore have a desirable cardiovascular safety profile.
[0292] Some aspects of the invention involve administering an effective amount of a composition to a subject to achieve a particular outcome. Accordingly, small molecule compositions useful according to the methods of the invention can be formulated in any manner suitable for pharmaceutical use.
[0293] The formulations of the present invention are administered in pharmaceutically acceptable solutions which may routinely contain pharmaceutically acceptable concentrations of salts, buffering agents, preservatives, compatible carriers, adjuvants, and optionally other therapeutic ingredients.
[0294] For use in treatment, an effective amount of the compound can be administered to a subject by any method that allows the compound to be taken up by appropriate target cells.The "administration" of the pharmaceutical composition of the present invention can be achieved by any means known to those skilled in the art.Specific administration routes include, but are not limited to, oral, transdermal (for example, via a patch), parenteral injection (subcutaneous, intradermal, intramuscular, intravenous, intraperitoneal, intrathecal, etc.), or mucosal (intranasal, intratracheal, inhalation, intrarectal, intravaginal, etc.).Injection can be bolus or continuous infusion.
[0295] For example, pharmaceutical compositions according to the present invention are often administered intravenously, intramuscularly, or by other parenteral means. They can also be administered intranasally, by inhalation, topically, orally, or as an implant, and even rectally or vaginally. Suitable liquid or solid pharmaceutical preparation forms include, for example, aqueous or saline solutions for injection or inhalation, microencapsulated, cochleated, coated on fine gold particles, contained in liposomes, nebulized, aerosolized, pellets for implantation in the skin, or dried on a sharp object for scratching into the skin. Pharmaceutical compositions also include granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, drops, or preparations with extended release of active compounds, in which excipients and additives and / or adjuvants such as disintegrants, binders, coating agents, swelling agents, lubricants, flavoring agents, sweeteners, or solubilizers are commonly used as described above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief overview of this method for drug delivery, see Langer R (1990) Science 249:1527-33, which is incorporated herein by reference.
[0296] The concentration of the compound contained in the composition used in the method of the present invention can range from about 1 nM to about 100 μM. An effective dose is believed to be in the range of about 100 picomoles / kg to about 100 micromoles / kg.
[0297] Pharmaceutical compositions are preferably prepared and administered in dosage units. Liquid dosage units are vials or ampoules for injection or other parenteral administration. Solid dosage units are tablets, capsules, powders and suppositories. To treat a patient, different dosages may be required depending on the activity of the compound, the method of administration, the purpose of administration (i.e., preventive or therapeutic), the nature and severity of the disorder, and the age and weight of the patient. The administration of a given dosage can be carried out by both a single administration in the form of individual dosage units or several smaller dosage units. Repeated and multiple administration of the dosage at specific daily, weekly or monthly intervals is also contemplated by the present invention.
[0298] The composition can be administered per se (neat) or in the form of a pharmaceutically acceptable salt. For medical use, the salt should be pharmaceutically acceptable, although non-pharmaceutically acceptable salts can be conveniently used to prepare pharmaceutically acceptable salts. Such salts include, but are not limited to, those prepared from the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, maleic acid, acetic acid, salicylic acid, p-toluenesulfonic acid, tartaric acid, citric acid, methanesulfonic acid, formic acid, malonic acid, succinic acid, naphthalene-2-sulfonic acid, and benzenesulfonic acid. These salts can also be prepared as alkali metal or alkaline earth salts, such as sodium, potassium, or calcium salts of the carboxylic acid group.
[0299] Suitable buffering agents include acetic acid and salts (1-2% w / v), citric acid and salts (1-3% w / v), boric acid and salts (0.5-2.5% w / v), and phosphoric acid and salts (0.8-2% w / v). Suitable preservatives include benzalkonium chloride (0.003-0.03% w / v), chlorobutanol (0.3-0.9% w / v), parabens (0.01-0.25% w / v), and thimerosal (0.004-0.02% w / v).
[0300] Compositions suitable for parenteral administration conveniently include sterile aqueous preparations that can be isotonic with the recipient's blood. Acceptable vehicles and solvents include water, Ringer's solution, phosphate-buffered saline, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally used as solvents or suspending media. For this purpose, any bland, fixed, or non-mineral oil, including synthetic mono- or diglycerides, can be used. In addition, fatty acids such as oleic acid have found use in the preparation of injectables. Carrier formulations suitable for subcutaneous, intramuscular, intraperitoneal, intravenous administration, etc. can be found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA.
[0301] The compounds useful in the present invention may be delivered in a mixture of three or more such compounds, which may further include one or more adjuvants in addition to the combination of compounds.
[0302] A variety of administration routes are available.The specific mode selected will naturally depend on the specific compound selected, the age and general health condition of the subject, the specific condition to be treated, and the dosage required for therapeutic effectiveness.The method of the present invention can be carried out using any medically acceptable administration mode, which generally means any mode that produces an effective level of response without causing clinically unacceptable adverse effects.Preferred administration modes are discussed above.
[0303] Composition can be conveniently provided in unit dosage form, and can be prepared by any method well known in the field of pharmacy.All methods comprise the step of associating compound with carrier that constitutes one or more accessory components.Generally, composition is prepared by associating compound with liquid carrier, finely divided solid carrier, or both, uniformly and intimately, and then, if necessary, shaping product.
[0304] Other delivery systems may include time-release, delayed-release, or sustained-release delivery systems. Such systems can avoid repeated administration of the compound, increasing convenience for patients and physicians. Many types of release delivery systems are available and known to those skilled in the art. These include polymer-based systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides. Drug-containing microcapsules of these polymers are described, for example, in U.S. Pat. No. 5,075,109. Delivery systems also include non-polymeric systems, such as lipids containing sterols, such as cholesterol, cholesterol esters, and fatty acids or neutral lipids, e.g., mono-, di-, and triglycerides; hydrogel release systems; silastic systems; peptide-based systems; wax coatings; compressed tablets using conventional binders and excipients; and partially fused implants. Specific examples include, but are not limited to, (a) erosion systems in which the agents of the invention are contained within a matrix, such as those described in U.S. Patent Nos. 4,452,775, 4,675,189, and 5,736,152, and (b) diffusion systems in which the active ingredient permeates through a polymer at a controlled rate, such as those described in U.S. Patent Nos. 3,854,480, 5,133,974, and 5,407,686. Additionally, pump-based hardware delivery systems, some of which are adapted for implantation, may be used.
[0305] Assay for efficacy of Kv1.3 potassium channel blockers In some embodiments, the compound described herein is tested for its activity against Kv1.3 potassium channel.In some embodiments, the compound described herein is tested for its Kv1.3 potassium channel electrophysiology.In some embodiments, the compound described herein is tested for its hERG electrophysiology.
[0306] equivalent The following representative examples are intended to help illustrate the present invention and are not intended to, and should not be construed as, limiting the scope of the present invention. Indeed, various modifications of the present invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the complete contents of this document, including the following examples, and with reference to the scientific and patent literature cited herein. It should be further understood that the contents of these cited references are incorporated herein by reference to help illustrate the prior art. The following examples contain important additional information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof. [Example]
[0307] Examples 1-76 describe various intermediates used in the synthesis of representative compounds of Formula I disclosed herein.
[0308] [Example 1] Intermediate 1 (1-(4-(4,5-dichloro-2-hydroxybenzoyl)piperidin-1-yl)ethanone)
[0309] [ka]
[0310] Step A: To a stirred solution of 1-acetylpiperidine-4-carboxylic acid (2.00 g, 11.68 mmol) in DCE (20 mL) under a nitrogen atmosphere at 0 °C, SOCl (10 mL) was added dropwise. The reaction solution was allowed to warm to room temperature. After stirring at room temperature for an additional 1.5 h, the resulting solution was concentrated under reduced pressure to give crude 1-acetylpiperidine-4-carbonyl chloride, which was used in the next step without further purification.
[0311] Step B: To a solution of 1-acetylpiperidine-4-carbonyl chloride (0.39 g, 2.03 mmol) in DCE (20 mL) was added 1,2-dichloro-4-methoxybenzene (0.30 g, 1.69 mmol) at room temperature under a nitrogen atmosphere. After stirring for 5 minutes, anhydrous AlCl (0.49 g, 3.73 mmol) was added in small portions at 0° C. under a nitrogen atmosphere. The reaction mixture was warmed to 50° C. and stirred for 2 hours under a nitrogen atmosphere. After cooling to 0° C., the resulting mixture was quenched with ice-water (30 mL) and extracted with DCM (3×30 mL). The combined organic layers were washed with brine (2×20 mL), dried over anhydrous NaSO, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with DCM / MeOH (10 / 1) to give the crude product as a dark yellow solid. The crude product was purified by preparative HPLC using the following conditions: Column: Sunfire Prep C18 OBD column, 10 μm, 19 × 250 mm; Mobile phase A: water (+0.05% TFA), Mobile phase B: ACN; Flow rate: 20 mL / min; Gradient: 56% B to 64% B in 9 min; Detector: UV 254 / 210 nm; Retention time: 6.98 min. Fractions containing the desired product were collected and concentrated under reduced pressure to give 1-(4-(4,5-dichloro-2-hydroxybenzoyl)piperidin-1-yl)ethanone as an off-white solid (85.6 mg, 16%): LCMS (ESI) C 14 H 15 Cl2NO3[M + H] + Calculated values: 316, 318 (3 : 2), measured values 316, 318 (3 : 2); 1H NMR (300 MHz, DMSO-d6) δ 11.65 (s, 1H), 7.94 (s, 1H), 7.22 (s, 1H), 4.31 (d, J = 13.2 Hz, 1H), 3.85 (d, J = 13.2 Hz, 1H), 3.69-3.54 (m, 1H), 3.21-3.03 (m, 1H), 2.75-2.58 (m, 1H), 1.96 (s, 3H), 1.86-1.71 (m, 2H), 1.53-1.18 (m, 2H).
[0312] [Example 2] Intermediate 2 ((4,5-dichloro-2-hydroxyphenyl)(piperidin-4-yl)methanone)
[0313] [ka]
[0314] Step A: A mixture of 1-[4-[(4,5-dichloro-2-hydroxyphenyl)carbonyl]piperidin-1-yl]ethan-1-one (0.15 g, 0.48 mmol) in aqueous HCl (6 N, 15 mL) was stirred at 105 °C for 4 hours. After cooling to room temperature, the resulting mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC using the following conditions: Column: XBridge Shield RP18 OBD column 19 × 250 mm, 10 μm; Mobile phase A: water containing 10 mmol / L NH4HCO3, Mobile phase B: ACN; Flow rate: 25 mL / min; Gradient: 20% B to 60% B in 9 min; Detector: UV 254 / 210 nm; Retention time: 8.5 min. Fractions containing the desired product were collected and concentrated under reduced pressure to give (4,5-dichloro-2-hydroxyphenyl)(piperidin-4-yl)methanone as a yellow solid (23.5 mg, 18%): LCMS (ESI) C 12 H 13 Cl2NO2[M + H] + Calculated values: 274, 276 (3 : 2), measured values: 274, 276 (3 : 2); 1H NMR (300 MHz, DMSO-d6) δ 7.85 (br, 1H), 7.57 (s, 1H), 6.67 (s, 1H), 3.96-3.76 (m, 1H).3.12 (d, J = 12.0 Hz, 2H), 2.83-2.62 (m, 2H), 1.81 (d, J = 13.1 Hz, 2H), 1.57-1.34 (m, 2H).
[0315] [Example 3] Intermediate 3 (tert-butyl 4-(amino(4,5-dichloro-2-methoxyphenyl)methyl)piperidine-1-carboxylate trifluoroacetate)
[0316] [ka]
[0317] Step A: To a stirred solution of tert-butyl 4-(4,5-dichloro-2-hydroxybenzoyl)piperidine-1-carboxylate (1.00 g, 2.68 mmol) in DMF (10 mL) was added K2CO3 (0.74 g, 5.36 mmol) and CHCl (0.75 g, 5.36 mmol) at room temperature under a nitrogen atmosphere. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 1 hour. The resulting mixture was diluted with water (60 mL) at room temperature and extracted with EA (3 × 50 mL). The combined organic layers were washed with brine (2 × 10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (4 / 1) to give tert-butyl 4-(4,5-dichloro-2-methoxybenzoyl)piperidine-1-carboxylate as a pale yellow solid (0.85 g, 83%): LCMS (ESI) C 18 H 23 Cl2NO4[M + H] + Calculated values: 388, 390 (3 : 2), measured values 388, 390 (3 : 2);
[0318] Step B: To a stirred solution of tert-butyl 4-[(4,5-dichloro-2-methoxyphenyl)carbonyl]piperidine-1-carboxylate (1.70 g, 4.38 mmol) in THF (20 mL) at 0 °C, NaBH (0.25 g, 6.58 mmol) was added portionwise. After stirring for an additional 1.5 h, the reaction mixture was quenched with saturated aqueous NH Cl (50 mL) and extracted with EA (3 × 50 mL). The combined organic layers were washed with brine (2 × 20 mL) and dried over anhydrous Na SO . After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with DCM / MeOH (30 / 1) to give tert-butyl 4-((4,5-dichloro-2-methoxyphenyl)(hydroxy)methyl)cyclohexane-1-carboxylate as an off-white solid (1.40 g, 82%): LCMS (ESI) C 18 H 25 Cl2NO4[M + H] + Calculated values: 390, 392 (3 : 2), measured values 390, 392 (3 : 2); 1 H NMR (300 MHz, DMSO-d6) δ 7.41 (s, 1H), 7.19 (s, 1H), 5..22 (d, J = 5.0 Hz, 1H), 4.61 (t, J = 5.2 Hz, 1H), 4.25 (d, J = 5.8 Hz, 1H), 3.99 (d, J = 5.8 Hz, 1H), 3.76 (s, 3H), 2.91-2.74 (m, 2H), 1.84-1.71 (m, 2H), 1.35 (s, 9H), 1.32-1.01 (m, 3H).
[0319] Step C: To a stirred solution of tert-butyl 4-[(4,5-dichloro-2-methoxyphenyl)(hydroxy)methyl]piperidine-1-carboxylate (2.50 g, 6.41 mmol) in DCM (18 mL) was added PBr (3.50 g, 12.81 mmol) dropwise at 0 °C. After stirring for an additional 1 h, the reaction solution was quenched with saturated aqueous NaHCO (30 mL) at 0 °C and extracted with EA (3 × 20 mL). The combined organic layers were washed with brine (2 × 10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give crude 4-(bromo(4,5-dichloro-2-methoxyphenyl)methyl)piperidine, which was used directly in the next step without further purification: LCMS (ESI) C 13 H 16 BrCl2NO [M + H] + Calculated values: 352, 354, 356 (2:3:1), measured values: 352, 354, 356 (2:3:1).
[0320] Step D: To a stirred solution of 4-[bromo(4,5-dichloro-2-methoxyphenyl)methyl]piperidine (2.00 g, 5.66 mmol) and EtN (0.90 g, 8.50 mmol) in DCM (20 mL) was added dropwise a solution of BocO (1.90 g, 8.50 mmol) in DCM (5 mL) at 0 °C. After stirring for an additional 1 h at 0 °C, the resulting solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (10 / 1) to give tert-butyl 4-(bromo(4,5-dichloro-2-methoxyphenyl)methyl)piperidine-1-carboxylate as a yellow oil (0.30 g, 12% overall for two steps): LCMS (ESI) C 18 H 24 BrCl2NO3[M + 1 - 56] + Calculated values: 396, 398, 400 (2 : 3 : 1), measured values: 396, 398, 400 (2 : 3 : 1); 1H NMR (300 MHz, CDCl3) δ 7.50 (s, 1H), 6.95 (s, 1H), 5.15 (d, J = 9.4 Hz, 1H), 4.18 (d, J = 13.5 Hz, 1H), 4.03 (d, J = 13.8 Hz, 1H), 3.85 (s, 3H), 2.81-2.54 (m, 2H), 2.27-2.02 (m, 2H), 1.48 (s, 9H), 1.32-0.97 (m, 3H).
[0321] Step E: To a stirred solution of tert-butyl 4-(bromo(4,5-dichloro-2-methoxyphenyl)methyl)piperidine-1-carboxylate (0.26 g, 0.58 mmol) in DMF (5 mL) was added NaN (0.11 g, 1.74 mmol) at room temperature. The reaction mixture was warmed to 100° C. and stirred for 16 h. The reaction mixture was diluted with water (30 mL) and extracted with EA (3×20 mL). The combined organic layers were washed with water (2×15 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to one-quarter of its volume. The residue was used directly in the next step without further purification: LCMS (ESI) C 18 H 24 Cl2N4O3[M + H] + Calculated values: 415, 417 (3:2), measured values: 415, 417 (3:2).
[0322] Step F: To a stirred solution of tert-butyl 4-[azido(4,5-dichloro-2-methoxyphenyl)methyl]piperidine-1-carboxylate (0.20 g, 0.48 mmol) and PPh3 (0.25 g, 0.96 mmol) in THF (2 mL) was added NH3·HO (1 mL, 28% in HO) dropwise at room temperature. The reaction solution was stirred at room temperature for 16 hours. The resulting solution was concentrated under reduced pressure. The residue was purified by reverse-phase chromatography eluting with 30% ACN in water (+0.05% TFA) to give tert-butyl 4-(amino(4,5-dichloro-2-methoxyphenyl)methyl)piperidine-1-carboxylate trifluoroacetate as a yellow oil (0.10 g, 45% overall for two steps): LCMS (ESI) C 18 H 26 Cl2N2O3[M + H] + Calculated values: 389, 391 (3 : 2), measured values 389, 391 (3 : 2); 1 H NMR (300 MHz, CD3OD) δ 7.46 (s, 1H), 7.29 (s, 1H), 4.21-4.09 (m, 2H), 4.05-3.93 (m, 1H), 3.86 (s, 3H), 2.82-2.53 (m, 1H), 2.20-2.06 (m, 2H), 1.95-1.83 (m, 1H), 1.40 (s, 9H), 1.32-0.97 (m, 3H).
[0323] [Example 4] Intermediate 4 (1-(4-(amino(4,5-dichloro-2-methoxyphenyl)methyl)piperidin-1-yl)ethanone)
[0324] [ka]
[0325] Step A: To a stirred solution of 1-[4-(4,5-dichloro-2-hydroxybenzoyl)piperidin-1-yl]ethan-1-one (1.00 g, 3.16 mmol) in DMF (10 mL) was added KCO (0.87 g, 6.33 mmol) and CHI (0.90 g, 6.33 mmol) at room temperature under a nitrogen atmosphere. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 1 hour. The resulting mixture was diluted with water (60 mL) at room temperature and extracted with EA (3 × 50 mL). The combined organic layers were washed with brine (2 × 10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (4 / 1) to give 1-[4-(4,5-dichloro-2-methoxybenzoyl)piperidin-1-yl]ethan-1-one as a pale yellow solid (1.00 g, 95%): LCMS (ESI) C 15 H 17 Cl2NO3[M + H] + Calculated values: 330, 332 (3:2), measured values: 330, 332 (3:2).
[0326] Step B: To a stirred solution of 1-[4-[(4,5-dichloro-2-methoxyphenyl)carbonyl]piperidin-1-yl]ethan-1-one (0.70 g, 2.12 mmol) in MeOH (5 mL) was added NaBH (0.12 g, 3.18 mmol) in small portions at 0 °C. The reaction mixture was warmed to room temperature and stirred for 3 h. The reaction mixture was quenched with saturated aqueous NH Cl (30 mL) at 0 °C, extracted with EA (3 × 50 mL), and dried over anhydrous Na SO . After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (3 / 1) to give 1-(4-((4,5-dichloro-2-methoxyphenyl)(hydroxy)methyl)piperidin-1-yl)ethanone as a yellow oil (0.46 g, 66%): LCMS (ESI) C 15 H 19 Cl2NO3[M + H] +Calculated values: 332, 334 (3:2), measured values: 332, 334 (3:2).
[0327] Step C: To a stirred solution of 1-[4-[(4,5-dichloro-2-methoxyphenyl)(hydroxy)methyl]piperidin-1-yl]ethan-1-one (0.46 g, 1.38 mmol) in DCM (5 mL) was added PBr (0.75 g, 2.77 mmol) dropwise at 0 °C. After stirring at 0 °C for 1 h, the reaction solution was quenched with water (30 mL) at 0 °C and extracted with EA (4 × 10 mL). The combined organic layers were washed with brine (2 × 10 mL) and dried over anhydrous Na SO . After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (2 / 1) to give 1-(4-(bromo(4,5-dichloro-2-methoxyphenyl)methyl)piperidin-1-yl)ethanone as a yellow oil (50 mg, 10%): LCMS (ESI) C 15 H 18 BrCl2NO2[M + H] + Calculated values: 394, 396, 398 (2 : 3 : 1), measured values 394, 396, 398 (2 : 3 : 1); 1 H NMR (300 MHz, CD3OD) δ 7.57 (s, 1H), 7.15 (s, 1H), 5.14 (dd, J = 9.5, 2.4 Hz, 1H), 3.99-3.90 (m, 1H), 3.85 (s, 3H), 3.84-3.80 (m, 1H), 3.18-2.91 (m, 1H), 2.69-2.45 (m, 1H), 2.38-2.17 (m, 2H), 2.05 (d, J = 15.0 Hz, 3H), 1.43-1.15 (m, 3H).
[0328] Step D: To a solution of 1-(4-(bromo(4,5-dichloro-2-hydroxyphenyl)methyl)piperidin-1-yl)ethanone (50 mg, 0.13 mmol) in DMF (3 mL) was added NaN (26 mg, 0.40 mmol) at room temperature. The reaction mixture was warmed to 100° C. and stirred for 8 h. After cooling to room temperature, the resulting mixture was diluted with water (20 mL) and extracted with EA (3×25 mL). The combined organic layers were washed with brine (3×10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to one-quarter of its volume. The residue was used directly in the next step without further purification: LCMS (ESI) C 15 H 18 Cl2N4O2[M + H] + Calculated values: 357, 359 (3:2), measured values: 357, 359 (3:2).
[0329] Step E: To a solution of 1-[4-[azido(4,5-dichloro-2-methoxyphenyl)methyl]piperidin-1-yl]ethan-1-one (0.10 g, 0.28 mmol) in THF (4 mL) at room temperature was added PPh (0.15 g, 0.56 mmol) and NH H O (1 mL, 28% in H O). The reaction mixture was stirred at room temperature for 16 h. The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse-phase chromatography eluting with 29% ACN in water (+0.05% TFA) to give 1-(4-(amino(4,5-dichloro-2-methoxyphenyl)methyl)piperidin-1-yl)ethanone as a pale yellow solid (30 mg, 71% overall for two steps): LCMS (ESI) C 15 H 20 Cl2N2O2[M + H] + Calculated values: 331, 333 (3 : 2), measured values 331, 333 (3 : 2); 1H NMR (300 MHz, CD3OD) δ 7.47 (d, J = 1.9 Hz, 1H), 7.16 (d, J = 1.4 Hz, 1H), 4.60-4.40 (m, 1H), 3.99-3.82 (m, 2H), 3.81 (s, 3H), 3.17-2.89 (m, 1H), 2.66-2.44 (m, 1H), 2.15-1.78 (m, 5H), 1.43-1.03 (m, 3H).
[0330] [Example 5] Intermediate 5 (N-((2-(allyloxy)-4,5-dichlorophenyl)(piperidin-4-yl)methyl)-2-methylpropane-2-sulfinamide)
[0331] [ka]
[0332] Step A: To a stirred solution of (4,5-dichloro-2-hydroxyphenyl)(piperidin-4-yl)methanone (17 g, 62.27 mmol) and EtN (31.44 g, 0.31 mol) in DCM (150 mL) was added BocO (14.90 g, 68.21 mmol) in small portions at 0 °C. The reaction solution was warmed to room temperature and stirred at room temperature for 4 h. The resulting solution was quenched with water (300 mL) at room temperature and extracted with EA (3 × 300 mL). The combined organic layers were washed with brine (2 × 100 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The crude product was used directly in the next step without further purification: LCMS (ESI) C 17 H 21 Cl2NO4[M + H] + Calculated values: 374, 376 (3:2), measured values: 374, 376 (3:2).
[0333] Step B: To a stirred mixture of tert-butyl 4-(4,5-dichloro-2-hydroxybenzoyl)piperidine-1-carboxylate (crude) and K2CO3 (33.20 g, 0.24 mmol) in DMF (200 mL) was added dropwise allyl bromide (14.48 g, 0.12 mmol) at room temperature under a nitrogen atmosphere. The reaction mixture was warmed to 40 °C and stirred for 12 h. The resulting mixture was diluted with water (500 mL) and extracted with EA (2 × 500 mL). The combined organic layers were washed with brine (2 × 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (5 / 1) to give tert-butyl 4-(2-(allyloxy)-4,5-dichlorobenzoyl)piperidine-1-carboxylate as a pale yellow solid (15.40 g, 64% overall for two steps): LCMS (ESI) C 20 H 25 Cl2NO4[M + H] + Calculated values: 414, 416 (3 : 2), measured values: 414, 416 (3 : 2); 1 H NMR (400 MHz, CDCl3) δ 7.69 (s, 1H), 7.07 (s, 1H), 6.16-6.00 (m, 1H), 5.55-5.36 (m, 2H), 4.62 (d, J = 5.7 Hz, 2H), 4.18-4.08 (m, 2H), 3.41-3.32 (m, 1H), 2.94-2.74 (m, 2H), 1.93-1.81 (m, 2H), 1.68-1.54 (m, 2H), 1.54 (s, 9H).
[0334] Step C: To a stirred mixture of tert-butyl 4-[4,5-dichloro-2-(prop-2-en-1-yloxy)benzoyl]piperidine-1-carboxylate (8.80 g, 21.24 mmol) and Ti(OEt) (21.51 g, 94.30 mmol) in THF (50 mL) was added 2-methylpropane-2-sulfinamide (3.86 g, 31.85 mmol) in small portions at room temperature under a nitrogen atmosphere. The reaction mixture was warmed to 70 °C and stirred for 16 h under a nitrogen atmosphere. The resulting mixture was quenched with water (200 mL) at room temperature. A solid formed, which was filtered. The filtrate was extracted with EA (3 × 200 mL). The combined organic layers were washed with brine (2 × 100 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give crude tert-butyl 4-((2-(allyloxy)-4,5-dichlorophenyl)((tert-butylsulfinyl)imino)methyl)piperidine-1-carboxylate. The crude product was used directly in the next step without further purification: LCMS (ESI) C 24 H 34 Cl2N2O4S [M + H] + Calculated values: 517, 519 (3 : 2), measured values 517, 519 (3 : 2); 1 H NMR (400 MHz, CDCl3) δ 7.16 (s, 1H), 6.95 (s, 1H), 6.05-5.95 (m, 1H), 5.43-5.26 (m, 2H), 4.56 (d, J = 5.8 Hz, 2H), 4.25-4.00 (m, 2H), 2.86-2.52 (m, 3H), 1.91-1.54 (m, 4H), 1.45 (s, 9H), 1.21 (s, 9H).
[0335] Step D: To a solution of tert-butyl 4-((2-(allyloxy)-4,5-dichlorophenyl)((tert-butylsulfinyl)imino)methyl)piperidine-1-carboxylate (crude) in MeOH (80 mL) was added NaBH (1.21 g, 31.86 mmol) in small portions at 0° C. under a nitrogen atmosphere. After the addition, the reaction mixture was warmed to room temperature and stirred for 2 h under a nitrogen atmosphere. The resulting mixture was quenched with water (150 mL) at 0° C. and extracted with EA (3×100 mL). The combined organic layers were washed with water (2×50 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase chromatography eluting with 45% ACN in water (+0.05% TFA) to give tert-butyl 4-((2-(allyloxy)-4,5-dichlorophenyl)(1,1-dimethylethylsulfinamido)methyl)piperidine-1-carboxylate as a yellow oil (6.58 g, 60% over two steps): LCMS (ESI) C 24 H 36 Cl2N2O4S [M + H] + Calculated values: 519, 521 (3 : 2), measured values 519, 521 (3 : 2); 1 H NMR (300 MHz, CD3OD) δ 7.51 (s, 1H), 7.15 (s, 1H), 6.19-6.03 (m, 1H), 5.52-5.29 (m, 2H), 4.67-4.58 (m, 2H), 4.30 (d, J = 9.1 Hz, 1H), 4.04 (dd, J = 35.2, 13.5 Hz, 2H), 2.84-2.50 (m, 2H), 2.14-1.87 (m, 2H), 1.46 (s, 9H), 1.30-1.05 (m, 3H), 1.23 (s, 9H).
[0336] Step E: To a stirred solution of tert-butyl 4-((2-(allyloxy)-4,5-dichlorophenyl)(1,1-dimethylethylsulfinamido)methyl)piperidine-1-carboxylate (6.58 g, 12.68 mmol) in DCM (100 mL) was added dropwise at room temperature TFA (20 mL). The reaction solution was stirred at room temperature for 1 hour. The resulting solution was diluted with water (200 mL). The pH of the reaction was adjusted to 9 with saturated aqueous NaHCO at 0° C. The aqueous layer was extracted with EA (3×500 mL). The combined organic layers were washed with brine (2×50 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase chromatography eluting with 35% ACN in water (+0.05% TFA) to give N-((2-(allyloxy)-4,5-dichlorophenyl)(piperidin-4-yl)methyl)-2-methylpropane-2-sulfinamide as a pale yellow oil (4.24 g, 80%): LCMS (ESI) C 19 H 28 Cl2N2O2S [M + H] + Calculated values: 419, 421 (3 : 2), measured values: 419, 421 (3 : 2); 1 H NMR (300 MHz, DMSO-d6+ D2O) δ 7.50 (s, 1H), 7.19 (s, 1H), 6.06-5.92 (m, 1H), 5.42-5.18 (m, 2H), 4.63-4.48 (d, J = 4.8 Hz, 2H), 4.47-4.34 (d, J = 8.7 Hz, 1H), 3.38-3.14 (m, 2H), 2.84-2.65 (m, 2H), 2.20-2.05 (m, 1H), 1.96-1.82 (m, 1H), 1.42-1.18 (m, 3H), 0.97 (s, 9H).
[0337] [Example 6] Intermediate 6 ((S)—N-((R)-(2-(allyloxy)-4,5-dichlorophenyl)(piperidin-4-yl)methyl)-2-methylpropane-2-sulfinamide), Method A
[0338] [ka]
[0339] Step A: To a stirred solution of tert-butyl 4-(2-(allyloxy)-4,5-dichlorobenzoyl)piperidine-1-carboxylate (5.16 g, 12.45 mmol) and Ti(OEt) (8.52 g, 37.36 mmol) in THF (50 mL) was added (S)-2-methylpropane-2-sulfinamide (1.67 g, 13.70 mmol) at room temperature under a nitrogen atmosphere. The reaction solution was warmed to 70 °C and stirred for 36 h. After cooling to room temperature, the resulting solution was quenched with water (300 mL) at room temperature. A solid formed and was filtered. The filtrate was extracted with EA (2 × 500 mL). The combined organic layers were washed with brine (2 × 100 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was dried in a vacuum oven to give (S)-tert-butyl 4-((2-(allyloxy)-4,5-dichlorophenyl)((tert-butylsulfinyl)imino)methyl)piperidine-1-carboxylate as a pale yellow solid (6.00 g, 93%): LCMS (ESI) C 24 H 34 Cl2N2O4S [M + H] + Calculated values: 517, 519 (3 : 2), measured values 517, 519 (3 : 2); 1 H NMR (300 MHz, CDCl3) δ 7.28 (s, 1H), 6.97 (s, 1H), 6.06-5.94 (m, 1H), 5.46-5.26 (m, 2H), 4.58 (d, J = 5.7 Hz, 2H), 4.23-4.01 (m, 2H), 3.81-3.62 (m, 1H), 2.84-2.57 (m, 2H), 1.93-1.81 (m, 2H), 1.68-1.54 (m, 2H), 1.46 (s, 9H), 1.22 (s, 9H).
[0340] Step B: To a solution of (S)-tert-butyl 4-((2-(allyloxy)-4,5-dichlorophenyl)((tert-butylsulfinyl)imino)methyl)piperidine-1-carboxylate (1.50 g, 2.90 mmol) in toluene (10 mL) was added DIBAL-H (4.35 mL, 4.35 mmol, 1 M in toluene) dropwise over 30 min at −65° C. under a nitrogen atmosphere. After the addition, the reaction solution was stirred at −65° C. for 3 h under a nitrogen atmosphere. The resulting solution was quenched with water (20 mL) at −65° C. and then diluted with saturated aqueous potassium sodium tartrate solution (200 mL). The aqueous layer was extracted with EA (3×100 mL). The combined organic layers were washed with water (2×50 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase chromatography eluting with 45% ACN in water (+0.05% TFA) to give tert-butyl 4-((R)-(2-(allyloxy)-4,5-dichlorophenyl)((S)-1,1-dimethylethylsulfinamido)methyl)piperidine-1-carboxylate as a yellow oil (0.78 g, 52%): LCMS (ESI) C 24 H 36 Cl2N2O4S [M + H] + Calculated values: 519, 521 (3 : 2), measured values 519, 521 (3 : 2); 1 H NMR (400 MHz, CDCl3) δ 7.23 (s, 1H), 6.96 (s, 1H), 6.10-5.92 (m, 1H), 5.46-5.31 (m, 2H), 4.57 (d, J = 5.8 Hz, 2H), 4.50-4.37 (m, 1H), 4.28-4.04 (m, 2H), 3.84-3.64 (m, 1H), 2.71-2.49 (m, 2H), 2.01-1.81 (m, 2H), 1.47 (s, 9H), 1.49-1.22 (m, 3H), 1.17 (s, 9H).
[0341] Step C: To a stirred solution of tert-butyl 4-((R)-(2-(allyloxy)-4,5-dichlorophenyl)((S)-1,1-dimethylethylsulfinamido)methyl)piperidine-1-carboxylate (16.00 g, 30.80 mmol) in DCM (120 mL) was added dropwise at room temperature. The reaction solution was stirred at room temperature for 1 hour. The resulting solution was diluted with water (200 mL). The pH of the reaction was adjusted to 8 with saturated aqueous NaHCO3 at 0 °C. The aqueous layer was extracted with EA (3 × 500 mL). The combined organic layers were washed with brine (2 × 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase chromatography eluting with 35% ACN in water containing 10 mmol / L NH4HCO3 to give (S)-N-((R)-(2-(allyloxy)-4,5-dichlorophenyl)(piperidin-4-yl)methyl)-2-methylpropane-2-sulfinamide as a yellow oil (7.00 g, 46%): LCMS (ESI) C 19 H 28 Cl2N2O2S [M + H] + Calculated values: 419, 421 (3 : 2), measured values: 419, 421 (3 : 2); 1 H NMR (400 MHz, CDCl3) δ 7.25 (s, 1H), 6.98 (s, 1H), 6.10-5.97 (m, 1H), 5.46-5.31 (m, 2H), 4.57 (d, J = 5.8 Hz, 2H), 4.49-4.37 (m, 1H), 4.88-3.95 (m, 1H), 3.42-3.24 (m, 2H), 2.81-2.67 (m, 2H), 2.21-2.09 (m, 1H), 2.04-1.97 (m, 1H), 1.65-1.42 (m, 3H), 1.17 (s, 9H).
[0342] Intermediate 6 ((S)—N—((R)-(2-(allyloxy)-4,5-dichlorophenyl)(piperidin-4-yl)methyl)-2-methylpropane-2-sulfinamide), Method B
[0343] [ka]
[0344] Step A: To a stirred solution of 3,4-dichlorophenol (100.00 g, 613.49 mmol) in DCM (1000 mL) was added dropwise Br (98.04 g, 613.49 mmol) under a nitrogen atmosphere at 0 °C. The reaction solution was stirred at room temperature under a nitrogen atmosphere for 16 h. The reaction was quenched with saturated aqueous NaSO (500 mL) at 0 °C. The resulting mixture was extracted with EA (6 × 400 mL). The combined organic layers were washed with brine (2 × 400 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give 2-bromo-4,5-dichlorophenol as a yellow oil. The crude product was used directly in the next step without further purification: 1 H NMR (400 MHz, CDCl3) δ 7.57 (s, 1H), 7.15 (s, 1H).
[0345] Step B: To a stirred solution of 2-bromo-4,5-dichlorophenol (50.00 g, 206.71 mmol) and K2CO3 (57.14 g, 413.41 mmol) in DMF (500 mL) was added 3-bromoprop-1-ene (37.51 g, 310.06 mmol) dropwise at room temperature under a nitrogen atmosphere. The reaction mixture was stirred at 40 °C under a nitrogen atmosphere for 16 hours. The resulting mixture was diluted with water (1.5 L) and extracted with EA (3 × 0.5 L). The combined organic layers were washed with brine (4 × 0.5 L) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE to give 1-bromo-4,5-dichloro-2-(prop-2-en-1-yloxy)benzene as a pale yellow oil (40.00 g, 61%): 1H NMR (400 MHz, CDCl3) δ 7.65 (s, 1H), 6.98 (s, 1H), 6.12-6.06 (m, 1H), 5.60-5.29 (m, 2H), 4.69-4.57 (m, 2H).
[0346] Step C: To a stirred solution of 1-bromo-4,5-dichloro-2-(prop-2-en-1-yloxy)benzene (30.00 g, 106.39 mmol) in THF (800 mL) was added i-PrMgCl-LiCl (125 mL, 159.59 mmol, 1.3 M in THF) dropwise over 30 minutes at −15° C. under a nitrogen atmosphere. The resulting mixture was stirred for an additional 0.5 hours at −15° C. under a nitrogen atmosphere. To the resulting solution was added tert-butyl 4-[[(S)-2-methylpropane-2-sulfinyl]imino]methyl]piperidine-1-carboxylate (33.67 g, 106.39 mmol) under a nitrogen atmosphere at −15° C. After the addition, the reaction mixture was stirred at −15° C. for 2 hours. The reaction was quenched with saturated aqueous NH4Cl (100 mL) at -15 °C and extracted with EA (3 x 500 mL). The combined organic layers were washed with brine (3 x 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1 / 2) to give tert-butyl 4-[(R)-[4,5-dichloro-2-(prop-2-en-1-yloxy)phenyl]([[(S)-2-methylpropane-2-sulfinyl]amino])methyl]piperidine-1-carboxylate as an off-white solid (34.00 g, 58%): LCMS (ESI) C 24 H 36 Cl2N2O4S [M + H] + Calculated values: 519, 521 (3 : 2), measured values 519, 521 (3 : 2); 1H NMR (400 MHz, CD3OD) δ 7.44 (s, 1H), 7.17 (s, 1H), 6.18-6.03 (m, 1H), 5.49-5.31 (m, 2H), 4.62 (d, J = 5.2 Hz, 2H), 4.52 (d, J = 8.8 Hz, 1H), 4.13 (t, J = 10.0 Hz, 1H), 4.01 (d, J = 13.4 Hz, 1H), 2.70 (d, J = 35.8 Hz, 2H), 2.12 (d, J = 13.6 Hz, 1H), 2.01-1.88 (m, 1H), 1.46 (s, 9H), 1.36-1.19 (m, 3H), 1.13 (d, J = 1.4 Hz, 9H).
[0347] Step D: To a stirred mixture of tert-butyl 4-[(R)-[4,5-dichloro-2-(prop-2-en-1-yloxy)phenyl]([[(S)-2-methylpropane-2-sulfinyl]amino])methyl]piperidine-1-carboxylate (5.70 g, 10.97 mmol) in DCM (40 mL) was added dropwise at room temperature. The reaction solution was stirred at room temperature for 1 hour. The mixture was neutralized to pH 9 with saturated aqueous NaHCO3 at 0 °C. The resulting mixture was extracted with EA (2 × 100 mL). The combined organic layers were washed with brine (2 × 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by reverse-phase chromatography eluting with 40% ACN in water containing 10 mmol / L NH4HCO3 to give (S)-N-[(R)-[4,5-dichloro-2-(prop-2-en-1-yloxy)phenyl](piperidin-4-yl)methyl]-2-methylpropane-2-sulfinamide as a yellow solid (3.50 g, 68%): LCMS (ESI) C 19 H 28 Cl2N2O2S [M + H] + Calculated values: 419, 421 (3 : 2), measured values: 419, 421 (3 : 2); 1H NMR (400 MHz, CDCl3) δ 7.25 (s, 1H), 6.98 (s, 1H), 6.10-5.97 (m, 1H), 5.46-5.31 (m, 2H), 4.57 (d, J = 5.8 Hz, 2H), 4.49-4.37 (m, 1H), 4.88-3.95 (m, 1H), 3.42-3.24 (m, 2H), 2.81-2.67 (m, 2H), 2.21-2.09 (m, 1H), 2.04-1.97 (m, 1H), 1.65-1.42 (m, 3H), 1.17 (s, 9H).
[0348] [Example 7] Intermediate 7 (N-((2-hydroxynaphthalen-1-yl)(pyridin-4-yl)methyl)acetamide)
[0349] [ka]
[0350] Step A: To a stirred mixture of naphthalen-2-ol (3.50 g, 24.28 mmol), acetamide (1.72 g, 29.13 mmol), and pyridine-4-carbaldehyde (2.60 g, 24.28 mmol) was added AlCl (0.49 g, 3.64 mmol) in several portions at 110 °C under a nitrogen atmosphere. The reaction mixture was stirred at 110 °C for 8 h under a nitrogen atmosphere. After cooling to room temperature, the reaction mixture was quenched with water (60 mL). The aqueous layer was extracted with EA (3 × 50 mL). The combined organic layers were washed with brine (3 × 30 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with DCM / MeOH (8 / 1) to give N-[(2-hydroxynaphthalen-1-yl)(pyridin-4-yl)methyl]acetamide as a yellow-green solid (1.00 g, 14%): LCMS (ESI) C 18 H 16 N2O2[M + H] + Calculated value: 293, measured value 293;1 H NMR (400 MHz, CD3OD) δ 8.39 (d, J = 8.4 Hz, 2H), 8.03 (d, J = 8.6 Hz, 1H), 7.87 (t, J = 9.0 Hz, 2H), 7.54 (t, J = 7.7 Hz, 1H), 7.38 (t, J = 7.5 Hz, 1H), 7.29-7.24 (m, 3H), 7.21 (d, J = 8.6 Hz, 1H), 2.10 (s, 3H).
[0351] [Example 8] Intermediate 8 (N-((2-(allyloxy)-4,5-dichlorophenyl)(piperidin-4-yl)methyl)-2,2,2-trifluoroacetamide trifluoroacetic acid)
[0352] [ka]
[0353] Step A: To a stirred solution of tert-butyl 4-((2-(allyloxy)-4,5-dichlorophenyl)(1,1-dimethylethylsulfinamido)methyl)piperidine-1-carboxylate (0.50 g, 0.96 mmol) in 1,4-dioxane (5 mL) at room temperature was added aqueous HCl (6 N, 0.5 mL). The reaction solution was stirred at room temperature for 1 hour. The resulting solution was neutralized to pH 7 with saturated aqueous NaHCO3 and then concentrated under reduced pressure. The residue was purified by reverse-phase chromatography eluting with 60% ACN in water containing 20 mmol / L NH4HCO3 to give tert-butyl 4-((2-(allyloxy)-4,5-dichlorophenyl)(amino)methyl)piperidine-1-carboxylate as a brown oil (0.40 g, 90%): LCMS (ESI) C 20 H 28 Cl2N2O3[M + H] + Calculated values: 415, 417 (3:2), measured values: 415, 417 (3:2).
[0354] Step B: To a stirred solution of tert-butyl 4-((2-(allyloxy)-4,5-dichlorophenyl)(amino)methyl)piperidine-1-carboxylate (0.11 g, 0.27 mmol) and EtN (54 mg, 0.53 mmol) in DCM (3 mL) was added dropwise at 0 °C. The reaction solution was stirred at 0 °C for 0.5 h. The reaction solution was diluted with DCM (50 mL). The solution was washed with brine (2 × 20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give tert-butyl 4-((2-(allyloxy)-4,5-dichlorophenyl)(2,2,2-trifluoroacetamido)methyl)piperidine-1-carboxylate as a yellow solid (0.13 g, 95%): LCMS (ESI) C 22 H 27 Cl2F3N2O4[M + H] + Calculated values: 511, 513 (3 : 2), measured values 511, 513 (3 : 2); 1 H NMR (400 MHz, CDCl3) δ 7.25 (s, 1H), 7.02 (s, 1H), 6.11-5.99 (m, 1H), 5.47-5.38 (m, 2H), 4.78 (t, J = 12.0 Hz, 1H), 4.86-4.57 (m, 2H), 4.31-3.93 (m, 2H), 2.75-2.48 (m, 2H), 2.01-1.91 (m, 1H), 1.83-1.72 (m, 1H), 1.46 (s, 9H), 1.49-1.22 (m, 3H).
[0355] Step C: To a solution of tert-butyl 4-((2-(allyloxy)-4,5-dichlorophenyl)(2,2,2-trifluoroacetamido)methyl)piperidine-1-carboxylate (0.13 g, 0.25 mmol) in DCM (3 mL) was added dropwise at room temperature. The reaction solution was stirred at room temperature for 0.5 hours. The reaction solution was concentrated under reduced pressure to give N-((2-(allyloxy)-4,5-dichlorophenyl)(piperidin-4-yl)methyl)-2,2,2-trifluoroacetamidotrifluoroacetic acid as a yellow solid (0.10 g, 90%): LCMS (ESI) C 17 H 19 Cl2F3N2O2[M + H] + Calculated values: 411, 413 (3:2), measured values: 411, 413 (3:2).
[0356] [Example 9] Intermediate 9 (1-(allyloxy)-2-bromo-3,4,5-trichlorobenzene)
[0357] [ka]
[0358] Step A: To a stirred solution of (3,4,5-trichlorophenyl)boronic acid (5.00 g, 22.20 mol) in THF (15 mL) was added HO (1.51 g, 44.39 mmol, 30%) and NaOH (1.78 g, 44.39 mmol) at room temperature. The resulting mixture was stirred at room temperature for 2 hours. The reaction was quenched with saturated aqueous NaSO (10 mL) at room temperature. The mixture was acidified to pH 3 with aqueous HCl (1 N). The resulting mixture was extracted with EA (3 × 80 mL). The combined organic layers were washed with brine (2 × 80 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (5 / 1) to give 3,4,5-trichlorophenol as a pale yellow solid (4.30 g, 95%): 1H NMR (300 MHz, CDCl3) δ 6.92 (s, 2H).
[0359] Step B: To a stirred solution of 3,4,5-trichlorophenol (4.60 g, 23.30 mol) in AcOH (20 mL) was added dropwise Br (3.70 g, 23.15 mol) under an argon atmosphere at room temperature. After stirring for 6 h, the reaction was quenched with saturated aqueous NaSO (80 mL) and extracted with EA (3 × 80 mL). The combined organic layers were washed with brine (3 × 80 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (20 / 1) to give 2-bromo-3,4,5-trichlorophenol as an off-white solid (2.40 g, 37%): 1 H NMR (400 MHz, DMSO-d6) δ 11.43 (s, 1H), 7.15 (s, 1H).
[0360] Step C: To a stirred solution of 2-bromo-3,4,5-trichlorophenol (2.40 g, 8.69 mmol) and K2CO3 (2.40 g, 17.37 mmol) in DMF (15 mL) was added allyl bromide (1.26 g, 10.42 mmol) at room temperature. The reaction was warmed to 50 °C and stirred for 1 h. The reaction mixture was diluted with EA (80 mL) and water (80 mL) and then extracted with EA (3 × 80 mL). The combined organic layers were washed with brine (6 × 80 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (20 / 1) to give 2-bromo-3,4,5-trichloro-1-(prop-2-en-1-yloxy)benzene as a pale yellow oil (1.80 g, 66%).
[0361] [Example 10] Intermediate 10 ((S)-tert-butyl 4-(((tert-butylsulfinyl)imino)methyl)piperidine-1-carboxylate)
[0362] [ka]
[0363] Step A: To a stirred solution of tert-butyl 4-formylpiperidine-1-carboxylate (50.00 g, 0.23 mol) and (S)-2-methylpropane-2-sulfinamide (43.00 g, 0.35 mmol) in THF (300 mL) was added Ti(OEt) (187.00 g, 0.82 mol) dropwise at room temperature under a nitrogen atmosphere. The reaction solution was stirred at room temperature for 4 hours under a nitrogen atmosphere. The resulting solution was quenched with saturated aqueous NH Cl (200 mL) at room temperature and extracted with EA (3 × 300 mL). The combined organic layers were washed with brine (3 × 200 mL) and dried over anhydrous Na SO . After filtration, the filtrate was concentrated under reduced pressure to give (S)-tert-butyl 4-(((tert-butylsulfinyl)imino)methyl)piperidine-1-carboxylate as an off-white solid (67 g, 81%): LCMS (ESI) C 15 H 28 N2O3S [M + H] + Calculated value: 317, measured value 317; 1 H NMR (300 MHz, CDCl3) δ 8.01 (d, J = 3.9 Hz, 1H), 4.09 (d, J = 13.4 Hz, 2H), 2.97-2.82 (m, 2H), 2.62 (m, 1H), 1.90 (dd, J = 13.4, 3.6 Hz, 2H), 1.71-1.43 (m, 2H), 1.47 (s, 9H), 1.20 (s, 9H).
[0364] [Example 11] Intermediate 11 (tert-butyl 4-(((tert-butylsulfinyl)imino)methyl)piperidine-1-carboxylate)
[0365] [ka]
[0366] Step A: To a stirred solution of tert-butyl 4-formylpiperidine-1-carboxylate (20.00 g, 93.90 mmol) and 2-methylpropane-2-sulfinamide (17.00 g, 0.14 mol) in THF (300 mL) was added Ti(OEt) (50.00 g, 0.18 mmol) dropwise at room temperature under a nitrogen atmosphere. The reaction solution was stirred at room temperature for 4 hours under a nitrogen atmosphere. The resulting solution was quenched with saturated aqueous NH Cl (200 mL) at room temperature and extracted with EA (3 × 500 mL). The combined organic layers were washed with brine (2 × 200 mL) and dried over anhydrous Na SO . After filtration, the filtrate was concentrated under reduced pressure to give tert-butyl 4-(((tert-butylsulfinyl)imino)methyl)piperidine-1-carboxylate as a pale yellow solid (24.00 g, 80%): LCMS (ESI) C 15 H 28 N2O3S [M + H] + Calculated value: 317, Measured value: 317.
[0367] [Example 12] Intermediate 12 ((S)-N-((1-((R)-2,2-dimethyl-1,3-dioxolane-4-carbonyl)piperidin-4-yl)methylene)-2-methylpropane-2-sulfinamide)
[0368] [ka]
[0369] Step A: To a stirred solution of tert-butyl 4-formylpiperidine-1-carboxylate (9.00 g, 42.20 mmol) in DCM (60 mL) at room temperature was added TFA (30 mL). The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was dried under reduced pressure. The crude product was used in the next step without further purification: LCMS (ESI) C6H 11NO [M + H] + Calculated value: 114, Measured value: 114.
[0370] Step B: To a stirred solution of (4R)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid (8.37 g, 57.27 mmol) and HATU (21.77 g, 57.26 mmol) in DMF (150 mL) was added piperidine-4-carbaldehyde (5.40 g, 47.72 mmol) and EtN (72.43 g, 0.72 mol) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 2 hours. The reaction was quenched with water (100 mL) at room temperature and extracted with EA (3 × 200 mL). The combined organic layers were washed with brine (3 × 100 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The crude product was used in the next step without further purification: LCMS (ESI) C 12 H 19 NO4[M + H] + Calculated value: 242, Measured value: 242.
[0371] Step C: To a stirred solution of 1-[(4R)-2,2-dimethyl-1,3-dioxolane-4-carbonyl]piperidine-4-carbaldehyde (4.30 g, 17.82 mmol) and (S)-2-methylpropane-2-sulfinamide (3.24 g, 26.73 mmol) in THF (40 mL) was added Ti(OEt) (12.20 g, 53.48 mmol) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 4 hours. The reaction was quenched with water (150 mL) at room temperature. The resulting mixture was extracted with EA (3 × 50 mL). The combined organic layers were washed with brine (3 × 30 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1:3) to give (S)-N-((1-((R)-2,2-dimethyl-1,3-dioxolane-4-carbonyl)piperidin-4-yl)methylene)-2-methylpropane-2-sulfinamide as a pale yellow oil (4.37 g, 71%): LCMS (ESI) C 16 H 28 N2O4S [M + H] + Calculated value: 345, Measured value: 345. 1 H NMR (400 MHz, DMSO-d6) δ 7.92 (d, J = 3.9 Hz, 1H), 4.91-4.77 (m, 1H), 4.36-4.12 (m, 2H), 4.11-3.94 (m, 1H), 3.16 (dt, J = 25.1, 12.4 Hz, 1H), 2.91-2.73 (m, 2H), 1.90 (d, J = 14.6 Hz, 2H), 1.56-1.40 (m, 1H), 1.39-1.25 (m, 8H), 1.11 (d, J = 1.3 Hz, 9H).
[0372] [Example 13] Intermediate 13 (2,2-dimethyl-1,3-dioxolane-4-carboxylic acid)
[0373] [ka]
[0374] Step A: To a stirred mixture of KOH (2.10 g, 37.42 mmol) in HO (9 mL) and EtOH (18 mL) was added methyl 2,2-dimethyl-1,3-dioxolane-4-carboxylate (3.00 g, 18.73 mmol) in small portions at room temperature. The reaction mixture was stirred at room temperature for 2 hours. The mixture was acidified to pH 4 with 10% aqueous HPO. The resulting mixture was extracted with EA (3 × 40 mL). The combined organic layers were washed with brine (2 × 20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give 2,2-dimethyl-1,3-dioxolane-4-carboxylic acid as a colorless oil (1.80 g, 65%): 1 H NMR (400 MHz, DMSO-d6) δ 12.81 (s, 1H), 4.58-4.50 (m, 1H), 4.17 (t, J = 7.9 Hz, 1H), 4.05-3.89 (m, 1H), 1.37 (s, 3H), 1.30 (s, 3H).
[0375] [Example 14] Intermediate 14 ((R)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid)
[0376] [ka]
[0377] Step A: To a stirred solution of KOH (3.50 g, 62.38 mmol) in HO (5 mL) and EtOH (10 mL) at room temperature, methyl (4R)-2,2-dimethyl-1,3-dioxolane-4-carboxylate (5.00 g, 31.22 mmol) was added in small portions. The reaction mixture was stirred at room temperature for an additional 2 h. The resulting mixture was diluted with HO (10 mL) and acidified to pH 3 with 10% aqueous HPO. The resulting mixture was extracted with EA (3 × 60 mL). The combined organic layers were washed with brine (3 × 10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give (4R)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid as a pale yellow oil (3.00 g, 66%): LCMS (ESI) CH 10 O4 [M - H] + Calculated value: 145, measured value 145; 1 H NMR (400 MHz, DMSO-d6) δ 12.80 (br, 1H), 4.59-4.50 (m, 1H), 4.27-4.10 (m, 1H), 4.00-3.91 (m, 1H), 1.45 (s, 3H), 1.38 (s, 3H).
[0378] [Example 15] Intermediate 15 (1,2-dichloro-3-iodo-4-methoxybenzene)
[0379] [ka]
[0380] Step A: To a stirred solution of 3,4-dichlorophenol (50.00 g, 306.75 mmol), DMAP (74.95 g, 613.50 mmol), and EtN (62.08 g, 613.50 mmol) in DCM (500 mL) was added dropwise diethylcarbamoyl chloride (62.39 g, 460.12 mmol) at room temperature under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 2 hours under a nitrogen atmosphere. The resulting mixture was diluted with water (300 mL) at room temperature and extracted with EA (3 × 500 mL). The combined organic layers were washed with brine (2 × 200 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (40 / 1) to give 3,4-dichlorophenyl N,N-diethylcarbamate as a yellow oil (72.00 g, 80%): LCMS (ESI) C 11 H 13 Cl2NO2[M + H] + Calculated values: 262, 264 (3 : 2), measured values: 262, 264 (3 : 2); 1 H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 8.8 Hz, 1H), 7.30 (d, J = 2.7 Hz, 1H), 7.03 (dd, J = 8.8, 2.7 Hz, 1H), 3.42 (dq, J = 14.2, 7.2 Hz, 4H), 1.24 (dt, J = 14.8, 7.2 Hz, 6H).
[0381] Step B: To a solution of diethylpropylamine (DIPA, 42.46 g, 419.64 mmol) in THF (400 mL) was added n-BuLi (29.32 g, 457.79 mmol, 2.5 M in hexane) dropwise under a nitrogen atmosphere at −78° C. for 0.5 h. After stirring at −78° C. for 20 min, a solution of 3,4-dichlorophenyl N,N-diethylcarbamate (100.00 g, 381.49 mmol) in THF (100 mL) was added dropwise over 20 min at −78° C. After the addition, the resulting mixture was stirred for an additional 0.5 h at −78° C. under a nitrogen atmosphere. To the above mixture was added a solution of I (101.67 g, 400.56 mmol) in THF (50 mL) dropwise over 0.5 h at −78° C. The resulting mixture was stirred at −78° C. for an additional 2 hours. The resulting mixture was quenched with saturated aqueous NaSO (300 mL) at −78° C. and extracted with EA (3×500 mL). The combined organic layers were washed with brine (2×200 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (40 / 1) to give 3,4-dichloro-2-iodophenyl N,N-diethylcarbamate as an off-white solid (117.00 g, 79%): LCMS (ESI) C 11 H 12 Cl2INO2[M + H] + Calculated values: 388, 390 (3 : 2), measured values 388, 390 (3 : 2); 1 H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 8.8 Hz, 1H), 7.08 (d, J = 8.7 Hz, 1H), 3.55 (q, J = 7.1 Hz, 2H), 3.42 (q, J = 7.1 Hz, 2H), 1.35 (t, J = 7.1 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H).
[0382] Step C: To a stirred solution of 3,4-dichloro-2-iodophenyl N,N-diethylcarbamate (65.80 g, 169.58 mmol) in MeOH (100 mL) was added a solution of NaOH (67.82 g, 1695.75 mmol) in HO (200 mL) at 0 °C. The resulting mixture was warmed to 50 °C and stirred for 10 h. The pH value of the solution was adjusted to 6-7 with aqueous HCl (1 N). The reaction mixture was diluted with water (400 mL) at room temperature and extracted with EA (3 × 400 mL). The combined organic layers were washed with brine (3 × 100 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (40 / 1) to give 3,4-dichloro-2-iodophenol as a yellow oil (47.00 g, 96%): 1 H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 8.8 Hz, 1H), 6.90 (d, J = 8.8 Hz, 1H), 6.09 (s, 1H).
[0383] Step D: To a stirred solution of 3,4-dichloro-2-iodophenol (100.00 g, 346.15 mmol) in DMF (300 mL) was added CHI (73.70 g, 519.23 mmol) and KCO (95.68 g, 692.31 mmol) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 5 hours. The reaction was diluted with water (500 mL) at room temperature and extracted with EA (3 × 600 mL). The combined organic layers were washed with brine (3 × 1000 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (20 / 1) to give 1,2-dichloro-3-iodo-4-methoxybenzene as an off-white solid (88.00 g, 84%): 1 H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 8.9 Hz, 1H), 6.69 (d, J = 8.8 Hz, 1H), 3.91 (s, 3H).
[0384] [Example 16] Intermediate 16 (1-(allyloxy)-3,4-dichloro-2-iodobenzene)
[0385] [ka]
[0386] Step A: To a stirred solution of 3,4-dichloro-2-iodophenol (25.00 g, 86.54 mmol) and K2CO3 (35.88 g, 259.61 mmol) in DMF (100 mL) was added 3-bromoprop-1-ene (15.70 g, 129.81 mmol) dropwise at room temperature. The resulting mixture was warmed to 40 °C and stirred for 4 h under a nitrogen atmosphere. After cooling to room temperature, the resulting mixture was diluted with water (300 mL) at room temperature and extracted with EA (3 × 500 mL). The combined organic layers were washed with brine (3 × 500 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (5 / 1) to give 1,2-dichloro-3-iodo-4-(prop-2-en-1-yloxy)benzene as a yellow solid (16.00 g, 50%): 1 H NMR (400 MHz, CD3OD) δ 7.49 (d, J = 8.9 Hz, 1H), 6.88 (d, J = 8.9 Hz, 1H), 6.17-6.00 (m, 1H), 5.54 (dt, J = 17.3, 1.7 Hz, 1H), 5.31 (dt, J = 10.7, 1.7 Hz, 1H), 4.65 (dd, J = 4.0, 2.3 Hz, 2H).
[0387] [Example 17] Intermediate 17 (tert-butyl 4-(1-(4,5-dichloro-2-methoxyphenyl)vinyl)piperidine-1-carboxylate)
[0388] [ka]
[0389] Step A: To a stirred solution of methyltriphenylphosphonium bromide (1.10 g, 3.09 mmol) in THF (15 mL) was added NaH (0.12 g, 3.09 mmol, 60% in mineral oil) in small portions at 0 °C under a nitrogen atmosphere. The reaction mixture was warmed to room temperature and stirred for 15 min. Then, a solution of tert-butyl 4-[(4,5-dichloro-2-methoxyphenyl)carbonyl]piperidine-1-carboxylate (0.80 g, 2.06 mmol) in THF (3 mL) was added. The reaction mixture was stirred at room temperature for an additional 2 h under a nitrogen atmosphere. The resulting mixture was quenched with saturated aqueous NH4Cl (40 mL) and extracted with EA (3 × 10 mL). The combined organic layers were washed with brine (3 × 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (5 / 1) to give tert-butyl 4-[1-(4,5-dichloro-2-methoxyphenyl)ethenyl]piperidine-1-carboxylate as a pale yellow oil (0.50 g, 63%): LCMS (ESI) C 19 H 25 Cl2NO3[M + H] + Calculated values: 386, 388 (3 : 2), measured values 386, 388 (3 : 2); 1 H NMR (400 MHz, CD3OD) δ 7.18 (s, 1H), 7.14 (s, 1H), 5.18 (s, 1H), 4.99 (s, 1H), 4.17-4.07 (m, 2H), 3.82 (s, 3H), 2.83-2.70 (s, 2H), 2.64-2.52 (m, 1H), 1.81-1.70 (m, 2H), 1.50-1.37 (s, 9H), 1.35-1.21 (m, 2H).
[0390] [Example 18] Intermediate 18 ((S)-N-((R)-(3,4-dichloro-2-fluoro-6-hydroxyphenyl)(piperidin-4-yl)methyl)-2-methylpropane-2-sulfinamide)
[0391] [ka]
[0392] Step A: To a solution of 5-bromo-1,2-dichloro-3-fluorobenzene (4.00 g, 16.40 mmol) in THF (50 mL) was added i-PrMgCl LiCl (25 mL, 32.80 mmol, 1.3 M in THF) dropwise at −65 °C under a nitrogen atmosphere for 30 min. After stirring for an additional 30 min, a solution of B(OMe) (2.56 g, 24.60 mmol) in THF (10 mL) was added dropwise at −65 °C. After the addition, the reaction mixture was stirred for 30 min at −65 °C under a nitrogen atmosphere. The resulting mixture was quenched with water (100 mL) at −65 °C and extracted with EA (2 × 300 mL). The combined organic layers were washed with brine (2 × 60 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase chromatography eluting with 50% ACN in water containing 10 mmol / L NH4HCO3 to give (3,4-dichloro-5-fluorophenyl)boronic acid as a yellow solid (0.36 g, 94%): LCMS (ESI) C6H4BCl2FO2[M - H] + Calculated values: 207, 209 (3 : 2), measured values: 207, 209 (3 : 2); 1 H NMR (400 MHz, CD3OD) δ 7.66 (s, 1H), 7.47 (d, J = 9.2 Hz, 1H).
[0393] Step B: To a stirred mixture of (3,4-dichloro-5-fluorophenyl)boronic acid (3.60 g, 18.66 mmol) and KOH (4.19 g, 74.71 mmol, 4.00 equiv.) in MeOH (20 mL) was added dropwise HO (2.54 g, 74.71 mmol, 30% in water) at room temperature under an air atmosphere. The reaction mixture was stirred at room temperature for 2 hours under an air atmosphere. The resulting mixture was quenched with saturated aqueous NaHSO (100 mL) at room temperature, and then the solution was acidified to pH 4 with citric acid. The resulting mixture was extracted with EA (2 × 400 mL). The combined organic layers were washed with brine (2 × 60 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (2 / 1) to give 3,4-dichloro-5-fluorophenol as a yellow solid (2.65 g, 70%): 1 H NMR (400 MHz, CDCl3) 6.83 (s, 1H), 6.64 (dd, J = 9.8, 2.8 Hz, 1H), 5.64 (s, 1H).
[0394] Step C: To a stirred solution of 3,4-dichloro-5-fluorophenol (2.60 g, 14.36 mmol), EtN (4.36 g, 43.09 mmol), and DMAP (3.51 g, 28.73 mmol) in DCM (20 mL) was added dropwise diethylcarbamoyl chloride (2.33 g, 17.24 mmol) at room temperature under a nitrogen atmosphere. After stirring at room temperature for 2 hours under a nitrogen atmosphere, the reaction solution was quenched with water (130 mL) at room temperature and extracted with EA (2 × 200 mL). The combined organic layers were washed with brine (2 × 50 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (6 / 1) to give 3,4-dichloro-5-fluorophenyl N,N-diethylcarbamate as an off-white solid (3.20 g, 70%): LCMS (ESI) C 11 H 12 Cl2FNO2[M + H] +Calculated values: 280, 282 (3 : 2), measured values: 280, 282 (3 : 2); 1 H NMR (400 MHz, CDCl3) δ 7.15 (s, 1H), 7.00 (dd, J = 9.3, 2.6 Hz, 1H), 3.49-3.32 (m, 4H), 1.31-1.15 (m, 6H).
[0395] Step D: To a solution of 3,4-dichloro-5-fluorophenyl N,N-diethylcarbamate (0.50 g, 1.79 mmol) in THF (10 mL) was added LDA (1.34 mL, 2.68 mmol, 2 M in THF) over 10 min at −65° C. under a nitrogen atmosphere. After the addition, the reaction solution was stirred at −65° C. for 30 min, and then a solution of (S)-tert-butyl 4-(((tert-butylsulfinyl)imino)methyl)piperidine-1-carboxylate (0.85 g, 2.68 mmol) in THF (5 mL) was added dropwise over 10 min at −65° C. under a nitrogen atmosphere. After stirring for an additional 1 h at −65° C. under a nitrogen atmosphere, the resulting mixture was quenched with water (30 mL) at −65° C. and extracted with EA (2×70 mL). The combined organic layers were washed with brine (2 × 10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give crude tert-butyl 4-((R)-(3,4-dichloro-6-((diethylcarbamoyl)oxy)-2-fluorophenyl)((S)-1,1-dimethylethylsulfinamido)methyl)piperidine-1-carboxylate. The crude product was used in the next step without further purification: LCMS (ESI) C 26 H 40 Cl2FN3O5S [M + H] + Calculated values: 596, 598 (3:2), measured values: 596, 598 (3:2).
[0396] Step E: To a solution of tert-butyl 4-((R)-(3,4-dichloro-6-((diethylcarbamoyl)oxy)-2-fluorophenyl)((S)-1,1-dimethylethylsulfinamido)methyl)piperidine-1-carboxylate (crude) in MeOH (20 mL) at room temperature was added NaOH (0.45 g, 11.32 mmol) in small portions. The resulting mixture was warmed to 50° C. and stirred for 3 h. After cooling to room temperature, the reaction mixture was diluted with water (20 mL) at room temperature and acidified to pH 4 with citric acid. The resulting solution was extracted with EA (2×200 mL). The combined organic layers were washed with brine (2×10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase chromatography eluting with 60% ACN in water (+0.05% TFA) to give tert-butyl 4-[(S)-(3,4-dichloro-2-fluoro-6-hydroxyphenyl)([[(R)-2-methylpropane-2-sulfinyl]amino])methyl]piperidine-1-carboxylate as a yellow solid (0.60 g, 68% over two steps): LCMS (ESI) C 21 H 31 Cl2FN2O4S [M + H] + Calculated values: 497, 499 (3 : 2), Measured values: 497, 499 (3 : 2); 1 H NMR (400 MHz, CDCl3) δ 6.89 (d, J = 1.8 Hz, 1H), 4.59 (d, J = 8.2 Hz, 1H), 4.27-3.92 (m, 2H), 2.80-2.51 (m, 2H), 2.09-1.98 (m, 2H), 1.54-1.46 (m, 3H), 1.45 (s, 9H), 1.20 (s, 9H).
[0397] Step F: To a solution of crude tert-butyl 4-[(S)-(3,4-dichloro-2-fluoro-6-hydroxyphenyl)([[(R)-2-methylpropane-2-sulfinyl]amino])methyl]piperidine-1-carboxylate (crude) in DCM (10 mL) was added dropwise TFA (2 mL) at room temperature. The reaction solution was stirred at room temperature for 1 hour. The resulting solution was adjusted to pH 8 with saturated aqueous NaHCO3 and extracted with EA (2 × 80 mL). The combined organic layers were washed with brine (2 × 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give crude (R)-N-[(S)-(3,4-dichloro-2-fluoro-6-hydroxyphenyl)(piperidin-4-yl)methyl]-2-methylpropane-2-sulfinamide as a pale yellow oil (0.40 g, 83%). The crude product was used directly in the next step without further purification: LCMS (ESI) C 16 H 23 Cl2FN2O2S [M + H] + Calculated values: 397, 399 (3 : 2), measured values 397, 399 (3 : 2); 1 H NMR (400 MHz, CD3OD) δ 6.76 (s, 1H), 4.28 (d, J = 7.6 Hz, 1H), 3.52-3.40 (m, 1H), 3.30-3.20 (m, 1H), 3.03-2.80 (m, 2H), 2.55-2.40 (m, 1H), 2.38-2.22 (m, 1H), 1.59-1.37 (m, 3H), 1.10 (s, 9H).
[0398] [Example 19] Intermediate 19 (Lithio(2R)-1-methyl-5-oxopyrrolidine-2-carboxylate)
[0399] [ka]
[0400] Step A: To a stirred solution of ethyl (2R)-5-oxopyrrolidine-2-carboxylate (0.50 g, 3.18 mmol) in THF (4 mL) was added NaH (0.25 g, 6.36 mmol, 60% in mineral oil) at 0° C. under a nitrogen atmosphere. The resulting mixture was stirred at 0° C. for 10 minutes. Then, MeI (0.90 g, 6.36 mmol) was added to the mixture. The resulting mixture was stirred at 0° C. for 1 hour under a nitrogen atmosphere. The reaction was quenched with water (3 mL) at 0° C. The resulting mixture was diluted with DCM (30 mL) and water (30 mL), and then the aqueous layer was extracted with DCM (3×30 mL). The combined organic layers were washed with brine (3×20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give ethyl (2R)-1-methyl-5-oxopyrrolidine-2-carboxylate as a pale yellow oil (0.22 g, 40%): LCMS (ESI) C8H 13 NO3[M + H] + Calculated value: 172 Measured value 172; 1 H NMR (400 MHz, CDCl3) δ 4.26 (q, J = 8.6, 7.9 Hz, 2H), 4.18-4.08 (m, 1H), 2.89 (s, 3H), 2.58-2.29 (m, 3H), 2.16-2.05 (m, 1H), 1.44-1.30 (m, 3H).
[0401] Step B: To a stirred solution of ethyl (2R)-1-methyl-5-oxopyrrolidine-2-carboxylate (0.15 g, 0.95 mmol) in MeOH (2 mL) at room temperature was added a solution of LiOH HO (48 mg, 1.15 mmol) in HO (2 mL). The reaction mixture was stirred at room temperature for 16 h. The resulting solution was concentrated under reduced pressure to give lithio (2R)-1-methyl-5-oxopyrrolidine-2-carboxylate as an off-white solid (0.15 g, crude), which was used directly in the next step without further purification: LCMS (ESI) C6H9NO3 [M + H] + Calculated value: 144, Measured value: 144.
[0402] [Example 20] Intermediate 20 (1-Bromo-5-chloro-4-cyclobutyl-2-methoxybenzene)
[0403] [ka]
[0404] Step A: To a stirred mixture of 4-chloro-3-iodophenol (3.00 g, 11.79 mmol) and K2CO3 (3.26 g, 23.59 mmol) in DMF (30 mL) was added dropwise CHI (2.51 g, 17.69 mmol) at room temperature. The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with EA (50 mL) and water (100 mL). The aqueous solution was extracted with EA (3 x 50 mL). The combined organic layers were washed with brine (6 x 30 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (20 / 1) to give 1-chloro-2-iodo-4-methylbenzene as a colorless oil (2.90 g, 92%): 1 H NMR (400 MHz, CD3OD) δ 7.47-7.41 (m, 1H), 7.41-7.33 (m, 1H), 6.99-6.90 (m, 1H), 3.78 (s, 3H).
[0405] Step B: To a stirred solution of 1-chloro-2-iodo-4-methoxybenzene (1.00 g, 3.73 mmol) in THF (5 mL) was added n-BuLi (2.2 mL, 5.59 mmol, 2.5 M solution in hexane) dropwise at −78° C. under a nitrogen atmosphere. The solution was stirred at −78° C. for 30 minutes under a nitrogen atmosphere. Cyclobutanone (0.39 g, 5.59 mmol) was then added to the solution. The resulting solution was stirred at −78° C. for 1 hour under a nitrogen atmosphere. The reaction was quenched with saturated aqueous NH4Cl (3 mL). The resulting mixture was diluted with EA (30 mL) and water (30 mL), and the aqueous solution was then extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (3 × 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (3 / 1) to give 1-(2-chloro-5-methoxyphenyl)cyclobutan-1-ol as a pale yellow oil (0.56 g, 71%): 1 H NMR (400 MHz, CD3OD) δ 7.28 (dd, J = 8.7, 1.5 Hz, 1H), 6.96 (d, J = 3.0 Hz, 1H), 6.83 (dd, J = 8.7, 2.2 Hz, 1H), 3.81 (s, 3H), 2.75-2.63 (m, 2H), 2.50-2.37 (m, 2H), 2.23-2.12 (m, 1H), 1.78-1.66 (m, 1H).
[0406] Step C: To a stirred solution of 1-(2-chloro-5-methoxyphenyl)cyclobutan-1-ol (0.56 g, 2.63 mmol) and EtSiH (0.61 mg, 5.27 mmol) in DCM (3 mL) was added BF·EtO (0.75 g, 5.27 mmol) at room temperature under a nitrogen atmosphere. The solution was stirred at room temperature under a nitrogen atmosphere for 1 hour. The reaction was quenched with water (5 mL) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (20 / 1) to give 1-chloro-2-cyclobutyl-4-methoxybenzene as a colorless oil (0.49 g, 95%):1 H NMR (400 MHz, CD3OD) δ 7.21 (d, J = 8.7 Hz, 1H), 6.90 (d, J = 3.0 Hz, 1H), 6.74 (dd, J = 8.7, 3.0 Hz, 1H), 3.81 (s, 3H), 3.79-3.72 (m, 1H), 2.47-2.33 (m, 2H), 2.19-1.97 (m, 3H), 1.92-1.81 (m, 1H).
[0407] Step D: To a stirred solution of 1-chloro-2-cyclobutyl-4-methoxybenzene (0.48 g, 2.44 mmol) in HOAc (5 mL) was added dropwise Br (0.43 g, 2.69 mmol) at room temperature. The solution was stirred at room temperature for 1 hour. The reaction was quenched with saturated aqueous NaSO (2 mL) and diluted with EA (30 mL) and water (30 mL). The aqueous solution was extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (3 × 20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (20 / 1) to give 1-bromo-5-chloro-4-cyclobutyl-2-methoxybenzene as a colorless liquid (0.60 g, 72%): 1 H NMR (400 MHz, CD3OD) δ 7.48 (s, 1H), 6.98 (s, 1H), 3.92 (s, 3H), 3.83-3.71 (m, 1H), 2.51-2.34 (m, 2H), 2.24-2.02 (m, 3H), 1.94-1.80 (m, 1H).
[0408] [Example 21] Intermediate 21 (1-Bromo-5-chloro-4-fluoro-2-(prop-2-en-1-yloxy)benzene)
[0409] [ka]
[0410] Step A: To a stirred solution of 4-chloro-3-fluorophenol (2.00 g, 13.65 mmol) in DCM (15 mL) was added Br (2.62 g, 16.40 mmol) at room temperature. The resulting solution was stirred at room temperature for 1 hour. The reaction was quenched with saturated aqueous NaSO (30 mL) at room temperature. The aqueous layer was extracted with EA (3 × 50 mL). The combined organic layers were washed with brine (3 × 20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give 2-bromo-4-chloro-5-fluorophenol as a pale yellow oil (3.40 g, crude), which was used directly in the next step without further purification: 1 H NMR (400 MHz, CD3OD) δ 7.58 (d, J = 7.9 Hz, 1H), 6.79 (d, J = 10.5 Hz, 1H).
[0411] Step B: To a stirred mixture of 2-bromo-4-chloro-5-fluorophenol (3.40 g, 15.08 mmol) and K2CO3 (4.17 g, 30.17 mmol) in DMF (30 mL) was added 3-bromoprop-1-ene (2.74 g, 22.65 mmol) dropwise at room temperature. The resulting mixture was stirred at room temperature for 1 hour. The reaction was diluted with EA (50 mL) and water (50 mL). The aqueous solution was extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (6 × 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (20 / 1) to give 1-bromo-5-chloro-4-fluoro-2-(prop-2-en-1-yloxy)benzene as a colorless oil (2.40 g, 60%): 1H NMR (400 MHz, CD3OD) δ 7.68 (d, J = 7.9 Hz, 1H), 7.05 (d, J = 11.0 Hz, 1H), 6.14-6.02 (m, 1H), 5.50 (d, J = 17.2 Hz, 1H), 5.33 (d, J = 10.6 Hz, 1H), 4.65 (d, J = 4.3 Hz, 2H).
[0412] [Example 22] Intermediate 22 (tert-butyl 8-[methoxy(methyl)carbamoyl]-3-azabicyclo[3.2.1]octane-3-carboxylate)
[0413] [ka]
[0414] Step A: To a stirred solution of methyl 3-azabicyclo[3.2.1]octane-8-carboxylate hydrochloride (0.50 g, 2.43 mmol) and EtN (0.98 g, 9.72 mmol) in DCM (6 mL) was added BocO (0.80 g, 3.65 mmol) at room temperature. The reaction was stirred at room temperature for 1 h. The reaction was diluted with EA (20 mL) and water (30 mL). The aqueous solution was extracted with EA (3 × 20 mL). The combined organic layers were washed with brine (2 × 20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was evaporated under reduced pressure to give 3-tert-butyl 8-methyl 3-azabicyclo[3.2.1]octane-3,8-dicarboxylate as a yellow oil (0.65 g, crude), which was used directly in the next step without further purification: LCMS (ESI) C 14 H 23 NO4[M + H - 15] + Calculated value: 255, measured value 255; 1H NMR (400 MHz, CDCl3) δ 3.90 (d, J = 60.4 Hz, 1H), 3.79-3.60 (m, 4H), 3.17 (d, J = 41.4 Hz, 1H), 2.97-2.77 (m, 1H), 2.69-2.41 (m, 3H), 1.85-1.61 (m, 4H), 1.47 (d, J = 3.7 Hz, 9H).
[0415] Step B: To a stirred solution of 3-tert-butyl 8-methyl 3-azabicyclo[3.2.1]octane-3,8-dicarboxylate (0.65 g, 2.41 mmol) in MeOH (5 mL) was added a solution of NaOH (0.19 g, 4.83 mmol) in water (2 mL) at room temperature. The reaction was stirred at 40° C. for 1 h. After cooling to room temperature, the resulting solution was diluted with EA (20 mL) and water (30 mL). The aqueous solution was acidified to pH 3 with citric acid and then extracted with EA (3×30 mL). The combined organic layers were washed with brine (2×20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was evaporated under reduced pressure to give 3-(tert-butoxycarbonyl)-3-azabicyclo[3.2.1]octane-8-carboxylic acid as a yellow oil (0.70 g, crude), which was used directly in the next step without further purification: LCMS (ESI) C 13 H 21 NO4[M + H -56] + Calculated value: 200, measured value 200; 1 H NMR (400 MHz, CD3OD) δ 3.88 (d, J = 12.5 Hz, 1H), 3.68 (d, J = 13.1 Hz, 1H), 3.32-3.13 (m, 1H), 3.05-2.75 (m, 3H), 2.73-2.36 (m, 2H), 1.89-1.74 (m, 2H), 1.64-1.55 (m, 1H), 1.47 (s, 9H).
[0416] Step C: To a stirred solution of 3-(tert-butoxycarbonyl)-3-azabicyclo[3.2.1]octane-8-carboxylic acid (0.70 g, 2.74 mmol), HOBt (0.56 g, 4.11 mmol), and EDCI (0.79 g, 4.11 mmol) in DMF (6 mL) was added N,O-dimethylhydroxylamine hydrochloride (0.40 g, 4.11 mmol) and EtN (0.55 g, 5.48 mmol) at room temperature. The reaction was stirred at room temperature for 16 hours. The reaction was diluted with EA (30 mL) and water (30 mL). The aqueous solution was extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (6 × 10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was evaporated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (2 / 1) to give tert-butyl 8-[methoxy(methyl)carbamoyl]-3-azabicyclo[3.2.1]octane-3-carboxylate as a pale yellow oil (0.43 g, 53%): LCMS (ESI) C 15 H 26 N2O4[M + H - 56] + Calculated value: 243, measured value 243; 1 H NMR (400 MHz, CDCl3) δ 3.91 (d, J = 47.8 Hz, 1H), 3.73 (d, J = 10.9 Hz, 3H), 3.69-3.39 (m, 2H), 3.21 (d, J = 12.8 Hz, 3H), 3.03-2.84 (m, 1H), 2.74 (d, J = 17.2 Hz, 1H), 2.55-2.33 (m, 3H), 2.03-1.88 (m, 1H), 1.84-1.57 (m, 2H), 1.47 (d, J = 7.2 Hz, 9H).
[0417] [Example 23] Intermediate 23 ((S)-N-[(R)-(4-bromo-5-chloro-2-methoxyphenyl)([1-[(4R)-2,2-dimethyl-1,3-dioxolane-4-carbonyl]piperidin-4-yl])methyl]-2-methylpropane-2-sulfinamide)
[0418] [ka]
[0419] Step A: To a stirred mixture of 3-bromo-4-chlorophenol (5.00 g, 24.10 mmol) and K2CO3 (9.99 g, 72.31 mmol) in THF (50 mL) was added MeI (10.26 g, 72.31 mmol) dropwise at 40 °C. The reaction mixture was stirred at 40 °C for 16 h. The resulting mixture was diluted with water (50 mL) and extracted with EA (3 × 100 mL). The combined organic layers were washed with brine (2 × 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE to give 2-bromo-1-chloro-4-methoxybenzene as a colorless oil (4.50 g, 84%): 1 H NMR (400 MHz, CD3OD) δ 7.41 (d, J = 8.9 Hz, 1H), 7.26 (d, J = 2.9 Hz, 1H), 6.93 (dd, J = 8.9, 2.9 Hz, 1H), 3.81 (s, 3H).
[0420] Step B: To a stirred solution of 2-bromo-1-chloro-4-methoxybenzene (2.00 g, 9.03 mmol) in DCM (20 mL) was added AgOTf (2.55 g, 9.93 mmol) at room temperature. After the addition, I (2.52 g, 9.93 mmol) was added to the reaction, and the mixture was stirred at room temperature for 3 hours. The reaction was quenched with saturated aqueous NaSO (50 mL) at room temperature and extracted with EA (3 × 60 mL). The combined organic layers were washed with brine (3 × 50 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE to give 1-bromo-2-chloro-4-iodo-5-methoxybenzene as an off-white solid (2.50 g, 80%): 1H NMR (400 MHz, CDCl3) δ 7.84 (s, 1H), 7.04 (s, 1H), 3.89 (s, 3H).
[0421] Step C: To a solution of 1-bromo-2-chloro-4-iodo-5-methoxybenzene (10.00 g, 28.79 mmol) in THF (20 mL) was added n-BuLi (11.5 mL, 28.75 mmol, 2.5 M in hexane) dropwise over 10 minutes at −90° C. under a nitrogen atmosphere. The solution was stirred at the same temperature for 30 minutes. A solution of tert-butyl 4-[[(S)-2-methylpropane-2-sulfinyl]imino]methyl]piperidine-1-carboxylate (9.10 g, 28.79 mmol) in THF (10 mL) was added quickly to the above solution at −90° C. (The reaction temperature rose from −90° C. to −70° C.). After the addition, the reaction was stirred at −75° C. for an additional 1.5 hours. The reaction was quenched with saturated aqueous NH4Cl (20 mL) and then diluted with water (100 mL). The aqueous phase was extracted with EA (3 × 100 mL). The combined organic layers were washed with brine (2 × 50 mL), dried over anhydrous NaSO, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase chromatography eluting with 60% ACN in water containing 10 mmol / L NHHCO to give tert-butyl 4-[(R)-(4-bromo-5-chloro-2-methoxyphenyl)([[(S)-2-methylpropane-2-sulfinyl]amino])methyl]piperidine-1-carboxylate as an off-white solid (12.40 g, 80%): LCMS (ESI) C 22 H 34 BrClN2O4S [M + H] + Calculated values: 537, 539 (2 : 3 : 1), measured values 537, 539 (2 : 3 : 1); 1H NMR (400 MHz, CD3OD) δ 7.43 (s, 1H), 7.30 (s, 1H), 4.44 (d, J = 8.9 Hz, 1H), 4.16 (d, J = 13.4 Hz, 1H), 4.01 (d, J = 13.1 Hz, 1H), 3.85 (s, 3H), 2.84-2.57 (m, 2H), 2.17-2.05 (m, 1H), 2.02-1.84 (m, 1H), 1.545 (s, 9H), 1.30-1.08 (m, 3H), 1.13 (s, 9H).
[0422] Step D: To a stirred solution of tert-butyl 4-[(R)-(4-bromo-5-chloro-2-methoxyphenyl)([[(S)-2-methylpropane-2-sulfinyl]amino])methyl]piperidine-1-carboxylate (6.00 g, 11.19 mmol) in DCM (60 mL) was added dropwise at room temperature TFA (10 mL). The resulting mixture was stirred at room temperature for 30 minutes. The reaction was neutralized with saturated aqueous NaHCO3 (50 mL) at room temperature. The aqueous layer was extracted with DCM (3 x 200 mL). The combined organic layers were concentrated under reduced pressure to give (S)-N-[(R)-(4-bromo-5-chloro-2-methoxyphenyl)(piperidin-4-yl)methyl]-2-methylpropane-2-sulfinamide as a yellow oil (4.60 g, crude). The crude product was used directly in the next step without further purification: LCMS (ESI) C 17 H 26 BrClN2O2S [M + H] + Calculated values: 437, 439 (2 : 3 : 1), measured values: 437, 439 (2 : 3 : 1); 1H NMR (400 MHz, CD3OD) δ 7.45 (s, 1H), 7.35 (s, 1H), 4.50 (d, J = 9.1 Hz, 1H), 3.90 (s, 3H), 3.47 (d, J = 12.8 Hz, 1H), 3.30-3.25 (m, 1H), 3.01-2.80 (m, 2H), 2.42-2.33 (m, 1H), 2.19-2.06 (m, 1H), 1.57-1.28 (m, 3H), 1.14 (s, 9H).
[0423] Step E: To a stirred solution of (4R)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid (1.70 g, 11.63 mmol) and HATU (4.43 g, 11.65 mmol) in DMF (10 mL) was added (S)—N—[(R)-(4-bromo-5-chloro-2-methoxyphenyl)(piperidin-4-yl)methyl]-2-methylpropane-2-sulfinamide (3.40 g, 7.76 mmol) and EtN (2.36 g, 23.29 mmol) at room temperature. The resulting solution was stirred at room temperature for 1 hour. The resulting solution was quenched with water (60 mL) and extracted with EA (3 × 100 mL). The combined organic layers were washed with brine (2 × 30 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase chromatography eluting with 70% ACN in water containing 10 mmol / L NH4HCO3 to give (S)-N-[(R)-(4-bromo-5-chloro-2-methoxyphenyl)([1-[(4R)-2,2-dimethyl-1,3-dioxolane-4-carbonyl]piperidin-4-yl])methyl]-2-methylpropane-2-sulfinamide as an off-white solid (3.80 g, 86%): LCMS (ESI) C 23 H 34 BrClN2O5S [M + H] + Calculated values: 565, 567 (2 : 3 : 1), measured values 565, 567 (2 : 3 : 1); 1H NMR (400 MHz, CD3OD) δ 7.43 (d, J = 2.7 Hz, 1H), 7.31 (d, J = 1.8 Hz, 1H), 5.48-5.32 (dd, J = 33.5, 7.5 Hz, 1H), 4.59-4.37 (m, 2H), 4.20-4.10 (m, 1H), 4.32-4.18 (m, 2H), 3.88 (d, J = 2.2 Hz, 3H), 3.20-2.90 (m, 1H), 2.73-2.56 (m, 1H), 2.25-2.06 (m, 2H), 1.48-1.33 (m, 8H), 1.17-1.09 (m, 10H).
[0424] [Example 24] Intermediate 24 ((S)-N-[(R)-[4-bromo-5-chloro-2-(prop-2-en-1-yloxy)phenyl]([1-[(4R)-2,2-dimethyl-1,3-dioxolane-4-carbonyl]piperidin-4-yl])methyl]-2-methylpropane-2-sulfinamide)
[0425] [ka]
[0426] Step A: To a stirred solution of 1-bromo-2-chloro-4-iodo-5-methoxybenzene (47.00 g, 135.30 mmol) in DCM (470 mL) was added BBr (101.00 g, 405.90 mmol) dropwise under a nitrogen atmosphere at 0 °C. The reaction solution was stirred at room temperature under a nitrogen atmosphere for 20 h. The reaction was quenched with water (500 mL) at 0 °C and extracted with EA (3 × 500 mL). The combined organic layers were washed with brine (3 × 500 mL) and dried over anhydrous Na SO . After filtration, the filtrate was concentrated under reduced pressure to give 5-bromo-4-chloro-2-iodophenol as a pale yellow solid (45.50 g, 95%), which was used in the next step without further purification.
[0427] Step B: To a stirred solution of 5-bromo-4-chloro-2-iodophenol (45.20 g, 141.59 mmol) in DMF (100 mL) was added dropwise K2CO3 (39.14 g, 283.18 mmol) and allyl bromide (29.12 g, 240.70 mmol) under a nitrogen atmosphere at room temperature. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 1 hour. The resulting mixture was diluted with water (200 mL). The resulting mixture was extracted with EA (3 x 200 mL). The combined organic layers were washed with brine (3 x 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE to give 1-bromo-2-chloro-4-iodo-5-(prop-2-en-1-yloxy)benzene as a colorless oil (28.50 g, 54%): 1 H NMR (400 MHz, CDCl3) δ 7.85 (d, J = 1.0 Hz, 1H), 7.02 (d, J = 0.9 Hz, 1H), 6.12-5.98 (m, 1H), 5.53 (dq, J = 17.2, 1.6 Hz, 1H), 5.37 (dq, J = 10.7, 1.4 Hz, 1H), 4.59 (dq, J = 4.6, 1.5 Hz, 2H).
[0428] Step C: To a stirred solution of 1-bromo-2-chloro-4-iodo-5-(prop-2-en-1-yloxy)benzene (10.00 g, 26.78 mmol) in THF (250 mL) was added n-BuLi (10.71 mL, 26.78 mmol, 2.5 M in hexane) dropwise at −100° C. under a nitrogen atmosphere. After stirring at −100° C. for 30 minutes under a nitrogen atmosphere, a solution of tert-butyl 4-[[(S)-2-methylpropane-2-sulfinyl]imino]methyl]piperidine-1-carboxylate (8.47 g, 26.7 mmol) in THF (40 mL) was added dropwise to the above mixture at −100° C. The resulting mixture was stirred at −100° C. for an additional hour. The reaction was quenched with saturated aqueous NH4Cl (200 mL) at −100° C. The aqueous layer was extracted with EA (3 x 200 mL). The combined organic layers were concentrated under reduced pressure. The residue was purified by reverse-phase chromatography eluting with 70% ACN in water (+0.05% TFA) to give tert-butyl 4-[(R)-[4-bromo-5-chloro-2-(prop-2-en-1-yloxy)phenyl]([[(S)-2-methylpropane-2-sulfinyl]amino])methyl]piperidine-1-carboxylate as a pale yellow oil (10.00 g, 60%): LCMS (ESI) C 24 H 36 BrClN2O4S [M + H] + Calculated values: 563, 565 (2 : 3 : 1), measured values: 563, 565 (2 : 3 : 1); 1 H NMR (400 MHz, CDCl3) δ 7.22 (s, 1H), 7.12 (s, 1H), 6.11-5.96 (m, 1H), 5.48-5.30 (m, 2H), 4.61-4.55 (m, 2H), 4.46 (s, 1H), 4.24-4.02 (m, 2H), 2.74-2.47 (m, 2H), 2.03-1.77 (m, 2H), 1.46 (s, 9H), 1.40-1.11 (m, 3H), 1.18 (s, 9H).
[0429] Step D: To a stirred solution of tert-butyl 4-[(R)-[4-bromo-5-chloro-2-(prop-2-en-1-yloxy)phenyl]([[(S)-2-methylpropane-2-sulfinyl]amino])methyl]piperidine-1-carboxylate (5.60 g, 9.96 mol) in DCM (50 mL) was added TFA (10 mL) dropwise at room temperature. The reaction solution was stirred at room temperature for 0.5 h. The reaction was neutralized with saturated aqueous NaHCO3 at room temperature. The aqueous layer was extracted with EA (3 × 100 mL). The combined organic layers were concentrated under reduced pressure to give (S)—N—[(R)-[4-bromo-5-chloro-2-(prop-2-en-1-yloxy)phenyl](piperidin-4-yl)methyl]-2-methylpropane-2-sulfinamide as a pale yellow semisolid (5.30 g, crude). The crude product was used directly in the next step without further purification: LCMS (ESI) C 19 H 28 BrClN2O2S [M + H] + Calculated values: 463, 465 (2 : 3 : 1), measured values: 463, 465 (2 : 3 : 1); 1 H NMR (400 MHz, CDCl3) δ 7.25 (s, 1H), 7.13 (s, 1H), 6.08-5.98 (m, 1H), 5.46-5.34 (m, 2H), 4.62-4.51 (m, 2H), 4.45-4.36 (s, 1H), 4.25-4.18 (m, 1H), 3.49-3.34 (dd, J = 32.3, 12.9 Hz, 2H), 2.90-2.73 (m, 2H), 2.26-1.97 (m, 2H), 1.80-1.52 (m, 3H), 1.18 - 1.09 (s, 9H).
[0430] Step E: To a stirred solution of (4R)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid (2.50 g, 17.13 mmol) and HATU (6.52 g, 17.13 mmol) in DMF (30 mL) was added (S)—N—[(R)-[4-bromo-5-chloro-2-(prop-2-en-1-yloxy)phenyl](piperidin-4-yl)methyl]-2-methylpropane-2-sulfinamide (5.30 g, 11.42 mmol) and EtN (3.47 g, 34.27 mmol) at room temperature. The reaction solution was stirred at room temperature for 1 hour. The resulting solution was quenched with water (60 mL) and extracted with EA (3 × 100 mL). The combined organic layers were washed with brine (2 × 30 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase chromatography eluting with 70% ACN in water containing 10 mmol / L NH4HCO3 to give (S)-N-[(R)-[4-bromo-5-chloro-2-(prop-2-en-1-yloxy)phenyl]([1-[(4R)-2,2-dimethyl-1,3-dioxolane-4-carbonyl]piperidin-4-yl])methyl]-2-methylpropane-2-sulfinamide as an off-white solid (3.80 g, 54%): LCMS (ESI) C 25 H 36 BrClN2O5S [M + H] + Calculated values: 591, 593 (2 : 3 : 1), measured values 591, 593 (2 : 3 : 1); 1 H NMR (400 MHz, CDCl3) δ 7.24 (d, J = 22.6 Hz, 1H), 7.12 (s, 1H), 6.07-5.97 (m, 1H), 5.46-5.30 (m, 2H), 4.68-4.58 (m, 2H), 4.60-4.50 (m, 3H), 4.49-4.33 (m, 1H), 4.21-4.01 (m, 2H), 3.92-3.88 (m, 1H) 3.09-2.82 (m, 1H), 2.56 (t, J = 12.7 Hz, 1H), 2.19-1.96 (m, 2H), 1.57-1.25 (m, 9H), 1.17 (d, J = 11.7 Hz, 9H).
[0431] [Example 25] Intermediate 25 ((S)-N-((R)-(2-(allyloxy)-5-chloro-4-methylphenyl)(piperidin-4-yl)methyl)-2-methylpropane-2-sulfinamide)
[0432] [ka]
[0433] Step A: To a stirred solution of 2-bromo-5-methylphenol (42.00 g, 224.56 mmol) in 1,1,1,3,3,3-hexafluoropropan-2-ol (500 mL) was added NCS (31.00 g, 235.78 mmol) in small portions at room temperature under air. The reaction solution was warmed to 50° C. and stirred for 16 hours under air. After cooling to room temperature, the resulting solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (50 / 1) to give 2-bromo-4-chloro-5-methylphenol as a pale yellow solid (47.00 g, 90%): 1 H NMR (400 MHz, CDCl3) δ 7.45 (s, 1H), 6.93 (d, J = 0.8 Hz, 1H), 2.32 (d, J = 0.7 Hz, 3H).
[0434] Step B: To a stirred mixture of 2-bromo-4-chloro-5-methylphenol (31.00 g, 0.14 mol) and K2CO3 (39.00 g, 0.28 mol) in DMF (300 mL) was added dropwise allyl bromide (29.00 g, 0.24 mol) under air atmosphere at room temperature. The reaction mixture was stirred at 40 °C under air atmosphere for 16 h. After cooling to room temperature, the resulting mixture was diluted with water (300 mL) and extracted with EA (3 × 150 mL). The combined organic layers were washed with brine (6 × 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (100 / 1) to give 1-bromo-5-chloro-4-methyl-2-(prop-2-en-1-yloxy)benzene as a colorless oil (24.50 g, 66%): 1 H NMR (400 MHz, CDCl3) δ 7.53 (s, 1H), 6.77 (s, 1H), 6.12-6.02 (m, 1H), 5.50 (d, J = 17.3 Hz, 1H), 5.34 (d, J = 10.4 Hz, 1H), 4.63-4.56 (m, 2H), 2.34 (s, 3H).
[0435] Step C: To a stirred solution of 1-bromo-5-chloro-4-methyl-2-(prop-2-en-1-yloxy)benzene (29.00 g, 0.12 mol) in THF (900 mL) was added n-BuLi (48 mL, 0.12 mol, 2.5 M in hexane) dropwise at −90° C. under a nitrogen atmosphere. After stirring for 40 minutes at −90° C. under a nitrogen atmosphere, a solution of tert-butyl 4-[[(S)-2-methylpropane-2-sulfinyl]imino]methyl]piperidine-1-carboxylate (35.57 g, 0.12 mol) in THF (80 mL) was added dropwise to the stirred solution at −90° C. over 20 minutes under a nitrogen atmosphere. The resulting mixture was stirred for an additional hour at −90° C. under a nitrogen atmosphere. The reaction was quenched with saturated aqueous NH4Cl (100 mL) at −90° C. The reaction solution was concentrated under reduced pressure to remove THF. The aqueous layer was extracted with EA (3 × 600 mL). The combined organic layers were washed with brine (3 × 200 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1 / 1) to give tert-butyl 4-[(R)-[5-chloro-4-methyl-2-(prop-2-en-1-yloxy)phenyl]([[(S)-2-methylpropane-2-sulfinyl]amino])methyl]piperidine-1-carboxylate as a pale yellow oil (25.40 g, 44%): LCMS (ESI) C 25 H 39 ClNOS [M + H] + Calculated values: 499, 501 (3 : 1), measured values: 499, 501 (3 : 1); 1H NMR (400 MHz, CDCl3) δ 7.09 (s, 1H), 6.74 (s, 1H), 6.10-5.93 (m, 1H), 5.47-5.26 (m, 2H), 4.61-4.50 (m, 2H), 4.41-4.28 (m, 1H), 4.21-4.04 (m, 2H), 3.95-3.73 (m, 1H), 2.82-2.47 (m, 2H), 2.41 (s, 3H), 2.10-1.96 (m, 1H), 1.93-1.75 (m, 1H), 1.47 (s, 9H), 1.37-1.21 (m, 3H), 1.12 (s, 9H).
[0436] Step D: To a stirred solution of tert-butyl 4-[(R)-[5-chloro-4-methyl-2-(prop-2-en-1-yloxy)phenyl]([[(S)-2-methylpropane-2-sulfinyl]amino])methyl]piperidine-1-carboxylate (48.00 g, 95.77 mmol) in DCM (380 mL) at room temperature was added TFA (96 mL) dropwise. The resulting mixture was stirred at room temperature for an additional 1 h. The mixture was basified to pH 8 with saturated aqueous NaHCO3. The resulting mixture was extracted with EA (3 × 1 L). The combined organic layers were washed with brine (3 × 300 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give (S)-N-[(R)-[5-chloro-4-methyl-2-(prop-2-en-1-yloxy)phenyl](piperidin-4-yl)methyl]-2-methylpropane-2-sulfinamide as a pale yellow oil (33.10 g, 88%): LCMS (ESI) C 20 H 31 ClN2O2S [M + 1] + Calculated values: 399, 401 (3 : 1), Measured values: 399, 401 (3 : 1); 1H NMR (400 MHz, CDCl3) δ 7.10 (s, 1H), 6.75 (s, 1H), 6.08-5.93 (m, 1H), 5.44-5.21 (m, 2H), 4.60-4.47 (m, 2H), 4.34-4.22 (m, 2H), 3.43 (d, J = 13.0 Hz, 1H), 3.34 (d, J = 13.0 Hz, 1H), 2.88-2.72 (m, 2H), 2.34 (s, 3H), 2.12 (d, J = 10.5 Hz, 2H), 1.69-1.51 (m, 3H), 1.10 (s, 9H).
[0437] [Example 26] Intermediate 26 (N-[(1-acetylpiperidin-4-yl)(4,5-dichloro-2-methoxyphenyl)methylidene]-2-methylpropane-2-sulfinamide)
[0438] [ka]
[0439] Step A: To a stirred solution of 1-[4-[(4,5-dichloro-2-methoxyphenyl)carbonyl]piperidin-1-yl]ethan-1-one (0.30 g, 0.91 mmol) and Ti(OEt) (0.41 g, 1.82 mmol) in THF (10 mL) was added 2-methylpropane-2-sulfinamide (0.22 g, 1.82 mmol) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred at 70 °C for 16 h under a nitrogen atmosphere. After cooling to room temperature, the reaction was quenched with saturated aqueous NH Cl (50 mL) at room temperature and extracted with EA (3 × 50 mL). The combined organic layers were washed with brine (2 × 50 mL) and dried over anhydrous Na SO . After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (2 / 1) to give N-[(1-acetylpiperidin-4-yl)(4,5-dichloro-2-methoxyphenyl)methylidene]-2-methylpropane-2-sulfinamide as a pale yellow oil (0.27 g, 68%): LCMS (ESI) C 19 H 26 Cl2N2O3S[M + H] + Calculated values: 433, 435 (3:2), measured values: 433, 435 (3:2).
[0440] [Example 27] Intermediate 27 ((2R,3S)-3-(benzoyloxy)oxolane-2-carboxylic acid)
[0441] [ka]
[0442] Step A: To a solution of (4R,5S)-5-(hydroxymethyl)oxolane-2,4-diol (15.00 g, 111.83 mmol) in MeOH (130 mL) at 0 °C was added H2SO4 (1.49 mL, 27.95 mmol, 97%) in MeOH (20 mL). The reaction was stirred at 0 °C to room temperature for 16 h. The mixture was neutralized to pH 7 with saturated aqueous NaHCO3. The resulting mixture was filtered, and the filter cake was washed with MeOH (3 × 20 mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1 / 4) to give (2S,3R)-2-(hydroxymethyl)-5-methoxyoxolan-3-ol as a pale yellow oil (15.00 g, 91%): 1 H NMR (400 MHz, DMSO-d6) δ 4.64 (t, J = 3.3 Hz, 1H), 4.52 (d, J = 5.5 Hz, 1H), 4.48-4.44 (m, 1H), 3.80-3.73 (m, 1H), 3.57-3.52 (m, 2H), 3.52-3.46 (m, 1H), 3.24-3.22 (m, 3H), 1.87-1.80 (m, 1H), 1.53 (dt, J = 12.8, 4.0 Hz, 1H).
[0443] Step B: A solution of (2S,3R)-2-(hydroxymethyl)-5-methoxyoxolan-3-ol (5.00 g, 33.75 mmol) and bis(trimethylsilyl)trifluoroacetamide (17.37 g, 67.48 mmol) in ACN (5 mL) was stirred at 80 °C for 5 hours. After cooling to room temperature, EtSiH (19.62 g, 168.74 mmol) and TMSOTf (37.50 g, 168.72 mmol) were added portionwise to the mixture at room temperature over a period of 15 minutes. The resulting mixture was stirred at room temperature for an additional 16 hours. The reaction was quenched with water (30 mL) at 0 °C and neutralized to pH 7 with saturated aqueous NaHCO solution. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EA to give (2S,3R)-2-(hydroxymethyl)oxolan-3-ol as a pale yellow semi-solid (1.40 g, 35%): 1 H NMR (400 MHz, DMSO-d6) δ 4.93-4.77 (m, 1H), 4.71-4.54 (m, 1H), 3.82-3.67 (m, 2H), 3.57 (td, J = 5.3, 2.9 Hz, 1H), 3.40-3.33 (m, 1H), 1.98-1.85 (m, 1H), 1.74-1.63 (m, 1H).
[0444] Step C: To a stirred solution of (2S,3R)-2-(hydroxymethyl)oxolan-3-ol (1.30 g, 11.01 mmol) and imidazole (0.76 g, 11.12 mmol) in DMF (8 mL) was added TBDMSCl (1.66 g, 11.01 mmol) dropwise at room temperature. The resulting solution was stirred at room temperature for 0.5 h. The reaction was diluted with EA (50 mL) and water (50 mL). The aqueous solution was extracted with EA (2 × 50 mL). The combined organic layers were washed with brine (3 × 30 mL) and dried over anhydrous NaSO. After filtration, the filtrate was purified by silica gel column chromatography eluting with PE / EA (2 / 1) to give (2S,3R)-2-[[(tert-butyldimethylsilyl)oxy]methyl]oxolan-3-ol as a colorless oil (1.54 g, 60%):1 H NMR (400 MHz, DMSO-d6) δ 4.88 (d, J = 4.2 Hz, 1H), 4.08-3.99 (m, 1H), 3.82-3.68 (m, 2H), 3.62-3.55 (m, 1H), 3.55-3.44 (m, 2H), 2.01-1.85 (m, 1H), 1.78-1.63 (m, 1H), 0.87 (s, 9H), 0.04 (d, J = 2.5 Hz, 6H).
[0445] Step D: To a stirred solution of (2S,3R)-2-[[(tert-butyldimethylsilyl)oxy]methyl]oxolan-3-ol (0.82 g, 3.53 mmol) and benzoic acid (0.56 g, 4.59 mmol) in THF (8 mL) at room temperature was added Ph3P (1.85 g, 7.05 mmol) and DEAD (1.23 g, 7.06 mmol). The resulting solution was stirred at room temperature for 1 h. The reaction was diluted with EA (30 mL) and water (30 mL). The aqueous solution was extracted with EA (2 × 30 mL). The combined organic layers were washed with brine (3 × 30 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was purified by silica gel column chromatography eluting with PE / EA (6 / 1) to give (2S,3S)-2-[[(tert-butyldimethylsilyl)oxy]methyl]oxolan-3-ylbenzoate as a colorless oil (1.00 g, 84%): 1 H NMR (400 MHz, CDCl3) δ 8.06 (dt, J = 8.2, 1.1 Hz, 2H), 7.66-7.55 (m, 1H), 7.47 (t, J = 7.7 Hz, 2H), 5.72-5.59 (m, 1H), 4.20-4.01 (m, 1H), 4.01-3.81 (m, 1H), 3.96 (td, J = 8.7, 4.8 Hz, 1H), 3.91 (dd, J = 6.3, 2.0 Hz, 2H), 2.48-2.32 (m, 1H), 2.20-2.08 (m, 1H), 0.85 (s, 9H), 0.05--0.05 (m, 6H).
[0446] Step E: To a stirred solution of (2S,3S)-2-[[(tert-butyldimethylsilyl)oxy]methyl]oxolan-3-ylbenzoate (0.50 g, 1.49 mmol) in THF (3 mL) and HOAc (0.1 mL) was added TBAF (2.97 mL, 2.970 mmol, 1 M in THF) at room temperature. The reaction was stirred at room temperature for 3 hours. The reaction was diluted with EA (30 mL) and water (30 mL). The aqueous solution was extracted with EA (2 × 30 mL). The combined organic layers were washed with brine (3 × 30 mL) and dried over anhydrous NaSO. After filtration, the filtrate was purified by silica gel column chromatography eluting with PE / EA (1 / 4) to give (2S,3S)-2-(hydroxymethyl)oxolan-3-ylbenzoate as a colorless oil (0.30 g, 91%): 1 H NMR (400 MHz, DMSO-d6) δ 7.96-7.91 (m, 2H), 7.68-7.62 (m, 1H), 7.53 (t, J = 7.6 Hz, 2H), 5.51-5.46 (m, 1H), 3.97-3.86 (m, 2H), 3.81-3.72 (m, 1H), 3.65-3.57 (m, 2H), 2.40-2.29 (m, 1H), 2.02-1.93 (m, 1H).
[0447] Step F: To a stirred solution of (2S,3S)-2-(hydroxymethyl)oxolan-3-ylbenzoate (0.34 g, 1.53 mmol) and (acetyloxy)(phenyl)-lambda 3-iodanyl acetate (0.74 g, 2.30 mmol) in ACN (3 mL) and water (3 mL) was added TEMPO (48 mg, 0.31 mmol) at room temperature. The reaction was stirred at room temperature for 16 hours. The resulting mixture was quenched with saturated aqueous NaSO (10 mL), and the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1 / 1) to give (2R,3S)-3-(benzoyloxy)oxolane-2-carboxylic acid as a colorless oil (0.20 g, 55%): 1H NMR (400 MHz, DMSO-d6) δ 12.77 (s, 1H), 8.07-7.81 (m, 2H), 7.68 (t, J = 7.3 Hz, 1H), 7.56 (t, J = 7.3 Hz, 2H), 5.93-5.64 (m, 1H), 4.69-4.51 (m, 1H), 4.17-3.84 (m, 2H), 2.38-2.23 (m, 1H), 2.20-2.02 (m, 1H).
[0448] [Example 28] Intermediate 28 (Lithio 4-methyl-5-oxomorpholine-2-carboxylate)
[0449] [ka]
[0450] Step A: To a stirred mixture of isoserine (50.00 g, 475.77 mmol) in MeOH (300 mL) was added SOCl (41 mL, 570.97 mmol) dropwise at 0 °C. The resulting mixture was stirred at room temperature for 1 h. The resulting mixture was concentrated under reduced pressure to give methyl 3-amino-2-hydroxypropanoate as an off-white solid (50.00 g, 71%): LCMS (ESI) C4H9NO3 [M + H] + Calculated value: 120, measured value 120; 1 H NMR (400 MHz, CD3OD) δ 4.50 (dd, J = 8.2, 4.0 Hz, 1H), 3.82 (s, 3H), 3.36-3.30 (m, 1H), (dd, J = 13.0, 8.3 Hz, 1H).
[0451] Step B: To a stirred solution of methyl 3-amino-2-hydroxypropanoate (22.50 g, 188.89 mmol) and EtN (57.34 g, 566.66 mmol) in DCM (300 mL) at room temperature, chloroacetyl chloride (21.33 g, 188.89 mmol) was added dropwise. The resulting mixture was stirred at room temperature for 1 hour. The reaction was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1 / 2) to give methyl 3-(2-chloroacetamido)-2-hydroxypropanoate as a yellow solid (13.00 g, 35%): LCMS (ESI) CH 10 ClNO4[M + H] + Calculated values: 196, 198 (3 : 1), measured values: 196, 198 (3 : 1); 1 H NMR (400 MHz, CDCl3) δ 6.97 (s, 1H), 4.35 (t, J = 5.0 Hz, 1H), 4.08 (s, 2H), 3.84 (s, 3H), 3.79-3.62 (m, 2H), 3.26 (s, 1H).
[0452] Step C: To a stirred solution of methyl 3-(2-chloroacetamido)-2-hydroxypropanoate (5.00 g, 25.56 mmol) in THF (300 mL) was added t-BuOK (5.74 g, 51.15 mmol) at room temperature under a nitrogen atmosphere. The reaction was stirred at room temperature for 1 hour. After complete consumption of the starting material, MeI (4.35 g, 30.65 mmol) was added to the reaction. The mixture was stirred at room temperature for an additional 2 hours. The solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EA to give methyl 4-methyl-5-oxomorpholine-2-carboxylate as a pale yellow semi-solid (0.90 g, 20%): LCMS (ESI) CH 11 NO4[M + H] + Calculated value: 174, measured value 174; 1H NMR (400 MHz, CD3OD) δ 4.61 (dd, J = 7.5, 4.8 Hz, 1H), 4.30 (d, J = 16.5 Hz, 1H), 4.19 (d, J = 16.6 Hz, 1H), 3.78 (s, 3H), 3.63 (dd, J = 6.2, 4.1 Hz, 2H), 2.98 (s, 3H).
[0453] Step D: To a stirred solution of methyl 4-methyl-5-oxomorpholine-2-carboxylate (0.15 g, 0.87 mmol) in MeOH (3 mL) at room temperature was added a solution of LiOH·HO (73 mg, 1.73 mmol) in water (1 mL). The reaction solution was stirred at 40 °C for 1 h. The reaction was concentrated under reduced pressure to give lithio 4-methyl-5-oxomorpholine-2-carboxylate as an off-white solid (0.14 g, crude), which was used directly in the next step without further purification: LCMS (ESI) C6H9NO4 [M + H] + Calculated value: 160, Measured value: 160.
[0454] [Example 29] Intermediate 29 (tert-butyl 3-[methoxy(methyl)carbamoyl]-8-azabicyclo[3.2.1]octane-8-carboxylate)
[0455] [ka]
[0456] Step A: To a stirred solution of methyl 8-azabicyclo[3.2.1]octane-3-carboxylate (1.00 g, 5.91 mmol) and EtN (1.20 g, 11.86 mol) in DCM (10 mL) was added BocO (1.60 g, 7.33 mmol) at room temperature. The reaction was stirred at room temperature for 1 h. The reaction was diluted with EA (50 mL) and water (50 mL). The isolated aqueous solution was extracted with EA (3 × 20 mL). The combined organic layers were washed with brine (3 × 30 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give 8-tert-butyl 3-methyl 8-azabicyclo[3.2.1]octane-3,8-dicarboxylate as a pale yellow oil (1.30 g, 99%): LCMS (ESI) C 14 H 23 NO4[M + H -15] + Calculated value: 255, measured value 255.
[0457] Step B: To a stirred solution of 8-tert-butyl 3-methyl 8-azabicyclo[3.2.1]octane-3,8-dicarboxylate (1.30 g, 4.83 mol) in MeOH (5 mL) was added a solution of NaOH (0.39 g, 9.65 mol) in HO (0.5 mL) at room temperature. The reaction was stirred at room temperature for 16 h. The reaction was diluted with EA (50 mL) and water (50 mL). The aqueous solution was extracted with EA (3 × 20 mL). The combined aqueous layers were acidified to pH 3 with citric acid and extracted with EA (3 × 50 mL). The combined organic layers were washed with brine (3 × 30 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give (8-[(tert-butoxy)carbonyl]-8-azabicyclo[3.2.1]octane-3-carboxylic acid) as a pale yellow oil (1.20 g, 97%): LCMS (ESI) C 13 H 21 NO4[M + Na] + Calculated value: 278, measured value 278; 1H NMR (300 MHz, CDCl3) δ 4.40-4.21 (m, 2H), 2.94-2.79 (m, 1H), 2.06-1.98 (m, 2H), 1.98-1.84 (m, 2H), 1.84-1.73 (m, 2H), 1.73-1.59 (m, 2H), 1.49 (s, 9H).
[0458] Step C: To a stirred solution of 8-[(tert-butoxy)carbonyl]-8-azabicyclo[3.2.1]octane-3-carboxylic acid (1.20 g, 4.70 mmol) and EtN (0.95 g, 9.40 mmol) in DCM (10 mL) at room temperature was added CDI (0.91 g, 5.64 mmol) and N,O-methoxy(methyl)amine hydrochloride (0.69 g, 7.05 mmol). The reaction was stirred at room temperature for 3 hours. The reaction was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1 / 1) to give tert-butyl 3-[methoxy(methyl)carbamoyl]-8-azabicyclo[3.2.1]octane-8-carboxylate as a pale yellow oil (1.10 g, 69% overall for 3 steps): LCMS (ESI) C 15 H 26 N2O4[M + H - 56] + Calculated value: 243, measured value 243; 1 H NMR (400 MHz, CDCl3) δ 4.40-4.23 (m, 1H), 3.82-3.76 (m, 1H), 3.76-3.71 (m, 3H), 3.35-3.21 (m, 1H), 3.19 (d, J = 2.6 Hz, 3H), 2.18-1.93 (m, 4H), 1.81-1.56 (m, 4H), 1.56-1.44 (m, 9H).
[0459] [Example 30] Intermediate 30 (tert-butyl 3-[methoxy(methyl)carbamoyl]azetidine-1-carboxylate)
[0460] [ka]
[0461] Step A: To a stirred solution of 1-[(tert-butoxy)carbonyl]azetidine-3-carboxylic acid (2.00 g, 9.94 mmol) and CDI (1.80 g, 10.9 mmol) in DCM (10 mL) was added EtN (1.20 g, 11.93 mmol) and N,O-methoxy(methyl)amine hydrochloride (0.90 g, 14.91 mmol) at room temperature. The reaction solution was stirred at room temperature for 1 hour. The resulting solution was diluted with water (30 mL) at room temperature and extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (2 × 20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1 / 1) to give tert-butyl 3-[methoxy(methyl)carbamoyl]azetidine-1-carboxylate as a pale yellow oil (2.10 g, 78%): LCMS (ESI) C 11 H 20 N2O4[M + H - 56] + Calculated value: 189, measured value 189; 1 H NMR (300 MHz, CD3OD) δ 4.14-3.99 (m, 4H), 3.89-3.76 (m, 1H), 3.72 (s, 3H), 3.22 (s, 3H), 1.46 (s, 9H).
[0462] [Example 31] Intermediate 31 (tert-butyl 4-fluoro-4-[methoxy(methyl)carbamoyl]piperidine-1-carboxylate)
[0463] [ka]
[0464] Step A: To a stirred solution of 1-[(tert-butoxy)carbonyl]-4-fluoropiperidine-4-carboxylic acid (2.00 g, 8.09 mmol) and CDI (2.60 g, 16.18 mmol) in DCM (10 mL) was added EtN (2.50 g, 24.27 mmol) and N,O-methoxy(methyl)amine hydrochloride (1.00 g, 16.18 mmol) at room temperature. The reaction solution was stirred at room temperature for 16 hours. The resulting solution was diluted with water (30 mL) at room temperature and extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (2 × 20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (3 / 1) to give tert-butyl 4-fluoro-4-[methoxy(methyl)carbamoyl]piperidine-1-carboxylate as a colorless oil (1.50 g, 57%): LCMS (ESI) C 13 H 23 FN2O4[M + H - 56] + Calculated value: 235, measured value 235; 1 H NMR (400 MHz, CDCl3) δ 4.01 (d, J = 13.5 Hz, 2H), 3.75 (s, 3H), 3.26 (s, 3H), 3.21-3.01 (m, 1H), 2.06 (dd, J = 19.6, 10.9 Hz, 5H), 1.49 (s, 9H).
[0465] [Example 32] Intermediate 32 (Lithio 5-((tert-butoxycarbonyl)amino)-1,3,4-oxadiazole-2-carboxylate)
[0466] [ka]
[0467] Step A: To a stirred solution of ethyl 5-amino-1,3,4-oxadiazole-2-carboxylate (0.10 g, 0.64 mmol) and EtN (0.19 g, 1.91 mmol) in DMF (1 mL) at room temperature was added BocO (0.17 g, 0.76 mmol). The resulting solution was stirred at room temperature for 12 hours. The reaction was concentrated under reduced pressure. The residue was purified by reverse-phase chromatography eluting with 55% ACN in water containing 10 mmol / L NHHCO to give ethyl 5-[[(tert-butoxy)carbonyl]amino]-1,3,4-oxadiazole-2-carboxylate as a pale yellow oil (0.10 g, 55%): LCMS (ESI) C 10 H 15 N3O5[M + H - 56] + Calculated value: 202, measured value 202; 1 H NMR (400 MHz, DMSO-d6) δ 4.38 (q, J = 7.1 Hz, 2H), 1.46 (d, J = 3.1 Hz, 9H), 1.32 (t, J = 7.1 Hz, 3H).
[0468] Step B: To a stirred solution of ethyl 5-[[(tert-butoxy)carbonyl]amino]-1,3,4-oxadiazole-2-carboxylate (0.16 g, 0.62 mmol) in MeOH (2 mL) was added a solution of LiOH·HO (78 mg, 1.87 mmol) in MeOH (3 mL) and a solution of LiOH·HO (48 mg, 1.15 mmol) in HO (2 mL) at room temperature. The resulting mixture was stirred at room temperature for 2 h. The resulting mixture was concentrated under reduced pressure to give lithio 5-((tert-butoxycarbonyl)amino)-1,3,4-oxadiazole-2-carboxylate as an off-white solid (0.16 g, crude), which was used directly in the next step without further purification: LCMS (ESI) CH 11 N3O5[M + H] + Calculated value: 230, measured value 230; 1H NMR (400 MHz, DMSO-d6) δ 8.53 (s, 1H), 2.50 (s, 9H).
[0469] [Example 33] Intermediate 33 (3-iodo-1-(triphenylmethyl)-1H-pyrazole)
[0470] [ka]
[0471] Step A: To a stirred solution of 3-iodo-1H-pyrazole (0.50 g, 2.59 mmol) in DCM (5 mL) was added TrtCl (0.86 g, 3.09 mmol) and EtN (0.52 g, 5.16 mmol) at room temperature. The resulting mixture was stirred at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (12 / 1) to give 3-iodo-1-(triphenylmethyl)-1H-pyrazole as an off-white solid (0.60 g, 48%): 1 H NMR (400 MHz, CDCl3) δ 7.19-7.10 (m, 15H), 6.42 (d, J = 2.5 Hz, 2H).
[0472] [Example 34] Intermediate 34 (4-iodo-1-(triphenylmethyl)-1H-pyrazole)
[0473] [ka]
[0474] Step A: To a stirred solution of 4-iodo-1H-pyrazole (0.50 g, 2.59 mmol) in DCM (5 mL) was added TrtCl (0.86 g, 3.09 mmol) and EtN (0.52 g, 5.16 mmol) at room temperature. The resulting mixture was stirred at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (10 / 1) to give 4-iodo-1-(triphenylmethyl)-1H-pyrazole as an off-white solid (0.80 g, 64%): 1 H NMR (400 MHz, DMSO-d6) δ 7.75 (s, 1H), 7.45 (s, 1H), 7.40-7.35 (m, 9H), 7.07-7.00 (m, 6H).
[0475] [Example 35] Intermediate 35 (Lithio (S)-3-methoxy-2-(trityloxy)propanoate)
[0476] [ka]
[0477] Step A: To a stirred solution of methyl (2S)-oxirane-2-carboxylate (2.00 g, 19.59 mmol) in MeOH (15 mL) at room temperature was added Mg(OSOCF) (3.15 g, 9.80 mmol). The resulting mixture was stirred at 40 °C for 16 h. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with DCM / MeOH (10 / 1) to give methyl (2S)-2-hydroxy-3-methoxypropanoate as a pale yellow oil (1.50 g, 46%): LCMS (ESI) CH 10 O4 [M + H] + Calculated value: 135, measured value 135; 1H NMR (400 MHz, CDCl3) δ 4.34 (t, J = 3.4 Hz, 1H), 3.83 (s, 3H), 3.75-3.65 (m, 2H), 3.41 (s, 3H), 2.65 (brs, 1H).
[0478] Step B: To a stirred solution of methyl (2S)-2-hydroxy-3-methoxypropanoate (0.70 g, 5.22 mmol) and DMAP (64 mg, 0.52 mmol) in pyridine (8 mL) was added TrtCl (1.60 g, 5.74 mmol) at room temperature. The resulting solution was warmed to 80 °C and stirred for 24 h. The resulting mixture was diluted with water (30 mL). The resulting mixture was extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (3 × 30 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (10 / 1) to give methyl (2S)-3-methoxy-2-(triphenylmethoxy)propanoate as an off-white solid (0.80 g, 33%): 1 H NMR (400 MHz, DMSO-d6) δ 7.45-7.19 (m, 15H), 4.16 (t, J = 5.2 Hz, 1H), 3.53 (dd, J = 10.6, 5.5 Hz, 1H), 3.32-3.27 (m, 1H), 3.23 (s, 3H), 3.21 (s, 3H).
[0479] Step C: To a stirred solution of methyl (2S)-3-methoxy-2-(triphenylmethoxy)propanoate (0.80 g, 2.13 mmol) in MeOH (8 mL) at room temperature was added a solution of LiOH·HO (0.45 g, 10.63 mmol) in water (3 mL). The resulting mixture was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure to give lithio (S)-3-methoxy-2-(trityloxy)propanoate (0.80 g, crude), which was used directly in the next step without further purification: LCMS (ESI) C 23 H22 O4[M + Na] + Calculated value: 385, Measured value: 385.
[0480] [Example 36] Intermediate 36 (Lithium 1-oxo-1,2-dihydroisoquinoline-4-carboxylate)
[0481] [ka]
[0482] Step A: To a stirred solution of methyl 1-oxo-2H-isoquinoline-4-carboxylate (0.20 g, 1.00 mmol) in MeOH (2 mL) at room temperature was added a solution of LiOH·HO (84 mg, 2.00 mmol) in water (3 mL). The resulting mixture was stirred at room temperature for 16 hours. The resulting mixture was concentrated under reduced pressure to give lithium 1-oxo-1,2-dihydroisoquinoline-4-carboxylate (0.20 g, crude), which was used directly in the next step without further purification: LCMS (ESI) C 10 H7NO3[M - H] + Calculated value: 188, Measured value: 188.
[0483] [Example 37] Intermediate 37 (Lithium 5-cyano-6-oxo-1,6-dihydropyridine-3-carboxylate)
[0484] [ka]
[0485] Step A: To a stirred solution of methyl 5-ethynyl-6-oxo-1H-pyridine-3-carboxylate (0.18 g, 1.00 mmol) in MeOH (2 mL) at room temperature was added a solution of LiOH·HO (84 mg, 2.00 mmol) in water (3 mL). The resulting mixture was stirred at 40 °C for 0.5 h. After cooling to room temperature, the resulting mixture was concentrated under reduced pressure to give lithium 5-cyano-6-oxo-1,6-dihydropyridine-3-carboxylate (0.20 g, crude), which was used directly in the next step without further purification: LCMS (ESI) C7H4N2O3 [M - H] + Calculated value: 163, Measured value: 163.
[0486] [Example 38] Intermediate 38 (N-[(R)-[4,5-dichloro-2-(prop-2-en-1-yloxy)phenyl](piperidin-4-yl)methyl]-2,2,2-trifluoroacetamide)
[0487] [ka]
[0488] Step A: To a stirred solution of tert-butyl 4-[(R)-[4,5-dichloro-2-(prop-2-en-1-yloxy)phenyl]([[(S)-2-methylpropane-2-sulfinyl]amino])methyl]piperidine-1-carboxylate (0.50 g, 0.96 mmol) in 1,4-dioxane (8 mL) was added aqueous HCl (4 N, 2 mL) at room temperature. The reaction solution was stirred at room temperature for 20 minutes. The reaction solution was adjusted to pH 8 with saturated aqueous Na2CO3 at room temperature. The resulting mixture was extracted with EA (3 × 50 mL). The combined organic layers were washed with brine (3 × 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give tert-butyl 4-[(R)-amino[4,5-dichloro-2-(prop-2-en-1-yloxy)phenyl]methyl]piperidine-1-carboxylate as a yellow oil (0.40 g, crude), which was used directly in the next step without further purification: LCMS (ESI) C 20 H 28 Cl2N2O3[M + H] + Calculated values: 415, 417 (3:2), measured values: 415, 417 (3:2).
[0489] Step B: To a stirred solution of tert-butyl 4-[(R)-amino[4,5-dichloro-2-(prop-2-en-1-yloxy)phenyl]methyl]piperidine-1-carboxylate (0.40 g, 0.96 mmol) and EtN (0.29 g, 2.89 mmol) in DCM (5 mL) was added TFAA (0.24 g, 1.16 mmol) at 0 °C. The reaction solution was stirred at 0 °C for 0.5 h. The reaction mixture was diluted with DCM (50 mL) and water (30 mL). The aqueous solution was extracted with DCM (2 × 20 mL). The combined organic layers were washed with brine (2 × 20 mL) and dried over Na SO . After filtration, the filtrate was concentrated under reduced pressure to give tert-butyl 4-[(R)-[4,5-dichloro-2-(prop-2-en-1-yloxy)phenyl](2,2,2-trifluoroacetamido)methyl]piperidine-1-carboxylate as a yellow oil (0.40 g, crude), which was used directly in the next step without further purification: LCMS (ESI) C 22 H 27 Cl2F3N2O4[M + Na] + Calculated values: 533, 535 (3 : 2), measured values: 533, 535 (3 : 2); 1 H NMR (400 MHz, CDCl3) δ 7.25 (s, 1H), 7.02 (s, 1H), 6.12-5.98 (m, 1H), 5.48-5.39 (m, 2H), 4.77 (t, J = 9.7 Hz, 1H), 4.69-4.56 (m, 2H), 4.10 (d, J = 16.0 Hz, 2H), 2.75-2.48 (m, 2H), 2.08-1.97 (m, 1H), 1.78 (d, J = 13.3 Hz, 1H), 1.45 (s, 9H), 1.31-1.20 (m, 3H).
[0490] Step C: To a stirred solution of tert-butyl 4-[(R)-[4,5-dichloro-2-(prop-2-en-1-yloxy)phenyl](2,2,2-trifluoroacetamido)methyl]piperidine-1-carboxylate (0.40 g, 0.78 mmol) in DCM (2 mL) at room temperature was added TFA (2 mL). The reaction solution was stirred at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse-phase chromatography eluting with 50% ACN in water containing 10 mmol / L NH4HCO3 to give N-[(R)-[4,5-dichloro-2-(prop-2-en-1-yloxy)phenyl](piperidin-4-yl)methyl]-2,2,2-trifluoroacetamide as a pale yellow solid (0.30 g, 76% overall for three steps): LCMS (ESI) C 17 H 19 Cl2F3N2O2[M + H] + Calculated values: 411, 413 (3:2), measured values: 411, 413 (3:2).
[0491] [Example 39] Intermediate 39 (Lithio 2-(oxetan-3-yloxy)acetate)
[0492] [ka]
[0493] Step A: To a stirred mixture of NaH (12.65 g, 316.16 mmol, 60%) in THF (300 mL) was added oxetan-3-ol (19.52 g, 263.47 mmol) dropwise at 0° C. under a nitrogen atmosphere. The reaction solution was stirred at room temperature for 0.5 h under a nitrogen atmosphere. To the above mixture was added ethyl 2-bromoacetate (44.00 g, 263.47 mmol) dropwise at 0° C. under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for an additional 2 h. The resulting mixture was quenched with water (200 mL) and extracted with EA (3×200 mL). The combined organic layers were washed with brine (30×100 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (5 / 1) to give ethyl 2-(oxetan-3-yloxy)acetate as a colorless oil (25.00 g, 59%): 1 H NMR (400 MHz, CDCl3) δ 4.79-4.72 (m, 2H), 4.72-4.67 (m, 2H), 4.67-4.59 (m, 1H), 4.21 (q, J = 7.1 Hz, 2H), 4.05 (s, 2H), 1.28 (t, J = 7.1Hz, 3H).
[0494] Step B: To a stirred solution of ethyl 2-(oxetan-3-yloxy)acetate (1.00 g, 6.24 mmol) in THF (2 mL) and MeOH (2 mL) at 0 °C was added LiOH·HO (0.29 g, 6.89 mmol). The reaction solution was stirred at room temperature for 1 h. The resulting solution was concentrated under reduced pressure to give lithio 2-(oxetan-3-yloxy)acetate as an off-white solid (0.70 g, crude), which was used directly in the next step without further purification: 1 H NMR (400 MHz, D2O) δ 4.77-4.74 (m, 1H), 4.71-4.68 (m, 2H), 4.59-4.53 (m, 2H), 3.79 (s, 2H).
[0495] [Example 40] Intermediate 40 (Lithio (R)-3-methoxy-2-(trityloxy)propanoate)
[0496] [ka]
[0497] Step A: To a stirred solution of methyl (2R)-oxirane-2-carboxylate (1.00 g, 9.80 mmol) in MeOH (10 mL) at room temperature was added Mg(OSOCF) (1.58 g, 4.90 mmol). The resulting mixture was stirred at 40 °C for 16 h. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with DCM / MeOH (10 / 1) to give methyl (2R)-2-hydroxy-3-methoxypropanoate as a pale yellow oil (0.90 g, 55%): LCMS (ESI) CH 10 O4 [M + H] + Calculated value: 135, measured value 135; 1 H NMR (400 MHz, CDCl3) δ 4.33 (t, J = 3.7 Hz, 1H), 3.83 (d, J = 1.5 Hz, 3H), 3.76-3.65 (m, 2H), 3.41 (d, J = 1.5 Hz, 3H), 2.91-2.39 (brs, 1H).
[0498] Step B: To a stirred solution of methyl (2R)-2-hydroxy-3-methoxypropanoate (0.50 g, 3.73 mmol) and DMAP (46 mg, 0.37 mmol) in pyridine (4 mL) was added TrtCl (1.14 g, 4.10 mmol) at room temperature. The resulting solution was stirred at 80° C. for 24 hours. The resulting mixture was diluted with water (20 mL) and extracted with EA (3×20 mL). The combined organic layers were washed with brine (3×20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (10 / 1) to give methyl (2R)-3-methoxy-2-(triphenylmethoxy)propanoate as an off-white solid (0.60 g, 34%): 1 H NMR (400 MHz, DMSO-d6) δ 7.49-7.09 (m, 15H), 4.16 (t, J = 5.2 Hz, 1H), 3.53 (dd, J = 10.6, 5.5 Hz, 1H), 3.32-3.27 (m, 1H), 3.23 (s, 3H), 3.21 (s, 3H).
[0499] Step C: To a stirred solution of methyl (2R)-3-methoxy-2-(triphenylmethoxy)propanoate (0.60 g, 1.59 mmol) in MeOH (6 mL) at room temperature was added a solution of LiOH·HO (0.33 g, 7.97 mmol) in water (2 mL). The resulting mixture was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure to give lithio (R)-3-methoxy-2-(trityloxy)propanoate (0.80 g, crude), which was used directly in the next step without further purification: LCMS (ESI) C 23 H 22 O4[M + Na] - Calculated value: 385, Measured value: 385.
[0500] [Example 41] Intermediate 41 (tert-butyl (1R,5S,6R)-6-[methoxy(methyl)carbamoyl]-3-azabicyclo[3.1.0]hexane-3-carboxylate)
[0501] [ka]
[0502] Step A: To a stirred solution of (1R,5S,6R)-3-[(tert-butoxy)carbonyl]-3-azabicyclo[3.1.0]hexane-6-carboxylic acid (0.50 g, 2.20 mmol), HOBt (0.45 g, 3.30 mmol), and EDCI (0.63 g, 3.30 mmol) in DMF (6 mL) was added N,O-dimethylhydroxylamine hydrochloride (0.40 g, 4.11 mmol) and EtN (0.45 g, 4.40 mmol) at room temperature. The reaction solution was stirred at room temperature for 2 hours. The reaction was diluted with EA (30 mL) and water (30 mL). The aqueous solution was extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (6 × 20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was evaporated under reduced pressure. The residue was purified by reverse phase chromatography eluting with 70% ACN in water (+0.05% TFA) to give tert-butyl (1R,5S,6R)-6-[methoxy(methyl)carbamoyl]-3-azabicyclo[3.1.0]hexane-3-carboxylate as a pale yellow oil (0.30 g, 45%): LCMS (ESI) C 13 H 22 N2O4[M + H - 56] + Calculated value: 215, measured value 215; 1 H NMR (400 MHz, CDCl3) δ 3.76 (s, 3H), 3.72-3.64 (m, 1H), 3.59 (d, J = 11.2 Hz, 1H), 3.52-3.41 (m, 3H), 3.22 (s, 3H), 2.15-2.04 (m, 1H), 2.02-1.93 (m, 1H), 1.47 (s, 9H).
[0503] [Example 42] Intermediate 42 (tert-butyl 4-[methoxy(methyl)carbamoyl]-2-methylpiperidine-1-carboxylate)
[0504] [ka]
[0505] Step A: To a stirred solution of 2-methylpyridine-4-carboxylic acid (2.00 g, 14.58 mmol) in MeOH (10 mL) at room temperature was added PtO (0.40 g, 1.75 mmol) and HCl (6 N, 1 mL). The reaction was degassed under hydrogen three times and stirred under H (50 atm) at 30 °C for 16 h. The reaction was filtered and the filtrate was concentrated under reduced pressure to give methyl 2-methylpiperidine-4-carboxylate as a pale yellow oil (2.00 g, 96%), which was used directly in the next step without further purification: LCMS (ESI) CH 15 NO2[M + H] + Calculated value: 158, measured value 158; 1 H NMR (400 MHz, CD3OD) δ 3.51-3.43 (m, 1H), 3.37 (s, 3H), 3.31-3.24 (m, 1H), 3.12-3.02 (m, 1H), 2.77 (tt, J = 12.4, 3.8 Hz, 1H), 2.30-2.16 (m, 2H), 1.77 (qd, J = 13.8, 4.3 Hz, 1H), 1.63-1.49 (m, 1H), 1.37 (d, J = 6.5 Hz, 3H).
[0506] Step B: To a stirred mixture of methyl 2-methylpiperidine-4-carboxylate (2.00 g, 12.72 mmol) and EtN (2.57 g, 25.40 mmol) in DCM (10 mL) at room temperature was added BocO (4.16 g, 19.06 mmol). The reaction was stirred at room temperature for 1 hour. The reaction was diluted with EA (50 mL) and water (50 mL). The aqueous solution was extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (2 × 30 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give 1-tert-butyl 4-methyl 2-methylpiperidine-1,4-dicarboxylate as a pale yellow oil (3.3 g, crude), which was used directly in the next step without further purification. LCMS (ESI) C 13 H 23 NO4[M + H - 56] + Calculated value: 202 Measured value 202; 1 H NMR (400 MHz, CDCl3) δ 4.28-4.09 (m, 1H), 3.91-3.76 (m, 1H), 3.72 (s, 3H), 3.11 (td, J = 13.1, 4.1 Hz, 1H), 2.76-2.51 (m, 1H), 2.10-1.86 (m, 3H), 1.85-1.69 (m, 1H), 1.47 (s, 9H), 1.09 (d, J = 6.5 Hz, 3H).
[0507] Step C: To a stirred solution of 1-tert-butyl 4-methyl 2-methylpiperidine-1,4-dicarboxylate (3.30 g, 12.82 mmol) in MeOH (10 mL) was added a solution of NaOH (1.03 g, 25.75 mmol) in water (2 mL) at room temperature. The reaction solution was stirred at 40° C. for 1 hour. The reaction was diluted with water (50 mL). The aqueous solution was acidified to pH 3 with citric acid and then extracted with EA (3×50 mL). The combined organic layers were washed with brine (2×30 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase chromatography eluting with 23% ACN in water (+0.05% TFA) to give 1-[(tert-butoxy)carbonyl]-2-methylpiperidine-4-carboxylic acid as a pale yellow semi-solid (2.20 g, 71%): LCMS (ESI) C 12 H 21 NO4[M + H -56] + Calculated value: 188, Measured value: 188.
[0508] Step D: To a stirred solution of 1-[(tert-butoxy)carbonyl]-2-methylpiperidine-4-carboxylic acid (1.80 g, 7.40 mmol), HOBt (1.50 g, 11.10 mmol), and EDCI (1.80 g, 11.10 mmol) in DCM (10 mL) was added N,O-dimethylhydroxylamine hydrochloride (1.08 g, 11.10 mmol) and EtN (1.50 g, 14.80 mmol) at room temperature. The reaction solution was stirred at room temperature for 1 hour. The reaction was diluted with water (50 mL). The aqueous solution was extracted with EA (3 × 50 mL). The combined organic layers were washed with brine (2 × 30 mL) and dried over anhydrous NaSO. After filtration, the filtrate was evaporated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (4 / 1) to give tert-butyl 4-[methoxy(methyl)carbamoyl]-2-methylpiperidine-1-carboxylate as a pale yellow oil (1.50 g, 71%): LCMS (ESI) C 14 H 26 N2O4[M + H] +Calculated value: 287 Measured value 287; 1 H NMR (400 MHz, CDCl3) δ4.04-3.92 (m, 1H), 3.89-3.81 (m, 1H), 3.71 (s, 3H), 3.21 (s, 3H), 3.20-3.10 (m, 1H), 2.88 (d, J = 10.4 Hz, 1H), 2.01-1.90 (m, 1H), 1.90-1.76 (m, 2H), 1.73-1.60 (m, 1H), 1.49 (s, 9H), 1.19 (d, J = 6.4 Hz, 3H).
[0509] [Example 43] Intermediate 43a (tert-butyl 4-[4,5-dichloro-2-(prop-2-en-1-yloxy)benzoyl]-2-methylpiperidine-1-carboxylate containing the cis isomer, racemic); Intermediate 43b (tert-butyl 4-[4,5-dichloro-2-(prop-2-en-1-yloxy)benzoyl]-2-methylpiperidine-1-carboxylate containing the trans isomer, racemic)
[0510] [ka]
[0511] Step A: To a stirred solution of 1-bromo-4,5-dichloro-2-(prop-2-en-1-yloxy)benzene (2.76 g, 9.78 mmol) in THF (10 mL) was added i-PrMgCl (4.86 mL, 9.72 mmol, 2 M solution in THF) dropwise at 0 °C under a nitrogen atmosphere. The reaction was stirred at 0 °C for 30 min. Then, tert-butyl 4-[methoxy(methyl)carbamoyl]-2-methylpiperidine-1-carboxylate (1.40 g, 4.89 mmol) was added to the reaction. The reaction mixture was stirred at 0 °C for 1 h under a nitrogen atmosphere. The resulting mixture was quenched with saturated aqueous NH Cl (5 mL) and diluted with water (30 mL). The aqueous solution was extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (2 × 30 mL) and dried over anhydrous Na SO . After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (4 / 1) to give tert-butyl 4-[4,5-dichloro-2-(prop-2-en-1-yloxy)benzoyl]-2-methylpiperidine-1-carboxylate as a pale yellow semi-solid (0.50 g, 24%): LCMS (ESI) C 21 H 27 Cl2NO4[M + H -56] + Calculated values: 372, 374 (3 : 2), measured values 372, 374 (3 : 2); 1 H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 10.3 Hz, 1H), 7.07 (s, 1H), 6.17-5.98 (m, 1H), 5.56-5.28 (m, 2H), 4.69-4.59 (m, 2H), 4.23-4.02 (m, 1H), 3.93-3.78 (m, 1H), 3.56-3.39 (m, 1H), 3.17-3.02 (m, 1H), 2.06-1.81 (m, 1H), 1.81-1.57 (m, 2H), 1.57-1.43 (m, 10H), 1.09 (d, J = 6.6 Hz, 3H). and tert-butyl 4-(4,5-dichloro-2-hydroxybenzoyl)-2-methylpiperidine-1-carboxylate as a pale yellow oil (1.00 g, 53%): LCMS (ESI) C18 H 23 Cl2NO4[M + H - 56] + Calculated values: 332, 334 (3 : 2), measured values 332, 334 (3 : 2); 1 H NMR (400 MHz, CDCl) δ 12.30 (s, 1H), 7.79 (s, 1H), 7.17 (s, 1H), 4.21-4.02 (m, 1H), 3.96 (dd, J = 14.0, 6.9 Hz, 1H), 3.50-3.37 (m, 1H), 3.25-3.06 (m, 1H), 2.08-1.96 (m, 2H), 1.96-1.81 (m, 1H), 1.81-1.67 (m, 1H), 1.53 (s, 9H), 1.20 (d, J = 6.4 Hz, 3H).
[0512] To a stirred mixture of tert-butyl 4-(4,5-dichloro-2-hydroxybenzoyl)-2-methylpiperidine-1-carboxylate (1.00 g, 2.56 mmol) and K2CO3 (0.71 g, 5.15 mmol) in DMF (5 mL) was added 3-bromoprop-1-ene (0.47 g, 3.86 mmol) at room temperature. The resulting mixture was stirred at room temperature for 1 hour. The resulting mixture was diluted with EA (30 mL) and water (30 mL), and the aqueous solution was extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (3 × 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (10 / 1) to give tert-butyl 4-[4,5-dichloro-2-(prop-2-en-1-yloxy)benzoyl]-2-methylpiperidine-1-carboxylate as a pale yellow oil (1.00 g, 90%). The total amount of tert-butyl 4-[4,5-dichloro-2-(prop-2-en-1-yloxy)benzoyl]-2-methylpiperidine-1-carboxylate was 1.50 g (72%).
[0513] Step B: tert-Butyl 4-[4,5-dichloro-2-(prop-2-en-1-yloxy)benzoyl]-2-methylpiperidine-1-carboxylate (1.50 g, 3.51 mmol) was separated under SFC using the following conditions: Column: CHIRALPAK IF, 2 × 25 cm, 5 μm; Mobile phase A: CO2: 75%, Mobile phase B: MeOH: 25%; Flow rate: 40 mL / min; Detector: UV: 220 / 254 nm; Retention times: RT1: 3.29 min; RT2: 3.85 min.
[0514] The first peak at 3.29 min was obtained from which tert-butyl 4-[4,5-dichloro-2-(prop-2-en-1-yloxy)benzoyl]-2-methylpiperidine-1-carboxylate containing the two cis enantiomers was obtained as a pale yellow semi-solid (0.50 g, 45%): LCMS (ESI) C 21 H 27 Cl2NO4[M + H -56] + Calculated for: 372, 374 (3:2), found 372, 374 (3:2); isolated as a second peak at 3.85 min from which tert-butyl 4-[4,5-dichloro-2-(prop-2-en-1-yloxy)benzoyl]-2-methylpiperidine-1-carboxylate containing the two trans enantiomers was obtained as a pale yellow semi-solid (0.40 g, 36%): LCMS (ESI) C 21 H 27 Cl2NO4[M + H -56] + Calculated: 372, 374 (3:2), found: 372, 374 (3:2).
[0515] [Example 44] Intermediate 44 ((2,3-dichloro-6-methoxyphenyl)(piperidin-4-yl)methanol trifluoroacetic acid)
[0516] [ka]
[0517] Step A: To a stirred solution of 3,4-dichlorophenol (100.00 g, 613.49 mmol) in DCM (1000 mL) was added Br (98.04 g, 613.49 mmol) dropwise under a nitrogen atmosphere at 0 °C. The reaction solution was stirred at room temperature under a nitrogen atmosphere for 16 h. The reaction was quenched with saturated aqueous NaSO (500 mL) at 0 °C. The resulting mixture was extracted with EA (6 × 400 mL). The combined organic layers were washed with brine (2 × 400 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give a mixture of 2-bromo-4,5-dichlorophenol and 2-bromo-3,4-dichlorophenol (100 g, crude) as a yellow oil. The crude product was used directly in the next step without further purification.
[0518] Step B: To a crude mixture of 2-bromo-4,5-dichlorophenol and 2-bromo-3,4-dichlorophenol (32 g, 125.04 mmol, 1 equiv.) and K2CO3 (54.9 g, 396.87 mmol, 3 equiv.) in MeCN (210 mL) was added MeI (16.5 mL, 116.05 mmol, 2 equiv.) dropwise at 0 °C. The reaction mixture was stirred at 50 °C for 4 h. The reaction mixture was filtered and concentrated. The residue was purified by silica gel column chromatography eluting with PE to give 2-bromo-3,4-dichloro-1-methoxybenzene (8.7 g, 25.7%) as a white solid: 1 H NMR (300 MHz, CDCl) δ 7.40 (dd, J = 9.0, 1.1 Hz, 1H), 6.79 (d, J = 8.9 Hz, 1H), 3.92 (s, 3H), and 1-bromo-4,5-dichloro-2-methoxybenzene (24.3 g, 71.77%) as a white solid: 1 H NMR (300 MHz, CDCl) δ 7.64 (s, 1H), 6.99 (s, 1H), 3.91 (s, 3H).
[0519] Step C: To a solution of 2-bromo-3,4-dichloro-1-methoxybenzene (0.80 g, 3.13 mmol) in THF (8 mL) was added i-PrMgCl (2.0 mL, 19.76 mmol, 2 M in THF) dropwise at 0° C. under a nitrogen atmosphere. The reaction solution was stirred at 0° C. for 0.5 h. Then, a solution of tert-butyl 4-formylpiperidine-1-carboxylate (0.67 g, 3.13 mmol) in THF (2 mL) was added dropwise at 0° C. under a nitrogen atmosphere. After stirring at 0° C. for an additional 0.5 h, the reaction mixture was warmed to room temperature and stirred under a nitrogen atmosphere for an additional 0.5 h. The reaction was quenched with saturated aqueous NH4Cl (40 mL) and extracted with EA (2 × 40 mL). The organic layers were combined and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (3 / 2) to give tert-butyl 4-[(2,3-dichloro-6-methoxyphenyl)(hydroxy)methyl]piperidine-1-carboxylate as an off-white foam (1.00 g, 82%): LCMS (ESI) C 18 H 25 Cl2NO4[M + Na] + Calculated values: 412, 414 (3 : 2), measured values: 412, 414 (3 : 2); 1 H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 8.9 Hz, 1H), 6.83 (d, J = 8.9 Hz, 1H), 4.98 (d, J = 8.9 Hz, 1H), 4.21 (d, J = 13.5 Hz, 1H), 4.07 (d, J = 13.5 Hz, 1H), 3.92 (s, 3H), 2.70 (td, J = 12.9, 2.8 Hz, 1H), 2.59 (td, J = 12.8, 3.0 Hz, 1H), 2.17-1.97 (m, 2H), 1.48 (s, 9H), 1.42-1.24 (m, 3H).
[0520] Step D: To a solution of tert-butyl 4-[(2,3-dichloro-6-methoxyphenyl)(hydroxy)methyl]piperidine-1-carboxylate (0.50 g, 1.28 mmol) in DCM (5 mL) was added TFA (2 mL) at room temperature. The reaction solution was stirred at room temperature for 1 hour and concentrated to give (2,3-dichloro-6-methoxyphenyl)(piperidin-4-yl)methanol trifluoroacetate as a colorless oil (0.60 g, crude): LCMS (ESI) C 13 H 17 Cl2NO2[M + H] + Calculated values: 290, 292 (3:2), measured values: 290, 292 (3:2).
[0521] [Example 45] Intermediate 45 ((S)-N-((R)-(2-(allyloxy)-4-chloro-5-methylphenyl)(piperidin-4-yl)methyl)-2-methylpropane-2-sulfinamide)
[0522] [ka]
[0523] Step A: To a stirred solution of 3-chloro-4-methylphenol (0.50 g, 3.51 mmol) in HOAc (5 mL) was added dropwise Br (0.56 g, 3.51 mmol) under a nitrogen atmosphere at room temperature. The reaction solution was stirred at room temperature for 3 hours. The reaction solution was quenched with saturated aqueous NaSO (50 mL) and extracted with EA (2 × 30 mL). The combined organic layers were washed with saturated aqueous NaHCO (2 × 30 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (5 / 1) to give 2-bromo-5-chloro-4-methylphenol as an off-white solid (0.70 g, 90%): 1H NMR (400 MHz, CDCl3) δ 7.33 (s, 1H), 7.06 (s, 1H), 5.46 (s, 1H), 2.30 (s, 3H).
[0524] Step B: To a stirred mixture of 2-bromo-5-chloro-4-methylphenol (0.70 g, 3.16 mmol) and K2CO3 (0.87 g, 6.32 mmol) in DMF (5 mL) was added 3-bromoprop-1-ene (0.50 g, 4.11 mmol) at room temperature. The reaction mixture was warmed to 40 °C and stirred for 3 h. The reaction mixture was diluted with water (50 mL) and extracted with EA (2 × 15 mL). The combined organic layers were washed with brine (3 × 10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE to give 1-bromo-4-chloro-5-methyl-2-(prop-2-en-1-yloxy)benzene as an off-white solid (0.45 g, 54%): 1 H NMR (400 MHz, CDCl3) δ 7.42 (s, 1H), 6.90 (s, 1H), 6.12-6.02 (m, 1H), 5.58-5.40 (m, 1H), 5.40-5.30 (m, 1H), 4.59 (dt, J = 5.0, 1.6 Hz, 2H), 2.30 (s, 3H).
[0525] Step C: To a stirred solution of 1-bromo-4-chloro-5-methyl-2-(prop-2-en-1-yloxy)benzene (0.43 g, 1.64 mmol) in THF (4 mL) was added dropwise n-BuLi (0.76 mL, 1.90 mmol, 2.5 M in hexane) under a nitrogen atmosphere at −65° C. After stirring for 30 min, a solution of tert-butyl 4-[[(S)-2-methylpropane-2-sulfinyl]imino]methyl]piperidine-1-carboxylate (0.40 g, 1.26 mmol) in THF (2 mL) was added dropwise under a nitrogen atmosphere at −65° C. The resulting mixture was warmed to room temperature and stirred for an additional 1 h. The reaction was quenched with saturated aqueous NH4Cl (30 mL). The resulting mixture was extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (2 × 30 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1 / 5) to give tert-butyl 4-((R)-2-(allyloxy)-4-chloro-5-methylphenyl)(((S)-tert-butylsulfinyl)amino)methyl)piperidine-1-carboxylate as a pale yellow oil (0.18 g, 30%): LCMS (ESI) C 25 H 39 ClNOS [M + H] + Calculated values: 499, 501 (3 : 1), measured values: 499, 501 (3 : 1); 1 H NMR (400 MHz, CDCl3) δ 6.96 (s, 1H), 6.87 (s, 1H), 6.09-5.99 (m, 1H), 5.50-5.27 (m, 2H), 4.61-4.45 (m, 2H), 4.42-3.82 (m, 4H), 2.66-2.57 (m, 2H), 2.29 (s, 3H), 1.92-1.91 (m, 1H), 1.66 (s, 3H), 1.45 (s, 9H), 1.13 (s, 9H).
[0526] Step D: To a stirred solution of tert-butyl 4-((R)-2-(allyloxy)-4-chloro-5-methylphenyl)(((S)-tert-butylsulfinyl)amino)methyl)piperidine-1-carboxylate (0.18 g, 0.38 mmol) in DCM (4 mL) at room temperature was added TFA (1 mL). The reaction solution was stirred at room temperature for 1 hour. The resulting solution was neutralized with saturated aqueous NaHCO (20 mL) and extracted with DCM (3 × 20 mL). The combined organic layers were washed with brine (2 × 10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give (S)—N-((R)-(2-(allyloxy)-4-chloro-5-methylphenyl)(piperidin-4-yl)methyl)-2-methylpropane-2-sulfinamide as a pale yellow oil (0.10 g, 70%): LCMS (ESI) C 20 H 31 ClNOS [M + H] + Calculated values: 399, 401 (3:1), measured values: 399, 401 (3:1).
[0527] [Example 46] Intermediate 46 (1-Bromo-4,5-dichloro-3-fluoro-2-(prop-2-en-1-yloxy)benzene)
[0528] [ka]
[0529] Step A: To a solution of 3-chloro-2-fluorophenol (1.50 g, 10.23 mmol) in MeCN (60 mL) and TFA (1.00 mL) was added NCS (1.37 g, 10.24 mmol) at room temperature under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (5 / 1) to give 3,4-dichloro-2-fluorophenol as an off-white solid (1.60 g, 86%): 1H NMR (400 MHz, DMSO-d6) δ 10.64 (s, 1H), 7.27 (dd, J = 9.0, 2.1 Hz, 1H), 6.97 (t, J = 8.9 Hz, 1H).
[0530] Step B: To a stirred solution of 3,4-dichloro-2-fluorophenol (1.60 g, 8.84 mmol) in AcOH (20 mL) was added dropwise Br (1.55 g, 9.72 mmol) at room temperature. The reaction solution was stirred at room temperature for 3 hours. The reaction mixture was poured into water (100 mL). The reaction mixture was then extracted with EA (2 × 50 mL). The organic phase was washed with saturated aqueous NaSO (2 × 50 mL), saturated aqueous NaHCO (2 × 50 mL), and brine (2 × 50 mL). The solution was then dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (5 / 1) to give 6-bromo-3,4-dichloro-2-fluorophenol as an off-white solid (1.80 g, 78%): 1 H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 2.3 Hz, 1H).
[0531] Step C: To a stirred mixture of 6-bromo-3,4-dichloro-2-fluorophenol (1.80 g, 6.97 mmol) and K2CO3 (2.00 g, 14.47 mmol) in DMF (20 mL) was added 3-bromoprop-1-ene (1.26 g, 10.39 mmol) at room temperature. The reaction was then stirred at 40 °C for 3 h. The reaction mixture was diluted with water (80 mL) and extracted with EA (2 × 50 mL). The combined organic layers were washed with brine (3 × 30 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was evaporated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE to give 1-bromo-4,5-dichloro-3-fluoro-2-(prop-2-en-1-yloxy)benzene as a colorless liquid (1.70 g, 82%): 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 2.3 Hz, 1H), 6.18-6.03 (m, 1H), 5.47-5.37 (m, 1H), 5.32 (dd, J = 10.2, 1.5 Hz, 1H), 4.70-4.60 (m, 2H); 19 F NMR (376 MHz, CDCl3) δ -121.32.
[0532] [Example 47] Intermediate 47 (Lithio (R)-2-methoxy-3-(trityloxy)propanoate)
[0533] [ka]
[0534] Step A: To a stirred solution of methyl (2R)-2,3-dihydroxypropanoate (0.50 g, 4.16 mmol) and (chlorodiphenylmethyl)benzene (3.50 g, 12.5 mmol) in DCM (4 mL) at room temperature, DMAP (30 mg, 0.25 mmol) and EtN (1.26 g, 12.5 mmol) were added portionwise. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 72 h. The resulting mixture was diluted with water (20 mL) and extracted with EA (3 × 25 mL). The combined organic layers were washed with brine (3 × 5 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (8 / 1) to give methyl (2R)-2-methoxy-3-(triphenylmethoxy)propanoate as an off-white solid (0.10 g, 6%). 1 H NMR (400 MHz, CDCl3) δ 7.37-7.29 (m, 15H), 4.31 (t, J = 3.5 Hz, 1H), 3.91 (dd, J = 14.0, 3.6 Hz, 2H), 3.87 (s, 3H).
[0535] Step B: To a stirred solution of methyl (2R)-2-hydroxy-3-(triphenylmethoxy)propanoate (0.50 g, 1.38 mmol) and CHI (1 mL) in EtO (5 mL) was added AgO (0.96 g, 4.14 mmol) in small portions at room temperature. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 16 hours. The resulting mixture was diluted with water (20 mL) and extracted with DCM (3 × 20 mL). The combined organic layers were washed with brine (3 × 5 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (6 / 1) to give methyl (2R)-2-methoxy-3-(triphenylmethoxy)propanoate as an off-white solid (0.40 g, 77%): LCMS (ESI) C 24 H 24 O4[M + Na] + Calculated value: 399, Measured value 399; 1 H NMR (400 MHz, CDCl3) δ 7.39-7.21 (m, 15H), 4.00-3.90 (m, 2H), 3.82 (s, 3H), 3.87-3.76 (m, 1H), 3.53 (s, 3H).
[0536] Step C: To a stirred mixture of methyl (2R)-2-methoxy-3-(triphenylmethoxy)propanoate (50 mg, 0.13 mmol) in MeOH (2 mL) at room temperature was added a solution of LiOH·HO (9 mg, 0.4 mmol) in HO (1 mL). The resulting mixture was stirred at room temperature for 16 h and concentrated under reduced pressure to give lithio (2R)-2-methoxy-3-(triphenylmethoxy)propanoate (50 mg, crude). The crude product was used directly in the next step without further purification: LCMS (ESI) C 23 H 22 O4[M + Na] + Calculated value: 385, Measured value: 385.
[0537] [Example 48] Intermediate 48 (Lithio(2S)-2-methoxy-3-(triphenylmethoxy)propanoate)
[0538] [ka]
[0539] Step A: To a stirred solution of methyl (2S)-2,3-dihydroxypropanoate (1.00 g, 8.32 mmol) and (chlorodiphenylmethyl)benzene (2.50 g, 9.16 mmol) in DCM (10 mL) was added EtN (1.26 g, 12.5 mmol) and DMAP (61 mg, 0.50 mmol) at room temperature. The resulting mixture was stirred at room temperature for 16 hours. The resulting mixture was diluted with water (15 mL) and extracted with DCM (3 × 20 mL). The combined organic layers were washed with brine (3 × 10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (5 / 1) to give methyl (2S)-2-hydroxy-3-(triphenylmethoxy)propanoate as an off-white solid (1.00 g, 33%): 1 H NMR (400 MHz, CDCl3) δ 7.49-7.39 (m, 5H), 7.33 (dt, J = 6.9, 1.5 Hz, 5H), 7.33-7.22 (m, 5H), 4.32-4.27 (m, 1H), 3.80 (s, 3H), 3.54-3.45 (m, 1H), 3.38 (dd, J = 9.4, 3.4 Hz, 1H).
[0540] Step B: To a stirred solution of methyl (2S)-2-hydroxy-3-(triphenylmethoxy)propanoate (0.50 g, 1.38 mmol) and CHI (1 mL) in EtO (5 mL) was added AgO (0.96 g, 4.14 mmol) in small portions at room temperature under an air atmosphere. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 16 hours. The resulting mixture was diluted with water (30 mL). The resulting mixture was extracted with DCM (3 × 20 mL). The combined organic layers were washed with brine (3 × 25 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (6 / 1) to give methyl (2S)-2-methoxy-3-(triphenylmethoxy)propanoate as an off-white solid (0.40 g, 77%): LCMS (ESI) C 24 H 24 O4[M + Na] + Calculated value: 399, Measured value 399; 1 H NMR (400 MHz, CDCl3) δ 7.49-7.42 (m, 6H), 7.36-7.25 (m, 6H), 7.29-7.21 (m, 3H), 3.97 (dd, J = 5.4, 4.0 Hz, 1H), 3.78 (s, 3H), 3.47 (s, 3H), 3.45-3.36 (m, 2H).
[0541] Step C: To a stirred solution of methyl (2S)-2-methoxy-3-(triphenylmethoxy)propanoate (0.20 g, 0.53 mmol) in MeOH (3 mL) was added LiOH·HO (38 mg, 1.59 mmol) in HO (1 mL) at room temperature under an air atmosphere. The resulting mixture was stirred at room temperature for 16 h. The resulting mixture was concentrated under reduced pressure to give lithio (2S)-2-methoxy-3-(triphenylmethoxy)propanoate as an off-white solid (0.10 g, crude). The crude product was used directly in the next step without further purification: LCMS (ESI) C 23 H 22 O4[M + Na]+ Calculated value: 385, Measured value: 385.
[0542] [Example 49] Intermediate 49 (tert-butyl 4-(1-(4,5-dichloro-2-methoxyphenyl)-2-oxoethyl)piperidine-1-carboxylate)
[0543] [ka]
[0544] Step A: To a stirred mixture of (methoxymethyl)triphenylphosphanium chloride (12.36 g, 36.06 mmol) in THF (60 mL) was added n-BuLi (10.30 mL, 25.75 mmol, 2.5 M in hexane) dropwise at −78° C. under a nitrogen atmosphere. The resulting mixture was stirred at −78° C. for 30 minutes under a nitrogen atmosphere. To the above mixture was added a solution of tert-butyl 4-(4,5-dichloro-2-methoxybenzoyl)piperidine-1-carboxylate (2.00 g, 5.15 mmol) in THF (5 mL) dropwise over 5 minutes at −78° C. The resulting mixture was stirred at −78° C. for an additional 2 hours. The reaction was quenched with saturated aqueous NH4Cl (80 mL) at 0° C. The resulting mixture was extracted with EA (3 × 50 mL). The combined organic layers were washed with brine (3 × 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1 / 1) to give tert-butyl 4-[1-(4,5-dichloro-2-methoxyphenyl)-2-methoxyethenyl]piperidine-1-carboxylate as a pale yellow oil (1.60 g, 59%): LCMS (ESI) C 20 H 27 Cl2NO4[M + H] + Calculated values: 416, 418 (3 : 2), measured values: 416, 418 (3 : 2); 1H NMR (400 MHz, CDCl3) δ 7.09 (d, J = 1.3 Hz, 1H), 6.91 (s, 1H), 5.87 (d, J = 1.3 Hz, 1H), 3.79 (s, 3H), 3.66 (s, 3H), 2.74-2.58 (m, 4H), 1.71-1.53 (m, 5H), 1.46 (d, J = 1.3 Hz, 9H).
[0545] Step B: To a stirred solution of tert-butyl 4-[(E)-1-(4,5-dichloro-2-methoxyphenyl)-2-methoxyethenyl]piperidine-1-carboxylate (1.80 g, 4.32 mmol) in 1,4-dioxane (10 mL) was added dropwise aqueous HCl (6N, 10 mL) at 0° C. The resulting mixture was then warmed to room temperature and stirred for 3 hours. The resulting mixture was concentrated under reduced pressure. The resulting crude mixture was used directly in the next step without further purification: LCMS (ESI) C 14 H 17 Cl2NO2[M + H] + Calculated value: 302, 304 (3:2), Measured value: 302, 304 (3:2)
[0546] Step C: To a stirred mixture of 2-(4,5-dichloro-2-methoxyphenyl)-2-(piperidin-4-yl)acetaldehyde (1.50 g, 4.96 mmol) in THF (15 mL) and saturated aqueous NaHCO (20 mL) was added BocO (1.62 g, 7.445 mmol) dropwise at 0 °C. The reaction mixture was stirred at room temperature for 1 h. The resulting mixture was extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (2 × 10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give tert-butyl 4-[1-(4,5-dichloro-2-methoxyphenyl)-2-oxoethyl]piperidine-1-carboxylate as a pale yellow oil (1.30 g, 65%): LCMS (ESI) C 19 H 25 Cl2NO4[M + H] +Calculated values: 402, 404 (3 : 2), measured values: 402, 404 (3 : 2); 1 H NMR (400 MHz, CDCl3) δ 9.68 (d, J = 1.6 Hz, 1H), 7.13 (s, 1H), 7.00 (s, 1H), 4.04 (d, J = 13.6 Hz, 1H), 3.83 (s, 3H), 3.67 (dd, J = 8.9, 1.7 Hz, 1H), 2.82-2.71 (m, 1H), 2.66 (t, J = 12.6 Hz, 1H), 2.36-2.21 (m, 1H), 1.89 (dt, J = 13.3, 2.9 Hz, 1H), 1.67 (s, 1H), 1.45 (s, 9H), 1.41 (s, 1H), 1.26-1.16 (m, 1H), 1.10-0.95 (m, 1H).
[0547] [Example 50] Intermediate 50 (tert-butyl 4-[(4,5-dichloro-2-[[2-(trimethylsilyl)ethoxy]methoxy]phenyl)[(2-methylpropane-2-sulfinyl)amino]methyl]-2,2-dimethylpiperidine-1-carboxylate)
[0548] [ka]
[0549] Step A: To a solution of (methoxymethyl)triphenylphosphanium chloride (1508 mg, 4.40 mmol) in THF (7 mL) was added dropwise n-BuLi (2.5 mL, 38.46 mmol, 2.5 M in hexane) under a nitrogen atmosphere at −10° C. The solution was stirred at 0° C. for 1 h. Then, a solution of tert-butyl 2,2-dimethyl-4-oxopiperidine-1-carboxylate (1 g, 4.40 mmol) in THF (5 mL) was added dropwise under a nitrogen atmosphere at −20° C. The mixture was stirred at room temperature for 15 h. The reaction mixture was quenched with saturated aqueous NH4Cl (30 mL) and extracted with EA (2 × 20 mL). The organic phase was dried over anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography eluting with PE / EA (1 / 1) to give tert-butyl 4-(methoxymethylidene)-2,2-dimethylpiperidine-1-carboxylate as a colorless oil (0.80 g, 71%): LCMS (ESI) C 14 H 25 NO3[M + H] + Calculated value: 256, measured value 256; 1 H NMR (300 MHz, methanol) δ 5.97 (d, J = 24.0 Hz, 1H), 3.62-3.45 (m, 5H), 2.37-2.27 (m, 2H), 2.26-2.20 (m, 1H), 2.18 (s, 1H), 1.46 (d, J = 1.7 Hz, 9H), 1.38 (d, J = 2.7 Hz, 6H).
[0550] Step B: To a solution of tert-butyl 4-(methoxymethylidene)-2,2-dimethylpiperidine-1-carboxylate (0.80 g, 3.13 mmol) in THF (10 mL) was added aqueous HCl (4 N, 5 mL) at room temperature. The reaction mixture was stirred at 50° C. for 4 hours. The reaction mixture was then basified to pH 9 with saturated aqueous NaHCO, and then BocO (821 mg, 3.76 mmol) was added. The mixture was stirred at room temperature for 1 hour. The resulting mixture was extracted with EA (2×15 mL). The organic phase was dried over anhydrous NaSO, filtered, and concentrated. The residue was purified by silica gel column chromatography eluting with PE / EA (2 / 1) to give tert-butyl 4-formyl-2,2-dimethylpiperidine-1-carboxylate as a colorless oil (360 mg, 48%): LCMS (ESI) C 13 H 23 NO3[M + H] + Calculated value: 242, Measured value: 242.
[0551] Step c': To a stirred solution of 2-bromo-4,5-dichlorophenol (31.00 g, 128.15 mmol) and [2-(chloromethoxy)ethyl]trimethylsilane (32.00 g, 192.23 mmol) in DCM (100 mL) was added DIEA (49.70 g, 384.46 mmol) at room temperature. The resulting mixture was stirred at room temperature for 5 hours. The reaction was quenched with water (200 mL). The resulting mixture was extracted with DCM (3 × 400 mL). The combined organic layers were washed with brine (3 × 200 mL) and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (50 / 1) to give [2-(2-bromo-4,5-dichlorophenoxymethoxy)ethyl]trimethylsilane (44.00 g, 83%) as a pale yellow oil: 1H NMR (300 MHz, DMSO-d6) δ 7.86 (s, 1H), 7.46 (s, 1H), 5.39 (s, 2H), 3.74 (t, J = 6.0 Hz, 2H), 0.79 (t, J = 6.0 Hz, 2H), −0.05 (s, 9H).
[0552] Step C: To a solution of [2-(2-bromo-4,5-dichlorophenoxymethoxy)ethyl]trimethylsilane (product of step c') (0.69 g, 1.86 mol) in THF (7 mL) was added i-PrMgCl (0.2 mL, 1.61 mmol, 2 M in THF) dropwise at −10° C. under a nitrogen atmosphere. The reaction mixture was stirred at −10° C. under a nitrogen atmosphere for 0.5 h. A solution of tert-butyl 4-formyl-2,2-dimethylpiperidine-1-carboxylate (300 mg, 1.24 mmol) in THF (3 mL) was added dropwise to the resulting solution at −10° C. under a nitrogen atmosphere. The reaction mixture was warmed to room temperature and stirred for 2 h under a nitrogen atmosphere. The resulting mixture was quenched with saturated aqueous NH4Cl (40 mL). The resulting mixture was extracted with EA (3 × 10 mL). The organic phases were combined and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (9 / 1) to give tert-butyl 4-[(4,5-dichloro-2-[[2-(trimethylsilyl)ethoxy]methoxy]phenyl)(hydroxy)methyl]-2,2-dimethylpiperidine-1-carboxylate as a colorless oil (0.20 g, 30%): LCMS (ESI) C 25 H 41 Cl2NO5Si [M + H] + Calculated values: 534, 536 (3 : 2), measured values 534, 536 (3 : 2); 1 H NMR (300 MHz, CDCl3) δ 7.67 (s, 1H), 7.41 (s, 1H), 5.30 (s, 2H), 3.83-3.72 (m, 2H), 3.71-3.50 (m, 2H), 3.46-3.28 (m, 1H), 1.97-1.89 (m, 1H), 1.84-1.73 (m, 2H), 1.71-1.65 (m, 1H), 1.52 (d, J = 4.0 Hz, 6H), 1.49 (s, 9H), 1.40 (s, 2H), 0.04 (s, 9H).
[0553] Step D: To a solution of tert-butyl 4-[(4,5-dichloro-2-[[2-(trimethylsilyl)ethoxy]methoxy]phenyl)(hydroxy)methyl]-2,2-dimethylpiperidine-1-carboxylate (0.18 g, 0.34 mmol) in DCM (8 mL) at room temperature was added Dess-Martin reagent (0.14 g, 0.34 mmol) in three portions. The reaction mixture was then stirred at room temperature for 2 hours. The reaction was quenched with saturated aqueous NaSO and then extracted with DCM (2 × 10 mL). The organic phase was dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give tert-butyl 4-[(4,5-dichloro-2-[[2-(trimethylsilyl)ethoxy]methoxy]phenyl)carbonyl]-2,2-dimethylpiperidine-1-carboxylate as a colorless oil (0.16 g, crude): LCMS (ESI) C 25 H 39 Cl2NO5Si [M + H] + Calculated values: 532, 534 (3:2), measured values: 532, 534 (3:2).
[0554] Step E: To a solution of tert-butyl 4-(4,5-dichloro-2-[[2-(trimethylsilyl)ethoxy]methoxy]benzoyl)-2,2-dimethylpiperidine-1-carboxylate (0.16 g, crude) in THF (10 mL) was added 2-methylpropane-2-sulfinamide (44 mg, 360 mmol) and Ti(OEt) (0.90 g, 3.95 mmol) in one portion at room temperature. The reaction mixture was stirred at 70 °C under a nitrogen atmosphere for 15 h. The reaction mixture was quenched with water (50 mL). A solid formed and was filtered. The filtrate was extracted with EA (2 × 40 mL). The organic layers were combined and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give tert-butyl 4-(4,5-dichloro-2-[[2-(trimethylsilyl)ethoxy]methoxy]phenyl)[(2-methylpropane-2-sulfinyl)imino]methyl]-2,2-dimethylpiperidine-1-carboxylate as a colorless oil (0.20 g, crude): LCMS (ESI) C 29 H48 Cl2N2O5SSi [M + Na] + Calculated values: 657, 659 (3:2), measured values: 657, 659 (3:2).
[0555] Step F: To a solution of tert-butyl 4-[(1E)-(4,5-dichloro-2-[[2-(trimethylsilyl)ethoxy]methoxy]phenyl)[(2-methylpropane-2-sulfinyl)imino]methyl]-2,2-dimethylpiperidine-1-carboxylate (0.20 g, 0.31 mmol) in MeOH (5 mL) was added NaBH (58 mg, 1.54 mmol) in five portions at room temperature under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 2 hours under a nitrogen atmosphere. The reaction mixture was quenched with saturated aqueous NH Cl (10 mL). The resulting mixture was concentrated under reduced pressure. The residue was purified by preparative TLC eluting with PE / EA (1 / 1) to give tert-butyl 4-[(4,5-dichloro-2-[[2-(trimethylsilyl)ethoxy]methoxy]phenyl)[(2-methylpropane-2-sulfinyl)amino]methyl]-2,2-dimethylpiperidine-1-carboxylate as a colorless oil (75 mg, 37%): LCMS (ESI) C 29 H 50 Cl2N2O5SSi [M + Na] + Calculated values: 659, 661 (3:2), Measured values: 659, 661 (3:2).
[0556] [Example 51] Intermediate 51 ((S)-N-((R)-(6-(allyloxy)-2,3-dichlorophenyl)(piperidin-4-yl)methyl)-2-methylpropane-2-sulfinamide)
[0557] [ka]
[0558] Step A: To a stirred solution of 1,2-dichloro-3-iodo-4-(prop-2-en-1-yloxy)benzene (1.25 g, 3.80 mmol) in THF (10 mL) was added n-BuLi (1.2 mL, 3.80 mmol, 2.5 M in hexane) at −65° C. under a nitrogen atmosphere. After stirring at −65° C. for 30 min under a nitrogen atmosphere, a solution of tert-butyl 4-[[(S)-2-methylpropane-2-sulfinyl]imino]methyl]piperidine-1-carboxylate (0.80 g, 2.53 mmol) in THF (5 mL) was added dropwise at −65° C. under a nitrogen atmosphere. After the addition, the reaction mixture was stirred for an additional 1 h at −65° C. under a nitrogen atmosphere. The reaction was quenched with water (40 mL) at −65° C. and extracted with EA (3×30 mL). The combined organic layers were washed with brine (3 × 10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (7 / 1) to give tert-butyl 4-((R)-(6-(allyloxy)-2,3-dichlorophenyl)(((S)-tert-butylsulfinyl)amino)methyl)piperidine-1-carboxylate as a pale yellow oil (0.80 g, 57%): LCMS (ESI) C 24 H 36 Cl2N2O4S [M + H] + Calculated values: 519, 521 (3 : 2), measured values 519, 521 (3 : 2); 1 H NMR (400 MHz, CDCL3) δ 7.34 (d, J = 8.8 Hz, 1H), 6.79 (dd, J = 9.0, 4.9 Hz, 1H), 6.11-5.94 (m, 1H), 5.49-5.28 (m, 2H), 4.79 (t, J = 9.7 Hz, 1H), 4.68-4.50 (m, 3H), 4.36-3.91 (m, 3H), 2.77-2.47 (m, 2H), 2.40-2.29 (m, 1H), 2.18-2.02 (m, 1H), 1.46 (s, 9H), 1.34-1.22 (m, 1H), 1.04 (s, 9H).
[0559] Step B: To a stirred solution of tert-butyl 4-[(R)-[2,3-dichloro-6-(prop-2-en-1-yloxy)phenyl]([[(S)-2-methylpropane-2-sulfinyl]amino])methyl]piperidine-1-carboxylate (0.80 g, 1.54 mmol) in DCM (6 mL) was added TFA (1.5 mL) at room temperature. The reaction solution was stirred at room temperature for 1 hour. The resulting solution was diluted with water (6 mL) and neutralized to pH 8 with saturated aqueous NaHCO3. The resulting mixture was extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (3 × 30 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give (S)-N-[(R)-2,3-dichloro-6-(prop-2-en-1-yloxy)phenyl](piperidin-4-yl)methyl]-2-methylpropane-2-sulfinamide as a pale yellow oil (0.60 g, 74%): LCMS (ESI) C 19 H 28 Cl2N2O2S [M + H] + Calculated values: 419, 421 (3 : 2), measured values: 419, 421 (3 : 2); 1 H NMR (400 MHz, CDCl3) δ 7.36-7.31 (m, 1H), 6.81-6.76 (m, 1H), 6.11-5.95 (m, 1H), 5.49-5.34 (m, 2H), 4.81 (t, J = 10.0 Hz, 1H), 4.67-4.50 (m, 3H), 3.26 (d, J = 12.5 Hz, 1H), 3.08 (d, J = 12.4 Hz, 1H), 2.68-2.36 (m, 5H), 2.13 (t, J = 10.7 Hz, 1H), 1.04 (s, 9H).
[0560] [Example 52] Intermediate 52 (Lithio 4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxylate)
[0561] [ka]
[0562] Step A: To a stirred mixture of 5-oxo-4H-pyrazine-2-carboxylic acid (3.00 g, 21.41 mmol) and K2CO3 (14.8 g, 1.07 mol) in DMF (30 mL) was added CHCl (15.2 g, 1.08 mol) at room temperature. The resulting mixture was stirred at 40 °C under a nitrogen atmosphere for 16 h. The resulting mixture was diluted with water (50 mL) and extracted with EA (5 × 60 mL). The combined organic layers were washed with brine (5 × 80 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give methyl 4-methyl-5-oxopyrazine-2-carboxylate as a dark brown solid (2.50 g, 69%): LCMS (ESI) C7H8N2O3 [M + H] + Calculated value: 169, measured value 169; 1 H NMR (400 MHz, CD3OD) δ 8.48 (s, 1H), 8.02 (s, 1H), 3.92 (s, 3H), 3.61 (s, 3H).
[0563] Step B: To a stirred mixture of methyl 4-methyl-5-oxopyrazine-2-carboxylate (0.60 g, 3.57 mmol) in MeOH (7 mL) was added a solution of LiOH (0.26 g, 10.71 mmol) in HO (1 mL) at room temperature. After stirring at room temperature for 20 h, the resulting mixture was concentrated under reduced pressure. The crude product was used directly in the next step without further purification: LCMS (ESI) C6H6N2O3 [M + H] + Calculated value: 155, Measured value: 155.
[0564] [Example 53] Intermediate 53 (1-Bromo-4-methyl-2-(prop-2-en-1-yloxy)benzene)
[0565] [ka]
[0566] Step A: To a stirred solution of 2-bromo-5-methylphenol (2.00 g, 10.69 mmol) in DMF (20 mL) was added K2CO3 (2.96 g, 21.41 mmol) and 3-bromoprop-1-ene (1.94 g, 16.04 mmol) at room temperature. The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with EA (50 mL) and water (50 mL). The aqueous solution was extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (3 × 30 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (10 / 1) to give 1-bromo-4-methyl-2-(prop-2-en-1-yloxy)benzene as a pale yellow oil (1.29 g, 53%): 1 H NMR (400 MHz, CD3OD) δ 7.38 (d, J = 8.0 Hz, 1H), 6.86 (d, J = 1.9 Hz, 1H), 6.69 (dd, J = 7.9, 2.0 Hz, 1H), 6.16-6.02 (m, 1H), 5.40-5.30 (m, 1H), 5.28-5.20 (m, 1H), 4.60 (d, J = 5.0 Hz, 2H), 2.32 (s, 3H).
[0567] [Example 54] Intermediate 54 (tert-butyl 4-[methoxy(methyl)carbamoyl]-3-methylpiperidine-1-carboxylate)
[0568] [ka]
[0569] Step A: To a stirred mixture of 3-methylpyridine-4-carboxylic acid (2.00 g, 14.58 mmol) and HCl (6 N, 3 mL) in MeOH (15 mL) at room temperature was added PtO (0.33 g, 1.46 mmol). The resulting mixture was stirred at 50 °C under an atmosphere of H (50 atm) for 12 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give methyl 3-methylpiperidine-4-carboxylate HCl as a yellow oil (2.30 g, 90%): LCMS (ESI) CH 15 NO2[M + H] + Calculated value: 158, Measured value: 158 ; 1 H NMR (400 MHz, DMSO-d6) δ 3.86-3.69 (m, 2H), 3.64 (s, 3H), 3.15-2.90 (m, 2H), 2.83 (q, J = 5.7 Hz, 1H), 2.35-2.23 (m, 1H), 1.91-1.81 (m, 2H), 0.93 (d, J = 7.2 Hz, 3H) .
[0570] Step B: To a stirred solution of methyl 3-methylpiperidine-4-carboxylate (2.30 g, 14.63 mmol) and EtN (2.96 g, 29.26 mmol) in THF (15 mL) and MeOH (30 mL) was added BocO (4.79 g, 21.95 mmol) at room temperature. The reaction solution was stirred at room temperature for 2 hours. The resulting mixture was diluted with EA (50 mL) and water (30 mL). The aqueous solution was extracted with EA (3 × 20 mL). The combined organic layers were washed with brine (2 × 10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase chromatography eluting with 20% ACN in water (+0.05% TFA) to give 1-tert-butyl 4-methyl-3-methylpiperidine-1,4-dicarboxylate as a yellow oil (2.90 g, 77% over two steps): LCMS (ESI) C 13 H 23 NO4[M + H - 15] + Calculated value: 243, measured value 243;1 H NMR (400 MHz, CDCl3) δ 4.02 (s, 1H), 3.80 (dd, J = 13.3, 1.5 Hz, 1H), 3.70 (s, 3H), 3.31-2.81 (m, 2H), 2.62 (dt, J = 10.5, 4.3 Hz, 1H), 2.27-2.15 (m, 1H), 1.92-1.77 (m, 1H), 1.75-1.58 (m, 1H), 1.47 (s, 9H), 0.90 (dd, J = 6.8, 2.5 Hz, 3H).
[0571] Step C: To a stirred solution of 1-tert-butyl 4-methyl-3-methylpiperidine-1,4-dicarboxylate (2.70 g, 10.49 mmol) in MeOH (20 mL) was added a solution of NaOH (0.83 g, 20.98 mmol) in HO (4 mL) at room temperature. The reaction mixture was stirred at room temperature for 12 hours and acidified to pH 3 with citric acid. The mixture was extracted with EA (3 × 50 mL). The combined organic layers were washed with brine (2 × 10 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give 1-[(tert-butoxy)carbonyl]-3-methylpiperidine-4-carboxylic acid as a yellow oil (1.30 g, 63%): LCMS (ESI) C 12 H 21 NO4[M +Na] + Calculated value: 266, measured value 266; 1 H NMR (400 MHz, DMSO-d6) δ 12.24 (s, 1H), 3.88 (s, 1H), 3.70 (dd, J = 13.1, 3.6 Hz, 1H), 3.09-2.65 (m, 2H), 2.56 (dt, J = 10.0, 4.5 Hz, 1H), 2.19-2.08 (m, 1H), 1.65-1.49 (m, 2H), 1.39 (s, 9H), 0.80 (d, J = 6.9 Hz, 3H).
[0572] Step D: To a stirred mixture of 1-[(tert-butoxy)carbonyl]-3-methylpiperidine-4-carboxylic acid (1.10 g, 4.52 mmol) and HOBt (0.91 g, 6.78 mmol) in DMF (10 mL) was added EDCI (1.30 g, 6.78 mmol), EtN (0.55 g, 5.43 mmol), and N,O-methoxy(methyl)amine (0.30 g, 4.97 mmol) at room temperature. The reaction solution was stirred at room temperature for 12 hours. The resulting solution was quenched with water (50 mL) at room temperature and extracted with EA (2 × 50 mL). The combined organic layers were washed with brine (2 × 50 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (4 / 1) to give tert-butyl 4-[methoxy(methyl)carbamoyl]-3-methylpiperidine-1-carboxylate as a colorless oil (1.00 g, 77%): LCMS (ESI) C 14 H 26 N2O4[M + H - 56] + Calculated value: 231 Measured value 231; 1 H NMR (400 MHz, CDCl3) δ 4.17-3.89 (m, 2H), 3.86-3.76 (m, 1H), 3.73 (s, 3H), 3.29-3.13 (m, 4H), 3.13-2.94 (m, 2H), 2.24-2.09 (m, 1H), 2.06-1.87 (m, 1H), 1.48 (s, 9H), 0.93 (d, J = 7.0 Hz, 3H).
[0573] [Example 55] Intermediate 55 (tert-butyl (3S,4S)-rel-4-(2-(prop-2-en-1-yloxy)-4,5-dichlorobenzoyl)-3-methylpiperidine-1-carboxylate; tert-butyl (3R,4S)-rel-4-(2-(prop-2-en-1-yloxy)-4,5-dichlorobenzoyl)-3-methylpiperidine-1-carboxylate)
[0574] [ka]
[0575] Step A: To a stirred solution of 1-bromo-4,5-dichloro-2-(prop-2-en-1-yloxy)benzene (2.12 g, 7.68 mmol) in THF (10 mL) was added i-PrMgCl (3.84 mL, 7.68 mmol, 2 M solution in THF) dropwise at 0 °C under a nitrogen atmosphere. The reaction was stirred at 0 °C for 30 min. Then, a solution of tert-butyl 4-[methoxy(methyl)carbamoyl]-3-methylpiperidine-1-carboxylate (1.10 g, 3.84 mmol) in THF (8 mL) was added dropwise to the solution. After the addition, the resulting solution was stirred at 0 °C for an additional 1 h. The reaction was quenched with saturated aqueous NH4Cl (5 mL). The reaction mixture was diluted with EA (30 mL) and water (30 mL), and the aqueous solution was then extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (3 × 20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give a mixture of tert-butyl 4-(2-(allyloxy)-4,5-dichlorobenzoyl)-3-methylpiperidine-1-carboxylate and tert-butyl 4-(4,5-dichloro-2-hydroxybenzoyl)-3-methylpiperidine-1-carboxylate. The residue was dissolved in DMF (10 mL), and KCO (0.88 g, 6.37 mmol) and allyl bromide (0.77 g, 6.37 mmol) were added at room temperature. The resulting mixture was stirred at room temperature for 1 hour. The resulting mixture was diluted with EA (30 mL) and water (30 mL). The aqueous solution was extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (6 × 20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (10 / 1) to give tert-butyl 4-[4,5-dichloro-2-(prop-2-en-1-yloxy)benzoyl]-3-methylpiperidine-1-carboxylate containing the two cis enantiomers as a pale yellow oil (0.90 g, 55%): LCMS (ESI) C 21 H27 Cl2NO4[M + H - 56] + Calculated values 372, 374 (3:2), measured values 372, 374 (3:2); 1 H NMR (400 MHz, CDCl3) δ 7.67 (s, 1H), 7.06 (s, 1H), 6.15-5.97 (m, 1H), 5.52-5.38 (m, 2H), 4.69-4.54 (m, 2H), 4.25-4.03 (m, 1H), 4.01-3.86 (m, 1H), 3.68-3.52 (m, 1H), 3.12-2.94 (m, 1H), 2.91-2.76 (m, 1H), 2.24-2.10 (m, 1H), 2.01-1.84 (m, 1H), 1.76-1.55 (m, 1H), 1.55-1.39 (m, 9H), 0.85 (d, J = 6.5 Hz, 3H).
[0576] tert-Butyl 4-[4,5-dichloro-2-(prop-2-en-1-yloxy)benzoyl]-3-methylpiperidine-1-carboxylate containing two trans enantiomers was isolated as a pale yellow oil (0.12 g, 7%): LCMS (ESI) C 21 H 27 Cl2NO4[M + Na] + Calculated values: 450, 452 (3 : 2), measured values: 450, 452 (3 : 2); 1H NMR (400 MHz, CDCl3) δ 7.68 (s, 1H), 7.07 (s, 1H), 6.11-5.93 (m, 1H), 5.44 (q, J = 11.2 Hz, 2H), 4.62 (d, J = 5.5 Hz, 2H), 4.19-4.10 (m, 1H), 3.92 (d, J = 13.0 Hz, 1H), 3.57 (d, J = 11.2 Hz, 1H), 3.01 (d, J = 13.1 Hz, 1H), 2.87-2.78 (m, 1H), 2.23-2.08 (m, 1H), 1.97-1.82 (m, 1H), 1.76-1.58 (m, 1H), 1.56-1.32 (m, 9H), 0.82-0.75 (m, 3H).
[0577] [Example 56] Intermediate 56 ((2S)-1-methyl-5-oxopyrrolidine-2-carboxylic acid)
[0578] [ka]
[0579] Step A: To a stirred solution of tert-butyl (2S)-5-oxopyrrolidine-2-carboxylate (0.50 g, 2.70 mmol) in THF (5 mL) was added NaH (0.22 g, 5.40 mmol, 60% in mineral oil) at 0° C. under a nitrogen atmosphere. The resulting mixture was stirred at 0° C. for 30 minutes under a nitrogen atmosphere. To the above mixture was added MeI (1.15 g, 8.10 mmol) dropwise at 0° C. The reaction mixture was stirred at room temperature for 16 hours. The resulting mixture was quenched with water (40 mL) and extracted with EA (3×50 mL). The combined organic layers were washed with brine (3×20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase chromatography eluting with 50% ACN in water (+0.05% TFA) to give tert-butyl (2S)-1-methyl-5-oxopyrrolidine-2-carboxylate as a pale yellow oil (0.34 g, 63%): LCMS (ESI) C10 H 17 NO3[2M + H] + Calculated value: 399, Measured value 399; 1 H NMR (400 MHz, CDCl3) δ 4.09-3.92 (m, 1H), 2.87 (s, 3H), 2.57-2.43 (m, 1H), 2.43-2.24 (m, 2H), 2.13-1.98 (m, 1H), 1.50 (s, 9H).
[0580] Step B: To a stirred solution of tert-butyl (2S)-1-methyl-5-oxopyrrolidine-2-carboxylate (50 mg, 0.25 mmol) in DCM (1 mL) was added TFA (1 mL) at room temperature. The reaction solution was stirred at room temperature for 2 hours. The resulting solution was concentrated under reduced pressure to give (2S)-1-methyl-5-oxopyrrolidine-2-carboxylic acid as a yellow oil (64 mg, crude), which was used directly in the next step without further purification: LCMS (ESI) C6H9NO3 [M + H] + Calculated value: 144, measured value 144; 1 H NMR (400 MHz, CDCl3) δ 4.35-4.12 (m, 1H), 2.96 (s, 3H), 2.75-2.36 (m, 3H), 2.31-2.10 (m, 1H).
[0581] [Example 57] Intermediate 57 (Bromo-5-chloro-4-ethyl-2-(prop-2-en-1-yloxy)benzene)
[0582] [ka]
[0583] Step A: To a stirred solution of 4-chloro-3-ethylphenol (3.00 g, 19.15 mmol) in DCM (20 mL) was added Br (3.67 g, 22.96 mmol) dropwise at room temperature. The resulting solution was stirred at room temperature for 1 h. The reaction was quenched with saturated aqueous NaSO (20 mL) at room temperature and extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (3 × 20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give 2-bromo-4-chloro-5-ethylphenol as a colorless oil (4.50 g, crude), which was used directly in the next step without further purification: 1 H NMR (400 MHz, CD3OD) δ 7.42 (s, 1H), 6.83 (s, 1H), 2.65 (q, J = 7.5 Hz, 2H), 1.20 (t, J = 7.5 Hz, 3H).
[0584] Step B: To a stirred solution of 2-bromo-4-chloro-5-ethylphenol (4.50 g, 19.10 mmol) and K2CO3 (5.28 g, 38.20 mmol) in DMF (40 mL) was added 3-bromoprop-1-ene (3.47 g, 28.68 mmol) at room temperature. The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with EA (50 mL) and water (50 mL). The aqueous solution was extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (6 × 30 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (10 / 1) to give 1-bromo-5-chloro-4-ethyl-2-(prop-2-en-1-yloxy)benzene as a colorless oil (2.40 g, 45% overall for two steps); 1H NMR (400 MHz, CD3OD)δ 7.52 (s, 1H), 6.96 (s, 1H), 6.16-5.91 (m, 1H), 5.53-5.38 (m, 1H), 5.35-5.21 (m, 1H), 4.73-4.48 (m, 2H), 2.72 (q, J = 7.5 Hz, 2H), 1.23 (t, J = 7.5 Hz, 3H).
[0585] [Example 58] Intermediate 58 (tert-butyl 5-[methoxy(methyl)carbamoyl]-2-azabicyclo[2.2.1]heptane-2-carboxylate)
[0586] [ka]
[0587] Step A: To a stirred solution of 2-[(tert-butoxy)carbonyl]-2-azabicyclo[2.2.1]heptane-5-carboxylic acid (0.50 g, 2.07 mmol) in DCM (5 mL) was added EDCI (0.60 g, 3.11 mmol) and HOBt (0.42 g, 3.11 mmol) at room temperature. After stirring at room temperature for 10 minutes, N,O-methoxy(methyl)amine hydrochloride (0.30 g, 3.11 mmol) and EtN (0.63 g, 6.22 mmol) were added to the mixture at room temperature. After stirring at room temperature for 5 hours, the resulting solution was diluted with water (30 mL) and extracted with DCM (3 × 30 mL). The combined organic layers were washed with brine (3 × 20 mL) and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase chromatography eluting with 40% ACN in water (+0.05% TFA) to give tert-butyl 5-[methoxy(met...
Claims
1. A compound of formula I or a pharma- ceutically acceptable salt thereof [Formula 1] (In the formula, structural part [Case 2] is a group in which R 3 is substituted; [C3] having the respective structure of R 3 is H, halogen, or alkyl; R 1 and R 2 are each independently H, alkyl, (CR 6 R 7 ) n4 OR a , (CR 6 R 7 ) n4 NR a R b , (CR 6 R 7 ) n4 NR a (C═O) R b , (CR 6 R 7 ) n4 NR a SO 2 R b , or (CR 6 R 7 ) n4 CONR a R b , wherein at least one occurrence of R 1 and R 2 is (CR 6 R 7 ) n4 NR a R b , (CR 6 R 7 ) n4 OR a , (CR 6 R 7 ) n4 NR a (C═O) R b , (CR 6 R 7 ) n4 NR a SO 2 R b , or (CR 6 R 7 ) n4 CONR a R b ; or R 1 , R 2 and the carbon atom to which they are attached together form a 3- to 5-membered carbocyclic ring; R 4 is (CR 6 R 7 ) n4 (C═O)R c , (C═O)(CR 6 R 7 ) n4 R c , (CR 6 R 7 ) n4 OR c , (CR 6 R 7 ) n4 COOR c , (CR 6 R 7 ) n4 NR c (C═O)R d , (C═O)(CR 6 R 7 ) n4 OR c , (CR 6 R 7 ) n4 SO 2 R c , an optionally substituted saturated heterocycle, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted cycloalkyl, or an optionally substituted cycloalkyl-alkyl; each occurrence of R 5 is independently H, alkyl, cycloalkyl, or oxo; or two R 5 groups together with the carbon atom to which they are attached form a 3- to 7-membered optionally substituted saturated carbocyclic ring; or the two R 5 groups are attached to different carbon atoms on the ring and taken together form a bond or an alkyl chain containing 1 to 3 carbons; each occurrence of R 6 and R 7 is independently H, alkyl, or cycloalkyl; each occurrence of R a and R b is independently H, alkyl, cycloalkyl, saturated heterocycle, aryl, or heteroaryl; or R a and R b together with the nitrogen atom to which they are attached form an optionally substituted heterocycle containing a nitrogen atom and 0-3 additional heteroatoms each selected from the group consisting of N, O, and S; each occurrence of R c and R d is independently H, alkyl, alkyl substituted with 1-4 substituents each of which is independently halogen, OR 8 or N(R 8 ) 2 , alkenyl, optionally substituted cycloalkyl, optionally substituted bicycloalkyl, optionally substituted spiroalkyl, optionally substituted saturated heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl-aryl, optionally substituted alkyl-heteroaryl, optionally substituted alkyl-heterocycle, optionally substituted alkyl-cycloalkyl, or optionally substituted cycloalkyl-alkyl; or R c and R d together with the nitrogen atom to which they are attached form an optionally substituted heterocycle containing a nitrogen atom and 0-3 additional heteroatoms each selected from the group consisting of N, O and S; each occurrence of R 8 is independently H, alkyl, or an optionally substituted heterocycle; or two R 8 groups, together with the nitrogen atom to which they are attached, form an optionally substituted heterocycle containing a nitrogen atom and 0-3 additional heteroatoms each selected from the group consisting of N, O, and S; R 9 is H, alkyl, halogen, or (CR 6 R 7 ) n4 OR b ; Where applicable, the alkyl, cycloalkyl, spiroalkyl, bicycloalkyl, heterocycle, aryl, and heteroaryl of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 9 , R a , R b , R c , and R d are optionally substituted, where valences permit, with from 1 to 4 substituents each independently selected from the group consisting of alkyl, cycloalkyl, halogenated cycloalkyl, halogenated alkyl, halogen, CN, —(CH 2 ) 0-2 OR 8 , N(R 8 ) 2 , (C═O)C 1-4 alkyl, (C═O)N(R 8 ) 2 , and oxo; each occurrence of n 1 is independently, where valences permit, an integer from 0 to 3; each occurrence of n 2 and n 3 is independently an integer that is 1, 2, or 0; Each occurrence of n 4 is independently an integer from 0 to 3.
2. (a) each occurrence of n 2 and n 3 is independently an integer from 0 to 1; or (b) Structural motif [C4] but, [C5] or (c) Structural motif [C6] but, [C7] 2. The compound of claim 1 having the structure: or a pharma- ceutically acceptable salt thereof.
3. Structural motif [C8] but, [C9] having the structure 3. The compound according to claim 1 or 2, or a pharma- ceutically acceptable salt thereof.
4. A compound according to any one of claims 1 to 3 or a pharma- ceutically acceptable salt thereof, wherein at least one occurrence of R1 and R2 is (CR6R7)n4ORa, (CR6R7)n4NRaRb, (CR6R7)n4NRa(C=O)Rb, (CR6R7)n4NRaSO2Rb, or (CR6R7)n4CONRaRb.
5. The compound of claim 4, or a pharma- ceutically acceptable salt thereof, wherein at least one occurrence of R 1 and R 2 is OR a or NR a R b .
6. The compound according to claim 1, wherein R 1 , R 2 and the carbon atom to which they are attached together form a 3- to 5-membered carbocyclic ring, or a pharma- ceutically acceptable salt thereof.
7. A compound according to any one of claims 1 to 6, or a pharma- ceutically acceptable salt thereof, wherein R4 is (CR6R7)n4ORc, (CR6R7)n4CORc, (C=O)(CR6R7)n4Rc, (CR6R7)n4COORc, (CR6R7)n4NRc(C=O)Rd, (C=O)(CR6R7)n4ORc, or (CR6R7)n4SO2Rc.
8. The compound of claim 7 or a pharma- ceutically acceptable salt thereof, wherein R4 is (CR6R7)2ORc, (C=O)Rc, (C=O)(CR6R7)1-2Rc, COORc, (CR6R7)1-2NRc(C=O)Rd, (C=O)(CR6R7)1-2ORc, or SO2Rc.
9. The compound of claim 8 or a pharma- ceutically acceptable salt thereof, wherein R4 is (CH2)2OH, (CH2)2OMe, (C=O)H, (C=O)Me, (C=O)CH2OH, (C=O)CH2OMe, (C=O)Et, (C=O)Ph, (C=O)isopropyl, (C=O)CH2NH2, (C=O)CH2NHMe, (C=O)CH(OH)CH2OH, (C=O)CH(OMe)CH2OH, (C=O)CH(OH)CH2OMe, (C=O)OMe, SO2Me, SO2Et, SO2CH2OH, or SO2CH2OMe.
10. The present invention relates to a method for the preparation of a cycloalkyl-heteroaryl ring comprising the steps of: R 4 is (C═O)R c , (C═O)(CR 6 R 7 ) 1-2 R c , (C═O)(CR 6 R 7 ) 1-2 OR c , or SO 2 R c ; and R c is selected from the group consisting of H, alkyl, alkyl substituted with 1-4 substituents each independently selected from the group consisting of halogen, OR 8 and N(R 8 ) 2 , alkenyl, optionally substituted cycloalkyl, optionally substituted bicycloalkyl, optionally substituted spiroalkyl, optionally substituted saturated heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl-aryl, optionally substituted alkyl-heteroaryl, optionally substituted alkyl-heterocycle, optionally substituted alkyl-cycloalkyl, and optionally substituted cycloalkyl-alkyl; 9. The compound of claim 8 or a pharma- ceutically acceptable salt thereof.
11. R 4 is (CR 6 R 7 ) 2 OR c , (C═O)R c , (C═O)(CR 6 R 7 ) 1-2 R c , COOR c , (CR 6 R 7 ) 1-2 NR c (C═O)R d , (C═O)(CR 6 R 7 ) 1-2 OR c , or SO 2 R c , (a) R c or R d is H, Me, Et, [C10] or (b) R c or R d is [C11] said heterocycle being optionally substituted, where valences permit, with one or more cyano, cycloalkyl, fluoroalkyl, fluorocycloalkyl, halogen, OH, NH 2 , oxo, or (C═O)C 1-4 alkyl; or (c) R c is cycloalkyl, spiroalkyl, or bicycloalkyl, each optionally substituted, where valences permit, with from 1 to 4 substituents each independently selected from the group consisting of alkyl, halogen, CN, —(CH 2 ) 0-2 OR 8 , N(R 8 ) 2 , (C═O)N(R 8 ) 2 , and oxo; or (d) R c is optionally substituted, if valences permit, with from 1 to 4 substituents each independently selected from the group consisting of alkyl, halogen, CN, —(CH 2 ) 0-2 OR 8 , N(R 8 ) 2 , (C═O)N(R 8 ) 2 , and oxo; [C12] That is, 7. A compound according to any one of claims 1 to 6, or a pharma- ceutically acceptable salt thereof. (a) R 4 is an optionally substituted saturated heterocycle, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted cycloalkyl, or an optionally substituted cycloalkyl-alkyl; or (b) R 4 is [C13] said heterocycle being optionally substituted, where valences permit, with one or more cyano, cycloalkyl, fluoroalkyl, fluorocycloalkyl, halogen, OH, NH 2 , oxo, or (C═O)C 1-4 alkyl; or (c) R 4 is cycloalkyl optionally substituted, where valences permit, with from 1 to 4 substituents each independently selected from the group consisting of alkyl, halogen, CN, —(CH 2 ) 0-2 OR 8 , N(R 8 ) 2 , (C═O)N(R 8 ) 2 , and oxo; or (d) R 4 is optionally substituted, if valences permit, with from 1 to 4 substituents each independently selected from the group consisting of alkyl, halogen, CN, —(CH 2 ) 0-2 OR 8 , N(R 8 ) 2 , (C═O)N(R 8 ) 2 , and oxo; [C14] That is, 7. A compound according to any one of claims 1 to 6, or a pharma- ceutically acceptable salt thereof.
13. R 4 is [Case 15-1] [C15-2] or a tautomer thereof, or a pharma- ceutically acceptable salt thereof. (a) at least one occurrence of R 5 is H, alkyl or cycloalkyl; or (b) at least one occurrence of R 5 is oxo; or (c) two R 5 groups are attached to different carbon atoms on the ring and, together, form a bond or an alkyl chain containing 1 to 3 carbons; or (d) two R 5 groups, together with the carbon atom to which they are attached, form a 3- to 7-membered, optionally substituted, saturated carbocyclic ring; 14. A compound according to any one of claims 1 to 13, or a pharma- ceutically acceptable salt thereof. (a) at least one of R a and R b is independently H, alkyl, cycloalkyl, saturated heterocycle, aryl, or heteroaryl; or (b) R a and R b together with the nitrogen atom to which they are attached form an optionally substituted heterocycle containing a nitrogen atom and 0 to 3 additional heteroatoms each selected from the group consisting of N, O and S; 15. A compound according to any one of claims 1 to 14, or a pharma- ceutically acceptable salt thereof. (a) each occurrence of R 6 and R 7 is independently H or alkyl; and / or (b) R 9 is (i) H, alkyl, or halogen; or (ii) (CR 6 R 7 ) n4 OR b , or (iii) H, F, or OH; 16. A compound according to any one of claims 1 to 15, or a pharma- ceutically acceptable salt thereof.
17. The compound according to any one of claims 1 to 16, or a pharma- ceutically acceptable salt thereof, wherein R3 is H or alkyl.
18. The compound according to any one of claims 1 to 16, or a pharma- ceutically acceptable salt thereof, wherein R3 is halogen.
19. The method of claim 19, wherein: (a) at least one occurrence of R 8 is H, alkyl, or an optionally substituted heterocycle; and optionally, R 8 is H, Me, Et, Pr, Bu, or [C16] said heterocycle being optionally substituted, where valences permit, with one or more cyano, cycloalkyl, fluoroalkyl, fluorocycloalkyl, halogen, OH, NH 2 , oxo, or (C═O)C 1-4 alkyl; or (b) two R 8 groups, together with the nitrogen atom to which they are attached, form an optionally substituted heterocycle containing a nitrogen atom and 0 to 3 additional heteroatoms each selected from the group consisting of N, O and S; 19. A compound according to any one of claims 1 to 18, or a pharma- ceutically acceptable salt thereof. (a) at least one occurrence of R c or R d is independently H, alkyl, alkyl substituted with 1 to 4 substituents each independently selected from the group consisting of halogen, OR 8 and N(R 8 ) 2 , alkenyl, optionally substituted cycloalkyl, optionally substituted bicycloalkyl, optionally substituted spiroalkyl, optionally substituted saturated heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl-aryl, optionally substituted alkyl-heteroaryl, optionally substituted alkyl-heterocycle, optionally substituted alkyl-cycloalkyl, or optionally substituted cycloalkyl-alkyl; or (b) at least one occurrence of R c or R d is independently H, Me, Et, [C17] That is, 7. A compound according to any one of claims 1 to 6, or a pharma- ceutically acceptable salt thereof.
21. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, selected from the group consisting of the following compounds and pharma- ceutically acceptable salts thereof: [Table 1] [Table 2] [Table 3] [Table 4] [Table 5] [Table 6] [Table 7] [Table 8] [Table 9] [Table 10] [Table 11] [Table 12] [Table 13] [Table 14] [Table 15] [Table 16] [Table 17] [Table 18] [Table 19] .
22. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 21 or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier or diluent.
23. A pharmaceutical comprising a compound according to any one of claims 1 to 21 or a pharma- ceutically acceptable salt thereof.
24. A pharmaceutical composition comprising a compound according to any one of claims 1 to 21 or a pharma- ceutically acceptable salt thereof for use in a method of treating a condition in a mammalian species in need thereof, wherein the condition is selected from the group consisting of cancer, an immunological disorder, a central nervous system (CNS) disorder, an inflammatory disorder, a gastroenterological disorder, a metabolic disorder, a cardiovascular disorder, and a renal disease; Optionally, the condition is: (a) an immunological disorder that is transplant rejection or an autoimmune disease, the autoimmune disease optionally being rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, or type I diabetes; or (b) a condition that is a central nervous system (CNS) disorder that is Alzheimer's disease; or (c) a condition that is an inflammatory disorder that is an inflammatory skin condition, arthritis, psoriasis, spondylitis, periodontitis, or inflammatory neuropathy; or (d) A condition that is a gastroenterological disorder that is inflammatory bowel disease; or (e) a condition that is a metabolic disorder that is obesity or type II diabetes; or (f) A condition that is a cardiovascular disorder that is an ischemic stroke; or (g) A condition that is a renal disease that is chronic kidney disease, nephritis, or chronic renal failure; or (h) a condition selected from the group consisting of cancer, transplant rejection, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, type I diabetes mellitus, Alzheimer's disease, inflammatory skin conditions, inflammatory neuropathy, psoriasis, spondylitis, periodontitis, Crohn's disease, ulcerative colitis, obesity, type II diabetes mellitus, ischemic stroke, chronic kidney disease, nephritis, chronic renal failure, and combinations thereof; Optionally, said mammalian species is human.
Citation Information
Patent Citations
Diaminoalkane aspartate protease inhibitor
JP2008515916A
Amine derivatives as potassium channel blockers
JP2014524886A
Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases
WO2006029182A2
Oxindole compounds and their uses as therapeutic agents
WO2006113864A2
Renin inhibitors
WO2007117482A2
